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Abstract  
 
Current therapy for PD is focused on dopamine replacement by the use of L-DOPA and 
dopamine agonists, which relieve the parkinsonian motor symptoms led by the 
degeneration of dopaminergic neurons in the substantia nigra par compacta (SNc). 
However, the long-term use of these agents could induce side effects and fail to slow 
down the progression of the nigral dopaminergic neuronal loss. Thus, there is an 
increasing demand for neuroprotective agents that can relieve the symptoms and alter 
the dopaminergic neuronal death in PD. Excitotoxicity, due to the excessive glutamate 
release from subthalamic nucleus (STN) to the SNc, could jeopardize the 
neurodegeneration in the SNc. Thus, the modulation of the glutamate could prevent the 
cellular loss in PD SNc.  Accordingly, the selective ligands acting on metabotropic 
glutamate receptors (mGluRs) were proved to be anti-parkinsonian in PD models. 
Furthermore, the group III mGluR agonist, L-(+)-2-amino-4-phosphonobutyric acid 
(L-AP4), was proved to be neuroprotective in the 6-OHDA PD model. In this study, 
therefore, the subtypes of group III mGluRs, such as mGluR4, 6, 7 and 8, was examined 
in order to provide a more specific neuroprotection. Thus, 
N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC) and 
(S)-3,4-dicarboxyphenylglycine ((S)-DCPG) were utilized for the activation of 
mGluR4 and 8 respectively which are expressed prevalently in basal ganglia. Herein, 
the concentration-dependent and receptor mediated neuroprotection of PHCCC and 
(S)-DCPG against 6-OHDA toxicity in rodent model of PD were demonstrated. 
Furthermore, PHCCC and (S)-DCPG are neuroprotective when administered to animal 
systemically. Moreover, the neuroprotective potential of PHCCC and (S)-DCPG were 
putatively demonstrated in another PD model of lactacystin, an ubiquitin-proteasome 
inhibitor. In this study, we also reported the effect of PHCCC and (S)-DCPG on the 
glial cells involved in the PD models, elucidating the underlying neuroprotective 
mechanism of these ligands. Thus, mGluR4 and 8 may be a promising therapeutic 
target for further pharmacological development.  
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Chapter 1: Introduction  
1.1 Background of Parkinson’s disease  
1.1.1 History 
In 1817, Dr James Parkinson, a British physician, published an Essay entitled 
the Shaking Palsy, describing Paralysis agitans. He described the motor deficits, such 
as resting tremor, rolling gait and bent trunk, based on the observation of 6 patients, 
however, without detail clinical diagnosis. In 1862, Jean-Martin Charcot, a French 
neurologist, added more clinical description of Paralysis agitans and saluted to James 
Parkinson, subsequently attaching the name Parkinson’s disease (PD) to the 
syndrome.  
The principle post mortem characteristic is the degeneration of dopaminergic 
neurons in the substantia nigra pars compacta (SNc, Olanow, 2007). This 
subsequently leads to a reduction in striatal dopamine (DA) which precipitates failure 
of motor control in the basal ganglia (BG) characterized by the symptoms of muscle 
rigidity, bradykinesia, akinesia and resting tremor (Imai et al, 1996).  
 
1.1.2 Epidemiology 
PD is the second most common neurodegenerative disease after Alzheimer’s 
disease (AD; Schapira, 2006). Generally, there are 0.3% of total populations suffering 
from PD whilst there are approximately 1-2% of patients aged over 60 and 4-5% in 
individuals over 85 affected by the disease (Weintraub et al, 2008). Ageing is one of 
the major risk factors in PD (Weintraub et al, 2008). There is also a higher prevalence 
of PD in males compared to females (Swerdlow et al, 2001), which may be due to the 
potential neuroprotective effect of estrogens (Gillies et al, 2004). Indeed, estrogens 
and their analogues have already reported to illustrate a promising therapeutic effect 
in clinical PD (Liu et al, 2007; Sohrabji and Lewis, 2006).  
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1.1.3 Genetic risk factors and familial PD 
Approximately 7% of total PD cases are hereditary associated with genetic 
defect (Farrer, 2006). A large series of linkage analysis studies has uncovered several 
genes mutations that cause the familial PD. To date, there are reports of multiple gene 
mutations of which six gene mutations mediate a significant number of familial PD 
cases. For instance, mutations of Parkin and UCHL-1, two of the enzymes involved in 
ubiquitin-proteasome-mediated protein degradation, leads to the build up of abnormal 
proteins in the cytoplasm. Another mutant gene, SNCA (α-synuclein), resists protein 
degradation due to the misfolded conformational structure of the protein and hence 
accumulates and eventually aggregates and is present in Lewy bodies (LB). 
Furthermore, DJ-1 and PINK1 are the mutants in familial PD cases which lead to a 
weaker tolerance to oxidative stress and mitochondria dysfunction. Of particular 
interest is the LRRK2 (leucine-rich repeated kinase 2) mutation which is the first 
dopaminergic system related PD mutant discovered in 2004 (Paisán-Ruíz et al, 2004). 
Although it is still unclear about the function of LRRK2, the expression of it in 
striatum further supports its role in the degeneration of the dopaminergic system in 
PD.  
 
1.1.4 Environmental risk factors for sporadic PD 
More than 90% of PD cases are sporadic or idiopathic in nature. The underlying 
pathological mechanism of idiopathic PD is not clear. In the 1980s, a group of opiate 
addicts developed Parkinsonian symptoms due to a contaminant, namely 
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP; Langston and Ballard, 1983). 
MPTP in the brain is converted to the pyridinium ionic form, MPP+, by monoamine 
oxidase B (MAO-B), which is then transported into the dopaminergic neurons by the 
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dopamine transporter (DAT). Intracellular MPP+ inhibits the activity of mitochondrial 
complex I (NADH dehydrogenase) leading to ATP depletion and ultimately death of 
the dopaminergic neurons via apoptosis (Blum et al, 2001; and Przedborski et al, 
2004). However, no other MPTP-like toxin has been identified in the environment that 
could cause idiopathic PD (Blum et al, 2001). At least, this coincidental tragedy 
proved that environmental factors could be involved in the development of 
Parkinsonism (Schapira, 2006).  
Furthermore, agricultural personnel have a higher risk of developing PD through 
the exposure to herbicides or pesticides (Gomez et al, 2007). Indeed, most of the 
pesticides and herbicides are mitochondrial respiratory toxins (Gomez et al, 2007; and 
Yang and Deng, 2007). Rotenone, one of the pesticides, induces the dopaminergic 
degeneration in a rodent model of PD (Betarbet et al, 2000; and Sherer et al 2003). 
Furthermore, other toxins, for instance the by-products of combustion from motor 
vehicles and other air pollutants, may also play a role in dopaminergic degeneration 
(Edwards and Myers, 2008). However, such factors cannot explain the presence of PD 
before the industrial revolution. 
Oxidative stress is also recognized as one of the major mechanisms of 
neurodegeneration in PD. From post-mortem tissue studies, antioxidant molecules 
including glutathione are decreased in the PD SNc (Foley and Riederer, 2000). This 
evidence indirectly suggests that the SNc has suffered severe oxidative stress. 
Supporting the concept of an involvement of oxidative stress in PD, anti-oxidant 
reagents have been shown to prevent dopaminergic neurodegeneration in animal 
models of PD (Chen et al, 2007). The increase in oxidative stress may be due to 
increased concentrations of iron in the PD SNc which is a potent stimulator of free 
radical formation (Youdim et al, 1993; Double et al, 1999). Indeed, iron chelators are 
being developed as one of the therapeutic approaches for treating PD (Youdim et al, 
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1993; and Mandel et al, 2003).  
Additionally, neuroinflammation is commonly detected in PD brains (Hunot and 
Hirsch, 2003; and Liu et al, 2003). Pro-inflammatory factors, including tumour 
necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6, and microglial activation are 
detected in the PD SNc (Teismann and Schulz, 2004; and Nagatsu and Sawada, 2005), 
indicating activation of the innate neuroinflammatory response during PD 
development. Indeed, the SNc has the highest number of resident microglia when 
compared to other brain regions suggesting that the SNc may be particularly 
vulnerable if the innate immune system is activated. This is possible due to the higher 
level of oxidative stress induced by the metabolism of monoamines in the SNc. 
Indeed, the chronic use of anti-inflammatory drugs, particularly ibuprofen, lowers the 
risk of developing PD (Hernan et al, 2006; Ton et al, 2006). Interestingly, in 
traditional Chinese medicine, chronic inflammation is prevented by a long term 
consumption of certain anti-inflammatory herbs, including Evodia rutaecarpa, 
Rhizoma coptidis and Radix scutellariae in typical Chinese diet or as health enhancers 
(Ko et al, 2007; and Liu et al, 2008b). 
Some other dietary habits are linked to a higher risk for the development of PD. 
For instance, people in certain oriental countries, including China and Japan, who 
have a western-like style diet, have an increased risk of developing PD (Abbott et al, 
2003; and Ma et al, 2006). Cigarette smoking has been shown to be associated with a 
lower risk of developing PD (Hernan et al, 2001; 2002). The neuroprotective property 
of nicotine has also been demonstrated in certain animal studies (Picciotto and Zoli, 
2008; Ward et al, 2008). Moreover, coffee drinking is beneficial in preventing the 
development of PD (Ross et al, 2000). Caffeine blocks the adenosine A2A receptor, 
which then produces neuroprotective effect against the PD neurotoxicity (Van der 
Schyf et al, 2006).  
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Hence, there are different environmental factors affecting the development of 
PD. Possibly, there are multiple factors emerging together in a chronic process. 
Therefore, it is believed that the biochemical causes of PD are a set of intrinsic and/or 
extrinsic risk factors producing triggering neurodegeneration.  
 
1.2 Symptomatic description of PD  
Parkinsonian symptoms manifest when the nigrostriatal lesion reaches a critical 
threshold of about 70-80% loss of striatal DA (Zigmond et al, 1984; Foley and 
Riederer, 1999). Consequently, the clinical motor symptoms of PD are not diagnosed 
until there is a severe degeneration of the nigrostriatal system (Schapira, 2006).  
 
1.2.1 Motor symptoms 
1.2.1.1 Bradykinesia and akinesia 
Akinesia, absence of movement, is recognized as one of the most important 
symptom in terms of contribution to patient disability (Imai et al, 1996). However, 
patients can usually still initiate movement (Klockgether, 2004). Also this is often 
described as bradykinesia, which literally means slowness of movement. Due to the 
poor control of motor function in the midbrain, PD patients cannot perform fine 
movements e.g. hand writing (Klockgether, 2004, Becker et al, 2002). Indeed, poverty 
of movement does not only affect the limbs but also other voluntary and involuntary 
movements such as blinking, swallowing, facial expression (Narabayashi et al, 1980). 
These symptoms prevent the patients from handling daily tasks without extra 
assistance.  
 
1.2.1.2 Muscle rigidity and resting tremor 
The failure to control the limbs in PD is also partly due to muscle rigidity caused 
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by abnormal antagonist muscle responses, leading to resistance in joint movement. 
Furthermore, PD patients also develop a stooped posture due to the stronger ventral 
flexors and failed antagonistic stretching by dorsal extensor in the whole trunk 
(Klockgether, 2004). It is still not clear how the deficiency of dopamine precipitates 
the loss of control of muscular responses (Klockgether, 2004). However, this 
abnormality is thought to be due to dysfunction of the motor loop in BG which affects 
the cerebellar output for involuntary and voluntary motor control (Bergman and 
Deuschl, 2002; Klockgether, 2004).  
Due to the uncontrolled alternative activation of flexor and extensor muscles, a 
resting tremor also develops (Boose et al, 1996). Resting tremor is probably one of the 
first and most obvious motor symptoms which occur in hands, legs and neck in some 
severe cases (Brunton, 2006). Usually the resting tremor is suppressed when patients 
initiate voluntary movements. Although the resting tremor is not necessarily disabling, 
it still affects the quality of life of the patient and contributes to anxiety and/or 
depression (Lang and Lozano 1998). 
 
1.2.2 Non-motor symptoms 
Originally in Dr Parkinson’s essay, PD was only characterized by motor deficits 
whilst the sense and intellect remained uninjured. However, it is now widely accepted 
that certain non-motor symptoms in PD are observed in the majority of clinical cases 
which may be due to the neurodegeneration in other brain regions (Chaudhuri et al, 
2006). Non-motor symptoms are usually not the primary signs for clinical diagnosis 
and usually affect the PD patient in the later stages of the disease but also affect the 
quality of life of the PD patients. Those PD patients with severe non-motor symptoms 
may need intensive care which subsequently induces a heavy burden for the patients’ 
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families (Hauser, 2006).  
Depression is one of non-motor symptoms of PD and can occur even in the early 
stages of the disease. From post-mortem studies, degeneration of the Locus Coeruleus 
(LC) and Raphe nucleus is also found in PD patients, which may relate to the 
development of depression (Braak et al, 2003 and 2004). Additionally, psychiatric 
symptoms, such as hallucination, dillusions and psychosis, are also observed in some 
PD patients (Rome and Grünewald, 1999; and Poewe, 2008). Furthermore, some PD 
patients develop cognitive problems e.g. they are unable to repeat visual based tasks, 
indicating the depletion of declarative memory formation and short-term memory 
consolidation (Emre, 2003; and Pagonabarraga et al, 2008). Some patients may also 
suffer from difficulties with attention and visuospartial coordination (Klepac et al, 
2008). As PD progresses, global dementia may also develop; hence patients may 
require intensive daily care (Schrag et al, 2006).  
More than half of PD patients suffer from sleep disorders and REM depletion 
due to the dopamine loss (Trenkwalder, 1998). Furthermore, there are also other 
psychological symptoms, such as depression and hallucination, due to the REM 
sleeping depletion.  
 
1.3 Pathology of PD  
The primary pathological characteristic of PD is the loss of the dopaminergic 
neurons in the SNc associated with cytoplasmic LB’s in the remaining dopaminergic 
neurons (Valls-Solé et al, 2002). Extracellular deposits of altered proteins are also 
found around degenerating SNc, which may be due to the secretion of altered proteins 
from cells or LB’s remaining after cells have died that haven’t yet been removed by 
phagocytosis (Valls-Solé, 2000). However, pathological changes are observed in other 
cell types apart from the SNc e.g. noradrenergic neurons in the locus coruleus and 
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cholinergic neurons in the nucleus basalis of mynert which may play important roles 
in the development and progression of PD. 
 
1.3.1 Pathophysiology of the Basal Ganglia in PD  
1.3.1.1 The classical model of the BG motor loop  
The BG is a complex of sub-cortical nuclei interconnecting with each other, 
consisting of the striatum, subthalamic nucleus (STN), globus pallidus (internal and 
external segment, GPi and GPe, respectively) and the substantia nigra pars compacta 
(SNc) and substantia nigra pars reticulata (SNr) (Lang, 1998). The primary input into 
the BG motor loops is a glutamatergic innervation projecting from the cerebral cortex 
to the putamen, activating the striatal GABAergic medium spiny neurons (MSNs; 
Alexander et al, 1990). The neural information is then processed in the putamen, 
subsequently passing through other BG nuclei with two parallel pathways, namely 
direct and indirect pathways. The direct pathway consists of GABAergic neurons, 
connecting the putamen and the GPi/SNr (Lange et al, 1997). Thus, the final output 
from the BG is inhibited by the direct pathway. On the contrary, the indirect pathway 
consists of the GABAergic neurons projecting from the putamen to the GPe, which 
connect with another GABAergic neuronal pathway running from GPe to STN, which 
connects via a glutamatergic pathway from STN to the GPi/SNr (Alexander et al, 
1990). Therefore, the final output of the BG is activated by the indirect pathway. 
These two parallel pathways modulate the output of signals from the BG motor loop 
to the thalamus, and ultimately the cortical motor area (Obeso et al, 2002). 
Furthermore, the direct and indirect pathways are further modulated by the 
dopaminergic projection from the SNc. The activation of the D1 DA receptor on 
GABAergic neurons in the direct pathway provides further inhibitory signal to the 
GPi/SNr whilst the activation of the D2 receptor on the first GABAergic neurons in 
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the indirect pathway (from putamen to GPe) suppress the signal to GPe, subsequently 
the suppression of the second GABAergic neurons in GPe and activation of the 
following glutamatergic neurons in STN (Conn et al, 2005). Therefore, the effect of 
the two parallel pathways is strengthened by the dopaminergic nigrostriatal 
innervation.  
The motor loop model of the BG is supported by evidence that activation of the 
direct and indirect pathways facilitates and suppress the control of motor activity 
respectively (Chevalier and Deniau, 1990). Increased activity through the indirect 
pathway leads to the inhibition of the GPe, resulting in disinhibition of STN, which 
causes the subsequent hyperactivity of the GPi/SNr. Based on this classical model of 
the BG motor loop, the activation of DA receptors in the striatum is reduced in PD 
due to the loss of dopaminergic neurons and subsequent loss of striatal DA. Reduced 
DA levels results in an overactive indirect but inhibited direct pathways. The net 
result of the BG motor loop is extra-inhibition due to the over activated glutamatergic 
neurons from STN to GPi/SNr and eventually the reduction in thalamo-cortical 
transmission, leading to the appearance of PD motor symptoms (Obeso et al, 2000). A 
simplistic diagram in Fig 1.1 summarizes the motor loop in the BG.  
Considerable evidence also exists to support the hypothesis that hyperactivity of the 
STN and pallidal output to the thalamus contribute to the development of PD motor 
symptoms. In electrophysiology studies in animal models of PD, the firing rates in 
STN increase but those in GPe decrease, indicating that the indirect pathway is over 
activated (Vila et al, 1996; Benazzouz et al, 2000). This hypothesis is also supported 
by improvement of the motor symptoms in PD models after lesioning of the STN 
which is over activated (Benazzouz et al, 2000; Carvalho and Nikkhah, 2001).  
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Fig 1.1: Schematic illustration of the Basal Ganglia in Parkinson’s brain (Conn et al, 
2005) 
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1.3.1.2 Criticisms of the classical model of basal ganglia function  
The classical model of BG motor loop successfully describes and explains the 
pathological mechanism of the motor symptoms in PD. However, some evidence 
suggests that the crosstalk among different BG nuclei is more complicated which fails 
to be illustrated by this classic model (Obeso et al, 2002). At the same time, a growing 
body of evidence disagree with this classic model where over activation of STN is 
proposed not to be a true physiological feature of PD (Vila et al, 1996).  
Furthermore, the classical model also does not fully describe the actual 
functional relationship among different nuclei in the BG. For instance, certain 
extrastriatal nuclei, GPi/e, SNr and STN, are innervated by the dopaminergic neurons 
originated from the SNc (Joel and Weiner, 1997). Furthermore, based on the classic 
model, the direct and indirect pathways are modulated by DA via the activation of D1 
and D2 receptors respectively. However, recent evidence suggests that both D1 and 2 
are co-expressed on striatal neurons; thus dopaminergic modulation in the striatum is 
more complicated (Aizman et al, 2000). Instead, some studies suggest that DA acts to 
modulate the neurotransmission inside the striatum rather than directly excite or 
inhibit the striatal neurons (Morari et al, 1998; Chase and Oh 2000). Moreover, the 
classic model does not describe the role of other brain nuclei such as the PPN which 
connects to both STN and SNc (Parent et al, 2000).  
There are the reciprocal connections between the BG nuclei providing the 
positive and/or negative feedback (Obeso et al, 2002; Breit et al, 2004). Such 
interrelationship stabilizes the neural function of the BG. Indeed, the loss of balance or 
equilibrium among these circuits should be the actual reasons for the failure of the 
motor control in BG (Obeso et al, 2000). However, the classical model does not 
describe such a relationship. Although the classic model of BG motor is too simplistic 
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to represent all neuropathology in PD BG, the hypothesis of the imbalance of indirect 
and direct pathways in the BG is still applicable for many different Parkinsonism 
studies, including the current one detailed in this thesis. 
 
1.3.2 Biochemical changes in PD 
The principal change is the reduction in striatal DA in the PD brain due to the 
loss of dopaminergic neurons in the SNc. The loss of DA induces neurotransmitter 
changes within the BG which lead to the dysfunction of the motor control. 
Furthermore, the decreased striatal DA content induces a loss of balance between 
other neurotransmitters and DA. For example DA acts as an inhibitory transmitter on 
striatal cholinergic interneurons. The removal of DA inhibition leads to enhanced 
activity in such cholinergic interneurons. Such an imbalance further impacts on the 
function of the BG. Additionally, the serotonergic system is also affected in PD with 
neurodegeneration in several brain areas including the raphe nucleus and the olfactory 
bulb with the presence of LBs, which lead to the hyposmia. The diminution of 
serotonin transmission is associated with a series of non-cognitive problems, 
including depression, sleep deregulation etc.  
 
1.3.3 Cellular pathology in PD  
1.3.3.1 Neuroinflammation 
In PD the neurodegenerative process is associated with astrogliosis (Hirsch et al, 
2003), however the role of astrocytic activation is not clear. Traditionally, activated 
astrocytes are associated with a neuroprotective response with the release of growth 
factors to stimulate tissue survival/repair (Hirsch et al, 2003), however recent 
evidence suggests that astrocytic activation can also mediate pro-inflammatory 
response which may endanger neurons (Mallajosyula et al, 2008). Neuronal loss in 
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PD is also associated with an infiltration and activation of microglia (Hirsch et al, 
2005; and Vroon et al, 2007). Morphologically, both activated astrocytes and 
microglia have enlarged cell bodies and increased numbers of processes (Hirsch et al, 
2005). Furthermore, microglial activation is not only detected in the nigrostriatal tract 
but also the other regions affected in PD, such as olfactory bulb (Vroon et al, 2007), 
suggesting that microglia-mediated neuroinflammation may be an underlying 
mechanism in the neurodegenerative process in PD.  
 Physiologically, the pro-inflammatory factors, including interleukin-(IL) 1β and 
6, and tumour necrosis factor α (TNFα), possibly synthesized and released by 
astrocytes, induce microglial activation and contribute to neuronal cell death 
(Rosenberg, 2005). Interestingly, microglia express and release paracrine cytokines 
which further activate adjacent microglia (Tanuma et al, 2006). These 
pro-inflammatory factors are found in PD brains, further confirming the 
neuropathological role of glial mediated neuroinflammation in PD. Clinically, 
anti-inflammatory reagents are being developed as the therapeutic agents in PD.  
 
1.3.3.2 Lewy Body pathology in PD 
LBs are found in the SNc, LC, cerebral cortex and several other brain structures 
(Halliwell et al, 1998; and Takahashi and Wakabayashi, 2001). LBs are packed with 
altered/oxidised proteins, such as ubiquitin, α-synuclein, Torsin A and tau (Rideout et 
al, 2001; Geetha et al, 2008). The role of LB formation is still not clear. However, it is 
believed that unwanted or damaged proteins are packaged into LBs to prevent the 
accumulation of damaged proteins in the cytosol which would otherwise be toxic to 
the cell (Johnston et al, 1998; Kopito, 2000). The ubiquitin-proteasome system (UPS) 
is the cellular machinery for the removal of altered/unwanted proteins. However, the 
activity and expression of the proteasome in PD brains has been shown to be 
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decreased (Grünblatt et al, 2004; and Marx et al, 2007). Interestingly, LBs are also 
found in glial cells, known as glial cell inclusions indicating that altered protein 
handling may not be specific to neurons (GCI; Wakabayashi et al, 1998). Furthermore, 
GCI are also found in brain regions outside the midbrain (Piao et al, 2000; Uryu et al, 
2006). Furthermore, the extracellular accumulation of α-synuclein has been shown to 
stimulate the activation of microglia and hence neuroinflammation (McGeer and 
McGeer, 2008).  
 
1.4 Clinical diagnosis and Current therapies of PD  
1.4.1 Clinical diagnosis  
Due to the absence of a biological marker of PD, there are no biochemical diagnostic 
test to confirm PD. Parkinsonism is usually defined clinically by the appearance of 
motor symptoms, such as bradykinesia (akinesia), muscle rigidity and rest tremor 
(Muller et al, 2006). However, any disorders with the striatal DA deficiency may also 
lead to Parkinsonism. Therefore, the full confirmation of such diagnosis cannot be 
concluded until post-mortem analysis (Tolosa et al, 2006). Indeed, PD is the most 
common cause of Parkinsonism, accounting for about 80% of cases (Hughes et al, 
1992). Recently imaging techniques such as positron emission tomography (PET) 
have improved the diagnostic accuracy of PD (Pavese and Brooks, 2009). PET 
imaging in PD often utilises the18F-DOPA tracer which is taken up by dopaminergic 
neurons where it is converted to dopamine and packaged into the storage vesicles thus 
allowing the imaging of dopaminergic nerve terminals in the caudate and putamen. 
Single photon emission computed tomography (SPECT) is another diagnostic 
imaging technique commonly utilised to assess dopaminergic function. Some other 
imaging approaches, such as magnetic resonance imaging (MRI) and computed 
tomography (CT), are also adopted for the structural scanning of the PD brains 
 38 
 
(Nandhagopal et al, 2008; Pavese and Brooks, 2009).  
 
1.4.2 Dopaminergic therapies: Replacement of dopamine by L-DOPA 
After the discovery that PD was associated with a deficiency of striatal DA, the 
replenishment of DA was shown to be effective in relieving motor deficits. The DA 
precursor, levodopa (L-DOPA), is able to cross the BBB, unlike DA (Hawkins et al. 
2005). Once inside the CNS, L-DOPA is taken up by neurons and converted to DA by 
dopa decarboxylase enzyme thus replenishing DA levels in the striatum. However, the 
dopa decarboxylase enzyme is also present in the periphery thus leading the 
conversion of the majority of the orally administered L-DOPA to be DA in the 
periphery, which can trigger side effects like nausea etc (Nomoto et al. 2009). In order 
to prevent the peripheral conversion of L-DOPA to DA, L-DOPA is co-administration 
with a peripherally acting dopa decarboxylase inhibitor, such as carbidopa, which thus 
enhances the CNS delivery of L-DOPA (Elwan and Sakuragawa, 2007). L-DOPA 
ameliorates the majority of the Parkinsonian symptoms particularly in the first few 
years of treatment but the patients’ response to L-DOPA declines as the disease 
progresses (Pahwa, 2006). This loss of L-DOPA effectiveness may be due to the 
progressive loss of dopaminergic neurons, where DA is synthesized or changes in the 
pharmacokinetic handling of L-DOPA (Pahwa, 2006).  
Asides from reductions in the response to L-DOPA, there are other clinical side 
effects associated with this therapy. In some patients receiving L-DOPA treatment for 
a reasonable period of time, fluctuations in drug response are observed which are 
called “on-off” phenomenon (Simonson et al, 2007). Where the improvement of 
mobility with L-DOPA, on-period, is associated with intermittent periods of akinesia 
and rigidity, called off-periods. Additionally, long term L-DOPA therapy is associated 
with dyskinesias which are abnormal movements in the limbs. 
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1.4.3 DA receptor agonists 
There are two major groups of DA receptor agonists for the clinical PD 
treatment, namely ergot and nonergot derivatives (Kehne et al, 2008). The latter have 
recently been developed and approved for the clinical use, and are associated with 
fewer side effects. For example, pergolide, a nonergot derivative, does not have 
potential to induce the heart valve dysfunction liked ergot compounds (Van Camp et 
al, 2004). Such DA receptor agonists directly stimulate DA2 receptors in the striatum 
to bring about modulation of motor function but also stimulate other DA2 receptors in 
the periphery and other brain regions and hence are not without serious side effect. 
There are many reported cases of gastrointestinal side effects, such as constipation, 
dyspepsia and peptic ulceration. Other side effects observed, include confusion, 
hallucination etc.  
 
1.4.4 Inhibition of DA metabolism: monoamine oxidase (MAO) and 
catechol-O-methyltransferase (COMT) inhibitors 
MAO-B is one of the two subtypes of MAOs responsible for the DA metabolism 
and is principally found in dopaminergic neurons. COMT is another DA degrading 
enzyme, which methylates DA and is mainly found in post-synaptic sites. COMT is 
also found in the periphery where it converts L-DOPA to 3-o-methyl-dopa (3-OMD) 
which competes with L-DOPA for uptake sites on the BBB to gain access to the brain. 
Both MAO-B and COMT inhibitors have been utilised clinically to not only preserve 
DA levels within the brain but to also enhance the delivery of L-DOPA to the brain 
thus decreasing off-periods (Gottwald and Aminoff, 2008; Abdel-Salam, 2008). 
Interestingly, some of the MAO-B inhibitors, such as deprenyl and rasagiline, have 
been reported to be neuroprotective due to their anti-oxidative/anti-apoptotic 
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properties but this remains controversial (Kiray et al, 2007; Schapira, 2008).  
Whilst the side effects associated with MAOB inhibitors are limited, 
hepatotoxicity has been reported with COMT treatment (Ferreira et al, 2008). Thus, 
the liver function should be monitored in the COMT treated patients.  
 
1.4.5 Non-dopaminergic treatment for PD 
Acetylcholine receptor antagonist, such as benzatropine, has been shown to 
relieve PD tremor (Brocks, 1999). However, the blockade of muscarinic cholinergic 
receptors globally expressed in CNS leads to the drowsiness, hallucination, delusion 
and failure of concentrating. Dryness of the mouth, blurring of vision, nausea and 
vomiting are also commonly observed (Brocks, 1999). Concerns that anti-cholinergic 
therapy may worsen the cognitive decline in PD patients limit the use of these drugs 
for PD therapy (Brocks, 1999). On the other hand, acetylcholinesterase inhibitors, 
such as rivastigmine have been introduced to relieve the dementia in PD (Poewe, 
2008). However, such acetylcholinesterase inhibition leads to a series of adverse 
effects such as transient tremor, due to the elevation of striatal acetylcholine levels or 
worsening of other PD motor symptoms (Oertel et al, 2008).  
Although the original clinical usage of amantadine was as an antiviral agent, it 
was accidentally discovered to have antiparkinsonian properties (Overstall and Clarke, 
2002). Amantadine is effective in improving Parkinsonian symptoms, especially for 
those patients who responsiveness to L-DOPA declines (Abdel-Salam, 2008). The 
mechanism for the antiparkinsonian effects of amantadine is not clear. However, it is 
believed that part of the action of amantadine is due its ability to block NMDA 
receptors in the BG. Amantadine also increases the synthesis and release of DA and 
has been reported to block the reuptake of DA, all of which contribute to its 
antiparkinsonian effects. However, the major problem with amantadine is that its 
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effects are short-lived in patients, being only effective for several months before 
tolerance develops. Furthermore, there are some common adverse effects with 
amantadine such as hallucination, confusion, depression and insomnia, which may be 
due to the blockade of NMDA receptors in other parts of the CNS (Rezak, 2007).  
 
1.4.6 Clinical limitation of current therapies 
The aforementioned drug approaches relieve only the Parkinsonian motor symptoms 
and are associated with long-term side effects. However, none of them successfully 
slow down the progression of PD. The degeneration of the dopaminergic system is 
believed to be the main reason for the reduction in responsiveness to these drugs. 
Hence, there is an urgent need to develop therapeutic approaches which can not only 
relieve the symptoms but also slow down the neurodegeneration of dopaminergic 
system. Recently, the neuroprotective effect of neurotrophic factors on human PD 
cases have been clinically examined (Peterson and Nutt, 2008). In one of the clinical 
studies the symptomatic relief was significant after the intraputaminal infusion of glial 
cell line-derived neurotrophic factors (GDNF, Gill et al, 2003). Furthermore, GDNF 
was observed to improve PD patients’ daily living capabilities whilst requiring less 
dopamine replacement therapy to manage their condition (Gill et al, 2003). 
Importantly, the loss of dopamine in putamen was reversed (Gill et al, 2003). 
Although there are some other reports disputing the clinical significance of 
neurotrophic factors in clinical PD, these clinical findings indicate that the 
neuroprotection could be a promising therapeutic approach for PD. Remarkably, the 
newly approved anti-Parkinson agent, rasagiline which is a MAO B inhibitor, was 
proved to be effective in improving motor symptoms and possibly in clinical 
neuroprotection which has been still under investigation (Schapira et al, 2008).  
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1.5 Mechanisms of neurodegeneration in PD  
Neuronal cell loss in PD is now thought to be a complex interplay of 
environmental, genetic and pathological processes including oxidative stress, 
mitochondrial dysfunction, altered protein handling and glutamate induced 
excitotoxicity (Mandel et al, 2003; McNaught and Jenner, 2001). Accumulation of 
these damaged cellular compartments leads to the cell death including apoptosis. In 
the following sections, we discuss these mechanisms of dopaminergic neuronal death 
in PD. 
 
1.5.1 Oxidative stress and mitochondrial dysfunction 
There is extensive evidence in the literature that enhanced oxidative damage 
occurs in the PD SNc to DNA, proteins and lipids possibly due to excessive formation 
of reactive oxygen species (ROS) such as superoxide or hydroxyl radicals and/or the 
inability to remove ROS due to deficiencies in antioxidants like reduced glutathione 
(Venarucci et al, 1999; Jenner, 2003). The neurodegenerative process in PD is also 
associated with an increase in iron levels, which in a reactive form can potently 
stimulate ROS formation (Lenaz et al, 2006; Chinta and Andersen, 2008). In addition, 
neurodegneration in the PD SNc is associated a mitochondrial dysfunction, principally 
a deficiency in complex I activity, which can itself lead to ROS formation or 
alternately increased ROS formation can lead to mitochondrial inhibition (Tretter et al, 
2004). Hence, there is a complex interplay between these two mechanisms both of 
which represent drug target sites to potentially slow down the neurodegenerative 
process in PD. 
 
1.5.2 Protein degradation dysfunction 
In many different neurodegenerative diseases, proteins aggregates are detected, 
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such as the LB in PD and senile plaques and neurofibrillary tangle in AD (Jenner and 
Olanow, 1998). Such formation of proteins aggregates is due to the accumulation of 
abnormal proteins generated within neurons. In such disorders, the proteasomal 
degradation of altered proteins in the neurons is defective; thus unwanted and 
damaged proteins are not degraded properly. Such altered proteins accumulate in the 
cytoplasm and ultimately form water-insoluble aggregates.  
In PD, dopaminergic neurons contain a large amount of oxidatively damaged 
proteins due to high levels of oxidative stress induced by catecholamine metabolism 
and the presence of catalytic iron. Such proteins, including Tau, α-synuclein and 
ubiquitin, are often tightly packed into protein inclusion identified as LB (Geetha et al, 
2008). Indeed, in the PD SNc, the ubiquitin dependent proteasome system (UPS) 
activity is inhibited due to the ATP depletion in the dopaminergic neurons resulting 
from mitochondrial dysfunction. Although the mechanism and role of the LB 
formation remains unclear, it is believed that the formation of LB prevents the 
accumulation of cytotoxic oxidized proteins (Sherman and Goldberg, 2001). LB are 
detected in both sporadic and some familial forms of PD (Jenner and Olanow, 1998) 
therefore, it is believed that the protein degradation dysfunction is one of the major 
pathological processes in PD.  
 
1.5.3 Neuroinflammation 
In PD the neurodegenerative process is associated with astrogliosis (Hirsch et al, 
2003). However the role of astrocytic activation is not clear. Traditionally activated 
astrocytes are associated with a neuroprotective response with the release of growth 
factors to stimulate tissue survival/repair (Hirsch et al, 2003), however recent 
evidence suggests that astrocytic activation can also mediate pro-inflammatory 
response which may endanger neurons (Rodrigues et al, 2001; Hirsch et al, 2005). 
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Indeed recently, the inflammation has been reported to be one of the pathological 
factors of the PD development (Hirsch et al, 2005). Neuronal loss in PD is also 
associated with an infiltration and activation of microglia (Hirsch et al, 2005; and 
Vroon et al, 2007). Furthermore, microglial activation is not only detected in the 
nigrostriatal tract but also the other regions affected in PD, such as olfactory bulb 
(Vroon et al, 2007), suggesting that microglia-mediated neuroinflammation may be an 
underlying mechanism in the neurodegenerative process in PD.  
Morphologically, both activated astrocytes and microglia have enlarged cell 
bodies and increased numbers of processes (Hirsch et al, 2003), which are found in 
human PD post-mortem tissue (Hirsch et al, 2005). Physiologically, the 
pro-inflammatory factors, including interleukin-(IL) 1β and 6, and tumour necrosis 
factor α (TNFα), possibly synthesized and released by astrocytes, induce microglial 
activation which may trigger neuronal cell death (Rosenberg, 2005). Interestingly, 
microglia express and release paracrine cytokines to further activate adjacent 
microglia and to stimulate infiltration of new microglia into the area (Tanuma et al, 
2006). Such pro-inflammatory factors are found in higher concentrations in the PD 
brain, further implicating a pathological role for glial mediated neuroinflammation in 
PD. In support of such a concept the intake of certain nonsteroidal anti-inflammatory 
drugs is associated with a lower incidence of PD. Therefore, anti-inflammatory drugs 
could be one approach for PD treatment.  
 
1.5.4 Glutamate toxicity  
Glutamate is the principle excitatory neurotransmitter in the CNS. 
Glutamatergic neurotransmission is mediated via the activation of two different 
families of glutamate receptors, namely the ionotropic and metabotropic glutamate 
receptors (iGluRs and mGluRs respectively, Salińska et al, 2005). iGluRs consist of 
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three receptor families, named after their selective pharmacological agonists, 
N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate 
(AMPA) and kainate (KA) receptors, all of which mediate fast synaptic transmission 
in the CNS (Hollmann and Heinemann, 1994; Ozawa et al, 1998). The activation of 
these receptors facilitates the influx of the cations, Ca2+ through NDMA receptor 
channel, whereas K+/Na+ for the AMPA and KA receptors. Activation of iGluR (and 
mGluR – see section 1.6) regulates the excitation of numerous BG nuclei and thus 
plays a central role in the normal functioning of the BG nuclei involved in movement 
control (Hauber W, 1998; Vezina and Kim, 1999). 
 
1.5.4.1 Principle and mechanism of glutamate mediated excitotoxicity 
Excessive glutamate activation of NMDA receptors can induce excitotoxicity 
which has been proposed to be a key feature of several neurological disorders, such as 
stroke, epilepsy, AD and PD (Hynd et al, 2004). Glutamate excitotoxicity develops 
following pathological increases in the extracellular concentrations of glutamate, 
which leads to a massive influx of Ca2+ into neurons (Meldrum and Garthwaite, 1990). 
Due to the accumulation of intracellular Ca2+, a series of stress-mediated cellular 
signalling pathways are activated, eventually leading to apoptosis.  
Glutamate excitotoxicity may occur through two mechanisms, referred to as 
“fast” and “slow” excitotoxicity, respectively (Cahusac et al, 1984). Fast 
excitotoxicity refers to toxicity resulting from direct activation of NMDA receptor and 
the Ca2+ influx (Pujol et al, 1999), whilst “slow excitotoxicity” is caused by 
mitochondrial dysfunction and positive feedback of the Ca2+ signal (Greenamyre et al, 
1999). Firstly, the direct effect of Ca2+ is to activate calcium-dependent proteolytic 
enzymes, such as calpains, non-lysosomal cysteine proteases (proteolytic enzymes), 
which then triggers both apoptosis and necrosis via caspase activation (Camins et al, 
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2006). Furthermore, calpains cleave other kinases, such as calmodulin dependent 
kinases (CaMKs) and PKC which are vital component in the apoptotic process 
(Colomer and Means, 2007; and Vittone et al, 2008). In addition, calpains cleave other 
signalling proteins such as p35 to form p25, which are also involved in the stimulation 
of apoptosis (Alvira et al, 2006).  
Other rapid cellular responses to the influx of Ca2+ are the activation of nitric 
oxide synthetases, particularly neuronal nitric oxide synthetase (nNOS). With the 
phosphorylation of NMDA receptor subunits by Ca2+-mediated PKC, nNOS binds to 
NMDA receptors connected by PSD-95 (a scaffold protein). Hence the NOSs activity 
was increased due to the higher concentration of Ca2+ influx at the NMDA receptor 
(Arundine et al, 2003; Cao et al, 2005). The synthesized NO activates downstream 
cGMP pathways which lead to apoptosis. Furthermore, NO react with superoxide, 
forming peroxynitrite (ONOO-), which leads to further oxidative damage within cells 
(Burley et al, 2007; Das et al, 2008; Obata, 2006). These early responses to the influx 
Ca2+ can initiate excitoxicity processes leading to cell death. The influx of Ca2+ and 
resultant dysfunction of mitochondria induces apoptotic signalling pathways, typically 
through the released of cytochrome c which activates caspase 9 and then caspase 3 via 
the formation of apoptosome consisting of apoptotic peptidase activating factor 1 
(Apaf-1; Shi, 2006). Furthermore, activation of MAPKs, responding to the influx of 
Ca2+, mediates apoptosis. For instance, c-Jun N-terminals kinase (JNK) and p38 
MAPK are thought to be involved in excitotoxicity mediated apoptosis (Chen et al, 
2003). Furthermore, the Ca2+-dependent formation of NO as mentioned above could 
also induce oxidative stress, activate calpains and further decrease mitochondrial 
function (Volbracht et al, 2001). Secondly, the rising intracellular levels of Ca2+ are 
modulated via mitochondria mediated reuptake of Ca2+ (Bernardi and Rasola, 2007; 
and Giorgi et al, 2008). This sustained reuptake of Ca2+ into mitochondria inhibits the 
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synthesis of ATP, since the mitochondrial membrane potential cannot be maintained 
for generation of ATP. Due to the ATP depletion, the membrane potential remains 
depolarization since the Na+/K+ ATP exchange pump is affected; thus, the neuron still 
remains depolarised and therefore glutamate signal remains as ‘on’ (Bers et al, 2002). 
Furthermore, the mitochondrial dysfunction leads to an increase in mitochondrial 
membrane permeability; therefore some mitochondrial proteins, cytochrome c and 
apoptosis inducing factor (AIF), leak from the mitochondria subsequently inducing 
apoptotsis (Nicholls and Ward, 2000). Therefore, mitochondrial dysfunction further 
magnifies the excitotoxicity.  
 
1.5.4.2 Glutamate excitotoxicity in PD and related models 
An increasing body of indirect evidence supports the concept of glutamate 
excitotoxicity in the pathogenesis of PD, such as increased glutamatergic activity in 
the BG in PD (Tremolizzo et al, 2004; and Jenner and Olanow, 2006). Furthermore, 
both the STN and PPN show increased metabolic activity under conditions of DA 
depletion in experimental models of PD (Oueslati et al, 2005). Therefore, overactivity 
in the STN and PPN could lead to the release pathological levels of glutamate in the 
SNc. In addition, dopaminergic neurons in the SNc express both NMDA and AMPA 
receptors (Ravenscroft and Brotchie, 2001), supporting the hypothesis that excessive 
levels of glutamate may trigger degeneration of SNc dopaminergic neurons via 
excitoxicity. In toxin based animal models of PD, the blockade of NDMA receptors or 
the surgical lesioning of the STN or PPN successfully attenuate the toxin induced 
degeneration of dopaminergic neurons in the SNc (Ampe et al, 2007; Stefani et al, 
2007). Consequently, glutamate mediated excitotoxicity is believed to contribute to the 
loss of SNc dopaminergic neurons in toxin based animal models of PD. In 
dopaminergic culture, such as PC12 cells (Czyzyk-Krzeska et al, 1996) and cerebellar 
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granule neurons (CGN; González-Polo et al, 2001), glutamate or NMDA induces 
apoptosis (Nishio et al, 2008; Giordano et al, 2008) 
Furthermore, deep brain stimulation (DBS) has been shown to provide effective 
improvements in Parkinsonian symptoms. The DBS electrodes are usually implanted to 
GPi, STN or PPN. However, the mechanism of DBS is still unclear. Most probably, the 
high frequency DBS current impulses induce a ‘current jam’ in the neurons to block 
neuronal transmission, thus relieving PD symptoms. In particular, DBS in the STN 
inhibits glutamate transmission to the SNc and GPi leading to the relief of Parkinsonian 
symptoms (Maesawa et al, 2004). However, DBS stimulation requires advanced 
technology, accurate surgical implantation of the electrodes and is associated with the 
possibility of brain damage. In addition, the DBS control unit is implanted under the 
skin in the chest and hence replacement of batteries with time can only be carried out 
surgically. Therefore DBS is not a common treatment for PD. However, this does give 
support for the glutamate hypothesis in PD and the potential for developing drugs to 
modify glutamate activity.  
 
1.5.4.3 Anti-Parkinsonian and Neuroprotective effect of glutamate antagonists 
As described previously, excitotoxicity may be one of the underlying 
mechanisms of the SNc degeneration in PD. Therefore, it could be predicted that 
glutamate antagonists might modulate the clinical symptoms of PD and eliminate 
glutamate toxicity. Indeed, anti-Parkinsonian effects of antagonists of iGluRs have 
been detailed in a number of in vivo studies (Dutra et al, 2002; Nash et al, 2002; and 
Périer et al, 2002). Blockade of NMDA receptors by MK-801 resulted in the reversal 
of reserpine-induced motor deficits (Dutra et al, 2002). Furthermore, administration of 
MK-801 prevented SNc dopaminergic cell death induced by 6-OHDA and MPP+ 
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(McNaught and Jenner, 1999). Non-subtype selective NMDAR antagonists such as 
amantadine and dextromethorphan are clinically effective at treating Parkinsonian 
symptoms, thus supporting the involvement of glutamate (Verhagen Metman et al, 
1998a; Hill et al, 2003). Interestingly, an anti-Alzheimer’s agent, memantine a NMDA 
partial agonist, has been shown to improve Parkinsonian symptoms independently 
without the presence of dopaminergic drugs (Merello et al, 1999). Therefore, 
pharmacological regulation of glutamatergic neurotransmission, particularly in 
striatum, STN and PPN, may be a promising approach to reduce the hyperactivity of 
the BG projection nuclei, thereby leading to an improvement in PD symptoms 
(Blandini et al, 2000).  
Several studies have demonstrated the neuroprotective effects of iGluR 
antagonists in in vivo and in vitro PD models, although the neuroprotective action of 
such compounds in the clinic is far from clear. It is only in recent studies that the 
neuroprotective actions of memantine are being evaluated clinically in PD (Aarsland 
et al, 2009; Lipton, 2006; and Lipton et al, 2007). One of these clinical studies 
demonstrated that memantine could actively modulate the neuronal activity and the 
hemodynamic response in the BG which may be relevant to the neuroprotective effect 
of memantine (Borghammer et al, 2008) 
 
1.5.4.4 Clinical limitations of targeting Ionotropic glutamate receptors  
Despite the symptomatic effects of iGluR antagonists, there are reports of a 
numbers of side effects in PD patients, some of which have prevented this approach 
from being further investigated. Firstly, psychological effects including hallucinations, 
agitation and failure in memory consolidation have been observed in clinical trials of 
NMDA antagonists (Muir and Lees, 1995). Furthermore, their usage can also induce 
peripheral sensory disturbances and autonomic/cardiovascular problems, such as 
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elevation of blood pressure (Muir and Lees, 1995). Such unwanted effects are due to 
the wide spread presence of NMDA receptors in the CNS and PNS and their role in 
many important functions like memory (Cull-Candy et al, 2001). Thus, competitive or 
non-competitive NMDA receptor antagonists result in global inhibition of total 
NMDA receptor activity in the brain, thus leading to severe extra-pyramidal effects 
(Lee et al, 2008). Furthermore, the therapeutic window for such antagonists was very 
narrow i.e. obtaining symptomatic relief of PD without inducing psychological side 
effects was almost impossible (Montastruc et al, 1992). Therefore, despite the efficacy 
of iGluR antagonists as symptomatic and neuroprotective agents in experimental 
models of PD, they are unlikely to be utilized further in the clinics (Muir, 2006). 
Furthermore, the therapeutic effect of the NDMA receptor antagonists remains 
controversial, as enhancement of Parkinsonian symptoms was observed in the MPTP 
primate model of PD (Fox et al, 2006) and no anti-parkinsonian effects was observed 
in another clinical study utilising memantine (Merello et al, 1999). These unexpected 
results could be due to the non-specific activation of the striato-cholinergic tract, 
which will counter-act the effects of dopamine in the BG. However, in similar studies 
to that described by Fox’s and colleagues, other researchers have demonstrated that 
NMDA receptor antagonists to be effective (Chassain et al, 2003; Wang et al, 2003). 
This could be due to the non-specific effect of certain NMDA receptor antagonist on 
other unknown target (Fox et al, 2006). In this respect, recent attention has shifted to 
the role of mGluRs in the BG nuclei in PD (Nicoletti et al, 1996; Marino et al, 2003; 
Conn et al, 2005).   
 
1.6 Metabotropic glutamate receptors  
There are eight different mGluRs subtypes classified into three main groups 
according to their genetic sequence homology and their pharmacological properties. 
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mGluRs are G-protein coupled receptors, the activation of which leads to the binding 
different G-proteins which trigger a variety of cellular events. Unlike iGluRs, certain 
mGluRs are highly expressed in the BG whilst there distribution in other brain 
structures, such as cortex, is limited (Melendez et al. 2004; Oueslati et al. 2005).  
 
1.6.1 Distribution and function of mGluR in the basal ganglia  
1.6.1.1 Group I mGluRs  
Group I mGluR consist of mGluR1 and 5, which are coupled to Gq-proteins 
(Francesconi and Duvoisin, 2000). The activation of group I mGluRs leads to the 
activation of phospholipase C which subsequently hydrolyze 
phosphatidylinositoldiphosphate (PIP3) into diacylglycerol (DAG) and inositol 
1,4,5-triphosphate (IP3). IP3 activates the release of Ca2+ from endoplasmic reticulum 
via Ca2+ channels. Both DAG and intracellular Ca2+ then activate the PKC (Morikawa 
et al, 2003). Furthermore, group I mGluRs modulate L-type voltage-gated calcium 
channel (VGCC) further increasing the level of intracellular Ca2+ (Choi and Lovinger, 
1996).  
Functionally, activation of group I mGluRs strengthens the excitatory signal of 
NMDA receptor via the enhancement of intracellular level of Ca2+ (Shigemoto et al, 
1993). Whilst presynaptic group I mGluRs facilitates glutamate release (Fazal et al, 
2003) thus enhancing the excitatory effects of glutamate. Additionally, evidence in the 
literature suggests that activation of group I mGluRs also leads to the transcription of 
certain genes for proteins involved in learning and memory such as c-fos (Mao and 
Wang, 2003).  
Within the BG, mRNA for group I mGluRs is expressed in the striatum, STN, 
pallidus, SNr and SNc (Messenger et al, 2002). In the striatum, both mGluR1 and 5 
amplify the glutamate signalling via the NMDA receptor on GABAergic neurons and 
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cholinergic inter neurons (Marti et al, 2003). In other parts of the BG, mRNA for 
mGluR1 and 5 is also expressed in STN neurons (Awad et al, 2000). In the GPe and 
SNr, activation of both mGluR1 and 5 increases neuronal excitability, thus enhancing 
the inhibitory output from the BG (Valenti et al, 2002). Dopaminergic neurons in the 
SNc express mRNA for both mGluR1 and 5 as assessed by in situ hybridization (Testa 
et al, 1994). In addition, in the striatum, mGluR1 is located presynaptically on 
nigrostriatal DA fibres, innervated by the corticostriatal glutamatergic fibres (Conn et 
al, 2005). Finally, excitatory transmission at subthalamonigral synapses is modulated 
by mGluR1 leading to the activation of dopaminergic neurons (Marino et al, 2006). 
Generally, group I mGluRs activation leads to the enhancement of the neural 
transmission by amplifying postsynaptic activity.  
 
1.6.1.2 Group II mGluRs  
Group II mGluRs (mGluR2 and 3) are coupled to Gi proteins and negatively 
regulate adenylate cyclase (AC) activity, suppressing cAMP formation (Schaffhauser 
et al, 1997). Group II mGluRs are found in both pre- and postsynaptic terminals on 
glutamatergic and GABAergic synapses (Shigemoto et al, 1997). Furthermore, 
activation of group II mGluRs inhibits the VGCCs and prevents the 
depolarization-dependent vesicular release of glutamate (Cartmell and Schoepp, 1997). 
Thus, group II mGluRs function as autoreceptors at glutamatergic synapses and as 
heteroreceptors at GABAergic synapses to negatively modulate both glutamate and 
GABA release (Wang et al, 2008b). Hence, group II mGluRs activation functions to 
prevent the build up of pathological levels of glutamate in the synaptic cleft, which 
could potentially cause excitotoxicity (Cartmell and Schoepp, 2000).  
In the striatum, activation of mGluR2/3 on presynaptic neurons of corticostriatal 
fibres negatively modulates their activity (Gubellini et al, 2004). In addition, 
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activation of presynaptic mGluR2/3 reduces excitatory drive from the STN to the SNr 
therefore modulating BG output (Murray et al, 2002). Furthermore, activation of 
mGluR2/3 negatively modulates glutamate transmission from the STN to the SNc 
(Wigmore and Lacey, 1998). Taken together, group II mGluRs activation tends to 
decrease neuronal activity through the indirect pathway, especially the 
subthalamonigral synapses and negatively modulates nigral neuronal excitability. 
 
1.6.1.3 Group III mGluRs  
Group III mGluRs (mGluR4, 6, 7 and 8) couple to Gi/o G-proteins and inhibit 
AC activity as do group II mGluRs (Schaffhauser et al, 1997). Similar to group II, 
group III mGluRs are also located presynaptically (Shigemoto et al, 1997), where they 
inhibit the glutamate release (Cartmell and Schoepp, 2000). Additionally, mGluR4 
and 7 are also found on both glutamatergic and GABAergic synapses, suggesting 
mGluR4 and 7 may also regulate GABA release (Bradley et al, 1999).  
By virtue of their negative modulatory role, it is noteworthy that both group II 
and III mGluRs also plays critical roles in synaptic plasticity, acting to shape the 
strength of glutamate transmission during LTP to prevent postsynaptic excitotoxicity 
Furthermore, activation of group II and III mGluRs is a critical requirement for the 
induction of LTD in the hippocampus and cerebellum, (Poschel et al, 2005; Naie et al, 
2006). Furthermore, group II mGluRs couple with different Gi/o proteins rather than 
only the Gi/o proteins for inhibiting AC (Wroblewska et al, 2006). Therefore, group 
III mGluRs may also mediate other cellular signalling.  
For group III mGluRs, the main role is to negatively modulate glutamate 
excitation and neurotransmitter release within the BG (Valenti et al, 2003). 
Importantly, activation of presynaptic mGluR4 at the striatopallidal synapse in the 
indirect pathway suppresses GABA release (Valenti et al, 2003; Conn et al, 2005). 
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Moreover, activation of group III mGluRs also reduces GABA release in the SNr 
(Wittmann et al, 2001). Importantly, both presynaptic and postsynaptic group III 
mGluRs, in particular mGluR4, also negatively modulate glutamate transmission from 
the STN to the SNc (Valenti et al, 2005).  
In situ hybridisation evidence suggests mGluR8 mRNA is expressed in the BG 
nuclei; particularly in the nucleus accumbens and SNc (Messenger et al, 2002) but to 
date no immunohistochemical studies exist describing the localization and function of 
mGluR8 protein (Valenti et al, 2005), although this does not preclude a functional role 
of this receptor in modulating glutamate neurotransmission in the BG.  
 
1.6.2 Metabotropic glutamate receptor expression in glial cells  
Glial activity plays a critical role in both neuroprotection and neurodegeneration. 
Microglia expresses all group I and II mGluRs subtypes and mGluR4 and 8 in human 
tissue (Geurts et al, 2003 and 2005). Recent evidence suggests that mGluRs are 
present on microglia and their activation is critical for the modulation of glial function 
(Geurts et al, 2008). Therefore, modulating glial mGluRs may also modulate 
pathological phenotype of microglia. Astrocytes also express all three groups of 
mGluRs, although mGluR3 and 5 are predominantly expressed on astrocytes (Aronica 
et al, 2005).  
In vitro evidence suggests that both mGluR3 and mGluR5 differentially 
modulate glutamate function by regulating the expression of the glutamate 
transporters in astrocytes and neurons (Aronica et al, 2005), suggesting that astrocytes 
play an important regulatory role in glutamate neurotransmission. Additionally, 
activation of glial mGluRs may influence the synthesis and secretion of trophic 
factors and/or cytokines. Indeed, activation of group III mGluRs on astrocytes inhibits 
the secretion of the inflammatory chemokines and cytokines, such as IL-6 (Besong et 
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al, 2003). Furthermore, activation of astrocytic group II and III mGluRs is associated 
with increased expression and secretion of certain trophic factors including 
transforming growth factor-β (TGF-β), nerve growth factor (NGF) and BDNF 
(Matarredona et al, 2001). Moreover, blockade of group I mGluRs has recently been 
suggested to increase BNDF expression (Legutko et al, 2006).  
Activation of microglial group III mGluRs reduces microglial toxicity to the 
co-cultured neuronal cell line in vitro and inhibits microglial proliferation (Taylor et al, 
2003). In contrast, activation of microglial mGluR2 promotes microglial toxicity and 
proliferation in vitro (Taylor et al, 2005). In addition, activation of PKC via the 
activation of mGluR5 is associated with secretion of inflammatory mediators such as 
tumour necrosis factor-α (TNF-α) from reactive microglia (Nakajima et al, 2003).  
 
1.6.3 Selective mGluR ligands as potential treatments for PD 
The focus of glutamate-modulation therapy has shifted to mGluRs, since they 
have been shown to modulate glutamate transmission rather than totally block its 
transmission (Conn and Pin, 1997). In addition, the proposed localization of mGluRs 
in the BG may generate a mild but significant therapy without the side effect 
associated with drugs targeting iGluRs (Marino and Conn, 2006). 
 
1.6.3.1 Potential anti-parkinsonian actions of mGluRs ligands  
The progressive delineation of the mGluRs distribution and function in the BG 
suggests that selective mGluRs ligands may induce anti-parkinsonian actions at 
several sites in the BG (Conn et al, 2005). Indeed, the inhibition of mGluR5 has been 
shown to normalize STN hyperactivity in the haloperidol animal model of PD (Valenti 
et al, 2003). Furthermore, blockade of striatal mGluR5 reduces the activity of striatal 
modulation of the indirect pathway and cholinergic interneurons. In support of this, 
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the results of several studies have demonstrated that mGluR5 antagonists, such as 
MPEP, are anti-Parkinsonian in 6-OHDA PD model of rats (Ossowska et al, 2001 and 
2003; Phillips et al, 2006). Furthermore, blocking mGluR1 at striatopallidal synapses 
produces anti-parkinsonian effects in the haloperidol PD model (Ossowska et al, 
2003). Activation of group II and III mGluRs also have anti-parkinsonian effects by 
reducing transmission at corticostriatal and subthalamonigral synapses in haloperidol 
PD models (Bradley et al, 1999; Rouse et al, 2000). In support of this, the 
administration of the mGluR2 and 3 agonists, such as 
(1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate-monohydrate 
(LY354740) and 1R,4R,5S,6R-2-oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate 
(LY379268) reverses parkinsonian symptoms in rodent model of PD (Murray et al, 
2002). Similarly, activation of group III mGluRs at striatopallidal synapses is 
anti-parkinsonian counteracting the increases in indirect pathway activity due to 
striatal DA depletion (Valenti et al, 2003). Consistent with this hypothesis, i.c.v 
injection of the board spectrum group III mGluRs agonist 
L-(+)-2-amino-4-phosphonobutyric acid (L-AP4) reverses akinesia in rodents (Valenti 
et al, 2003; MacInnes et al, 2004).  
Taken together, these findings provide substantial evidence to suggest that 
selective antagonists of group I mGluRs and selective agonists of group II and III 
mGluRs may be effective in relieving PD symptoms. 
 
1.6.3.2 Putative neuroprotective effects of mGluR ligands  
The above data supports the concept that the blockade of group I mGluRs and 
activation of group III mGluRs can not only reduce glutamate neurotransmission 
through the indirect striatal output pathway, but they may also reduce excitotoxic 
damage to nigral DA neurons (Nicoletti et al, 1996; Conn et al, 2005). Therefore, 
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aside from relieving the PD symptom, the modulation of mGluRs may be 
neuroprotective in PD. Indeed, pharmacological blockade of mGluR5 by MPEP has 
been shown to be neuroprotective against glutamate or NMDA-mediated toxicity in 
vitro cortical culture (O’Leary et al, 2000). Accordingly, the potential of this approach 
has been further confirmed by studies demonstrating neuroprotection in the MPTP 
animal model of PD (Battaglia et al, 2004). Furthermore, pharmacological activation 
of mGluR7 by high concentration of L-AP4 which could activates mGluR7 has also 
been shown to be neuroprotective against striatal glutamate or NMDA-mediated 
toxicity in CGNs which is recognized as a dopaminergic primary culture 
(González-Polo et al, 2001) and striatal GABAergic neurons (Lafon-Cazal et al, 
1999a and b). Furthermore, it has been suggested that the activation of astrocytic 
mGluRs may mediate dopaminergic neuroprotection in such models by facilitating the 
release of neurotrophic factors (Ferraguti et al, 2001). Moreover, the activation of 
group III mGluRs has been shown to inhibit microglial activation and the production 
of pro-inflammatory factors (Taylor et al, 2003). However, the role of astrocytes and 
microglia in mGluR mediated neuroprotection is far from clear. 
 
1.7 Parkinson related Experimental models 
In order to study the therapeutic effect of mGluRs ligands a number of PD 
animal models are available. Traditionally, dopaminergic specific toxins have been 
utilized to mimic certain aspects of PD in both animal and cell culture models. More 
recently, proteasome inhibitors have been controversially employed to mimic PD in 
animals since proteasome dysfunction is detected in PD. Genetic mouse models 
utilising the known gene defects in familial PD have also been established but these 
have been disappointing since they fail to mimic the clinical/neuropathological 
features of PD 
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1.7.1 Dopaminergic specific toxins animal models 
6-OHDA was found to be catecholaminergic specific toxins by Ungerstedt 
(1968). 6-OHDA is transported into the dopaminergic neurons via the DA transporter 
(DAT). Intracellular 6-OHDA inhibits mitochondrial complex I and V and induces the 
oxidative stress with the Fenton reaction involving Fe ions, which subsequently leads 
to cell death (Linert et al, 1996). Neuroinflammation is also detected in 6-OHDA PD 
model. Since 6-OHDA is specific and efficient at inducing dopaminergic neuronal 
death, it is widely utilize for modelling PD features in cell and animal models 
(Lehmensiek et al, 2006). However, 6-OHDA does not mimic all of the pathological 
characteristics, such as the formation of LBs nor does it produce a good behavioural 
PD phenotype in animals (Schober, 2004). Furthermore, 6-OHDA does not penetrate 
the BBB, hence needs to be administered stereotaxically under anaesthesia.  
As mentioned in section 1.1.4, MPTP was accidentally found to be 
dopaminergic specific toxin when found as a contaminant of a narcotic drug 
(Langston and Ballard, 1983). MPTP is converted to be MPP+ by the astrocytic 
MAO-B. The latter species being transported into dopaminergic neurons by DAT 
which subsequently inhibits mitochondrial complex I. Thus, the dopaminergic 
neuronal death is triggered by ATP depletion and oxidative stress (Blum et al, 2001; 
and Przedborski et al, 2004). Unlike 6-OHDA, MPTP can be systemically 
administered but only certain strains of mice are sensitive to this toxin, whilst rats are 
insensitive (Przedborski et al, 2004). Apart from this, functional recovery is observed 
3-5 weeks after MPTP administration to primates (Mounayar et al, 2007). Rotenone is 
another toxin found in some pesticides (Sherer et al 2003). Like MPTP it gains entry 
into the dopaminergic neurons via DAT and subsequently inhibits the ATP formation 
from the mitochondria (Betarbet et al, 2002). Similarly, rotenone can penetrate across 
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the BBB, allowing it to be systemically administered. Due to the ease of implanting 
indwelling cannulae for focal administration of drugs in rats versus mice and the 
stability of the 6-OHDA, in this study we decided to employ the 6-OHDA rat model 
of PD.   
 
1.7.2 UPS inhibition models 
Since the ubiquitin-dependent proteasome system (UPS) for protein degradation 
has been shown to be defective in PD, inhibition of UPS becomes another approach to 
mimic PD condition in experimental models utilising synthetic proteasome inhibitors 
(PSI), epoxomicin and lactacystin (McNaught and Jenner, 2001). These toxins inhibit 
the activity of proteasomes; thus damaged and oxidized proteins accumulate and 
induce cell death. Additionally, the inhibition of proteasome induces the LB-like 
structure formation which is absence in 6-OHDA model (Schober et al, 2004). PSI 
and epoxomicin, but not lactacystin, are brain penetrant allowing systemic 
administration (Mathur et al, 2007 and Kadoguchi et al, 2008). However, controversy 
surrounds the PSI model with several research groups failing to replicate the initial 
findings of McNaught (McNaught et al. 2001). Despite not being able to cross the 
BBB stereotaxic administration has recently been shown to produce a reliable and 
stable model of PD combining selective dopaminergic neuronal loss with altered 
protein deposition (McNaught et al. 2002; Zhu et al. 2007). Hence, in the final section 
of this thesis the lactacystein model was utilised to investigate whether mGluR 
ligands found to be neuroprotective in the 6-OHDA were also neuroprotective in this 
second model.  
 
1.8 Aims of study  
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From a previous study in this group, L-AP4, a broad-spectrum group III mGluRs 
agonist, was shown to be neuroprotective against the 6-OHDA neurotoxicity. L-AP4 
activates mGluR4, 6, 7 and 8, hence it is not clear which mGluR subtypes is involved 
in the neuroprotective effects of L-AP4. However, L-AP4 has a higher affinity for 
mGluR4 and 8, hence these receptor subtypes may be responsible for the 
neuroprotective effects. Therefore in these studies we aim to investigate the 
neuroprotective effects mGluR4 and 8 activation. 
Aims were:  
1. To examine the putative neuroprotective effects of focally administered 
mGluR4 allosteric modulator, PHCCC, and the mGluR8 agonist, (S)-DCPG, in 
rodent 6-OHDA model of PD and to determine if these effects are 
concentration-dependent and receptor-mediated.  
2. To examine whether PHCCC can enhance the neuroprotective effects of a low 
concentration of L-AP4 in the 6-OHDA lesion model, since PHCCC is a 
positive allosteric modulator of mGluR4 at which L-AP4 is an agonist. 
3. To examine whether the neuroprotective effects of intranigral administration of 
both PHCCC and (S)-DCPG can be replicated following their systemic 
administration in the 6-OHDA model of PD.  
4. To examine whether any neuroprotective effects of PHCCC and (S)-DCPG 
observed in the 6-OHDA model can be replicated in a second PD model, 
namely in the lactacystin lesion model.  
5. To examine the cellular localisation of mGluR4 and mGluR8 in the SNc 
utilising dual immunofluoresence, with the concept that knowledge concerning 
the distribution of mGluR4 and mGluR8 on the cellular components of the SNc 
(neurons, glia and astrocytes) would allow us to postulate possible mechanisms 
for any neuroprotection observed.  
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Chapter 2: Materials and Methods 
2.1 Overview 
 
2.1.1 Background of 6-OHDA-induced dopaminergic toxicity 
A reliable in vivo experimental model of PD was essential for the pathological and 
pharmacological studies outlined in this thesis. In order to mimic the degeneration of 
nigrostriatal system of PD, extrinsic toxins were applied to the nigrostriatal system to 
induce selective loss dopaminergic neurons. Currently, there are a number of different 
toxins utilized in the experimental models for PD, such as 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine 
(6-OHDA), rotenone etc. Although the different toxins are associated with different 
mechanisms they all produce relatively selective nigrostriatal dopaminergic 
degeneration. In the main part of the study, the neuroprotective effects of mGluR 
ligands were tested in the 6-OHDA lesion model.  
The neurotoxicity of 6-OHDA to dopaminergic neurons was first demonstrated 
by Ungerstedt in 1968 (Ungerstedt, 1968). 6-OHDA is the hydrolyzed analogue of 
dopamine. 6-OHDA utilises the dopamine uptake transporter (DAT) to gain access to 
the dopaminergic neurons and induces the cytotoxicity (Lehmensiek et al, 2006). The 
auto-oxidation of 6-OHDA produces the hydroxyl free radical and paraquinone, both 
of which could induce oxidative stress to dopaminergic neurons. In the Fenton 
reaction, the H2O2 formed in this reaction is reduced by the Fe2+ which is itself 
oxidized to Fe3+, producing the hydroxyl radical. Fe3+ is then reduced by 
neuromelanin to form Fe2+ (Fig. 2.1). By this non-enzymatic reaction, the oxidative 
species accumulates inside the dopaminergic neurons leading to cell death (Naoi et al, 
2005; Obata, 2002). The reactive oxygen species (ROS) and reactive nitrogen 
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6-OHDA   + O2    6-OHDA˙       +  H2O2    ----(1) 
 
6-OHDA˙ + O2    6-OHDA quinone  +  H2O2    ----(2)  
(1)+ (2),  
2 (6-OHDA) + 2 O2  2(6-OHDA quinone) + 2 H2O2 
 
where 6-OHDA˙ is the semiquinone free radicals 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
H2O2         HO.  + HO- 
Fe2+    e-    Fe3+   
Melanin 
Fig 2.1: Non-enzymatic oxidation induced by 6-OHDA. A) The oxidation of 
6-OHDA by superoxide with the production of quinone and hydrogen peroxide 
(H2O2). B) Fenton reaction of oxidation of peroxide with the formation of hydroxyl 
radicals with iron ions as the catalyst.  
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species (RNS) could induce oxidative damage of proteins, DNA and phospholipids in 
cell membrane of dopaminergic neurons in the substantia nigra par compacta (SNc). 
Such cellular damage and oxidative species will then activate the cascade of 
signalling pathways inducing programmed cell death, known as apoptosis. For 
instance, the activation of c-Jun N-terminal kinases (JNKs) is involved in the 
6-OHDA-induced apoptosis of dopaminergic neurons of the SNc (Pan et al, 2007 a & 
b). Similarly, another mitogen activating protein kinases (MAPs), p38 MAPK, could 
also be involved since this is activated by 6-OHDA in cell culture models (Hwang and 
Jeong, 2008). The activation of protein kinase C (PKC) mediated by caspase-3 has 
also been shown to be involved in the 6-OHDA apoptotic model in primary 
mesencephalic culture (Gomez-Lazaro et al, 2008). The oxidative damages of nucleic 
DNA may also provoke apoptosis in order to prevent the extension of genetic 
mutation. Damaged DNA triggers p53 mediated signals for DNA repair, however the 
failure of DNA repair will result in apoptosis (da Costa et al, 2003; Liang et al, 2007). 
Interestingly, 6-OHDA could also induce caspase 3-independent apoptotic pathways 
in which the activation of caspase 3 and 9 is absent (Ebert et al, 2008), implying that 
6-OHDA can also induce atypical apoptosis. Indeed, both necrosis and apoptosis is 
detected in several neurodegenerative disorders, including PD (Jellinger, 2000). In 
addition, the neurodegenerative process in PD is also associated with an inflammatory 
process (McGeer and McGeer, 2007; Rogers et al, 2007) where there is a proliferation 
of activated microglia in the SNc. Under some circumstances microglial activation 
may serve to promote tissue repair by the removal of cell debris and trigger growth 
factor secretion. However, excessive activation may promote the release of 
pro-inflammatory factors such as cytokines and free radicals that may trigger 
bystander neuronal damage. This phenomenon is also observed in 6-OHDA and other 
toxins models of PD (Nagatsu and Sawada, 2005). Although inflammation may not be 
64 
 
the initial triggering factor stimulating SNc neuronal loss the presence of activated 
microglia with a proinflammatory phenotype in PD may impede tissue repair and lead 
to bystander destruction of healthy dopaminergic neurons (McGeer and McGeer, 
2007).  
Dopamine depletion in striatum induced by the unilateral injected 6-OHDA 
induces asymmetric motor abnormalities in rat PD model, which can be enhanced by 
the administration of amphetamine to induce rotations (Carman et al, 1991; Cousins et 
al, 1993). Without dopamine associated modulation, the motor function control in the 
basal ganglia in the lesion hemisphere fails. Thus, motor functions of ipsilateral and 
contralateral sides are different, resulting in asymmetric phenotype of motion.  
There are several different techniques to generate a lesion to the nigrostriatal 
system using 6-OHDA. 6-OHDA can be administered to striata, rich in dopaminergic 
terminals projecting from the SNc. After uptake by DAT, 6-OHDA can induce slow 
retrograde degeneration of dopaminergic nigrostriatal neurons. Alternately, 6-OHDA 
can be injected into the medial forebrain bundle (MFB) which is bundle of the 
dopaminergic fibres projecting from the SNc to striata. The MFB also contains fibres 
projecting from the ventral tegmental area (VTA) which forms part of the mesolimbic 
system. Similarly, 6-OHDA is taken up by DAT expressed on dopaminergic fibres 
where it can induce a bi-direction degeneration of the dopaminergic neurons. Finally, 
6-OHDA can be administered to the SNc directly where it induces a more rapid 
degeneration. Although the striatal lesion model produces a more progressive model 
due to the size of striatum, a single 6-OHDA injection will only produce a very partial 
and regional loss of SNc dopaminergic neurons. Alternately, multiple injection sites 
can be used for 6-OHDA administration into striatum but this can lead to enhanced 
mechanical damage which is not desirable. Whilst the MFB and direct SNc 
administration produces more rapid cell loss this is across the whole SNc and can be 
65 
 
titrated to produce a partial lesion mimicking the early clinical stages of PD. In these 
PhD studies, for practical reasons, for the focal mGluR studies 6-OHDA was 
administered directly into the SNc via the implanted cannulae which also allowed the 
direct administration of mGluR ligands to the SNc. Whilst in the studies where 
mGluR ligands were administered peripherally, 6-OHDA was administered to the 
MFB thus avoiding any potential mechanical damage to the SNc. 
Although 6-OHDA has been widely adopted for the study of PD by different 
groups, there are some drawbacks with the 6-OHDA rodent model. Firstly, 6-OHDA 
cannot cross the BBB and must be administered by stereotaxic injection under 
anaesthesia. Secondly, 6-OHDA toxicity does not mimic all the clinical and 
neuropathological features of PD. Indeed, 6-OHDA is only selective for dopaminergic 
neurons and is without the appearance of the Lewy bodies which are characteristic of 
idiopathic PD. Bilateral lesioning with 6-OHDA to the basal ganglia induces a very 
rapid lesion with a high mortality rate. Accordingly, the unilateral injection on either 
side of the brain was adopted in this study. However, despite the above criteria that 
must be taken into account when utilizing this model of PD it does give a very 
reproducible model of dopaminergic cell loss and the mechanism of 6-OHDA toxicity 
i.e. oxidative stress, has been extensively documented in PD. In addition, neuronal 
cell loss in the 6-OHDA models is also associated with an innate inflammatory 
response, iron accumulation and mitochondrial dysfunction, which are also features 
observed in idiopathic PD. Consequently, 6-OHDA has been successfully utilized as a 
model of PD to explore molecular mechanisms of disease and act as a test bed for 
pre-clinical studies in conjunction with other models since no one animal model 
mimics all the features of PD. 
 
2.1.2 Background of Lactacystin-induced dopaminergic toxicity  
66 
 
After the discovery of a defective protein handling by the ubiquitin proteasome 
system (UPS) in PD, proteasome inhibitors were utilised to generate an animal model 
of PD (Bové et al, 2006). Such a model was reported to produce a wide spread of 
neurodegeneration involving other neuronal systems as seen in PD with the 
appearance of Lewy bodies. The enzymatic degeneration of damaged/unwanted 
proteins by the UPS involves a number of steps where they are firstly ‘labelled’ by 
conjugating with multiple ubiquitin molecules, known as ubiquitination. During this 
process, firstly the ubiquitin-activating enzyme (E1) activates ubiquitin by 
phosphorylating the cytosol-free ubiquitin molecules. Subsequently, the 
phosphorylated ubiquitins is transferred to the ubiquitin-conjugating enzyme (E2). 
Finally, the activated ubiquitins are ligated to the lysine residues of the target proteins 
by the ubiquitin ligase (E3). Afterward the ubiquitinated proteins are then digested to 
non-functional short peptides by proteasome which is a giant multicatalytic complex 
(Fig. 2.2). Altered proteins are toxic to cells and hence the UPS system is essential for 
the well being of cells. In addition, the mutation of some UPS-related genes occurs in 
familial forms of PD. For instance, the mutant of Parkin, one of the ubiquitin ligases, 
results in a failure to ligate ubiquitin to the target protein. Furthermore, mutation of 
ubiquitin C-terminal hydrolase L1 (UCH-L1) was found in some familial cases of PD, 
the wild type of which recycle ubiquitin after the protein degradation (Setsuie and 
Wada, 2007). Therefore, the mutant form of UCH-L1 reduces the ubiquitination of 
unwanted proteins. Another mutation found in familial PD is in the gene that encodes 
for the protein α-synuclein, the mutated form of which resists UPS degradation since 
the primary sequence of α-synuclein could not be recognized by UPS and the 
aggregated α-synuclein inhibits proteasome activity (Burke, 2004). Interestingly, the 
SNc is one of the brain regions requiring a high rate of UPS-mediated protein 
degradation due to the oxidative stress produced during the dopamine degradation. 
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Fig 2.2: The ubiquitination and proteolytic mechanism. A) Ubiquitination by 
E1, 2 and 3. B) The unwanted proteins were labelled by poly-ubiquitin molecules. 
C) The proteolytic process by proteasomes. D) The unwanted protein could be 
degraded by non-proteolytic pathway. (Kaiser and Huang, 2005) 
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However, the SNc has a relatively low proteasome activity when compared to other 
parts of brain. Also as we age, a predisposing factor in PD, the functional capacity of 
UPS declines which could result in the accumulation of altered proteins within 
neurons which could further inhibit the actions of UPS. 
In order to establish models mimicking the UPS-related PD models, certain 
inhibitors of UPS were developed, such as MG-132, epoxomicin, lactacystin and 
synthetic proteasome inhibitor (PSI). PSI has been the most widely studied inhibitor 
of UPS however variable results were obtained after system administration, with some 
researchers demonstrating a model which represents many features of PD (Bové et al, 
2006) whilst just as many researchers have shown that PSI produces no toxicity 
(Kordower et al, 2006). The lack of reproducibility has thrown serious doubt on the 
use of the UPS inhibitors as a reliable model of PD. However, recently the focal 
administration of the UPS inhibitor lactacystin to the nigrostriatal system has been 
shown to produce a more stable and reproducible model of PD (Zhu et al, 2007). The 
neurotoxic effects of lactacystin were firstly demonstrated in PC12 cells, a 
catcholaminergic cell line (Keller et al, 2000) and subsequently in an in vivo PD rat 
model demonstrating the induction of the dopaminergic degeneration (McNaught et al, 
2002). Lactacystin covalently binds to the catalytic subunits of UPS, preventing the 
accessibility of the ubiquitinized protein to the catalytic sites. This leads to the 
accumulation of unwanted proteins in the cytosol which subsequently lead to the 
oxidative stress and the triggering of cell death pathways. In the currently study 
lactacystin was infused to the SNc and MFB, where it diffuses into the dopaminergic 
neurons   leading to cell death. In this PhD study the lactacystin model will also be 
utilised, as a confirmatory model, to investigate the neuroprotective effects of drugs 
working at mGluR sites.  
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2.1.3 Outline of this chapter 
In this chapter, the methods utilised in three different sections of study are 
described. Firstly, the neuroprotective properties of mGluRs ligands focally injected 
to the SNc via indwelling cannulae in a 6-OHDA rodent model are detailed. Focal 
administration was chosen for a number of reasons. Firstly we wanted to investigate 
the neuroprotective effects from the action of mGluR ligands in the SNc alone 
without possible confounding actions in other parts of the CNS. Secondly, due to their 
chemistry mGluR ligands are renowned for their poor ability to cross the BBB e.g. 
L-AP4, or at the start of this project their ability to cross the BBB was not known, 
hence compounds were administered directly into the CNS. Subsequently, when 
DCPG and PHCCC had been shown to cross the BBB in adequate concentrations we 
replicated such neuroprotection studies in 6-OHDA utilising peripheral administration 
of mGluR ligands. In addition, the cost of mGluR ligands is very high, precluding 
their chronic peripheral use in neuroprotection studies. Consequently, in the final 
section of this project focal administration of mGluRs ligands was again used in the 
lactacystin models where chronic administration was required. 
 
2.2 Neuroprotective study of Focal injection of mGluRs ligands 
2.2.1 Overview 
In order to demonstrate the neuroprotective potential of the activation of the 
mGluR4 and mGluR8 receptors expressed in the SNc, 
N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carbox amide (PHCCC) and 
(S)-3,4-dicarboxyphenylglycine ((S)-DCPG) which are selective at these two 
receptors respectively were administered to the left SNc sub-chronically via a 
stainless steel cannula which were implanted just above the SNc. After recovery from 
the surgical implantation of the cannulae, the cannulated rats were dosed with the 
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ligands for 7 days. The 6-OHDA was administered one hour after the first injection of 
the ligand. At the end of experiments, the rats were sacrificed. The brains were 
removed and dissected for further analysis. The pathological changes in dopaminergic 
neurons and other cell types, including astrocytes and microglia, were analyzed by 
immunohistochemistry conducted on the fixed cryopreserved cryostat cut sections. To 
examine the functionality of the dopaminergic nigrostriatal system, striatal level of 
monoamines were measured by high performance liquid chromatography (HPLC). In 
order to investigate the proposed mechanism of the neuroprotection, the localization 
of mGluR4 and 8 receptors in the SNc was studied by dual immunofluoresecent 
staining. From these studies the cellular evidence of the neuroprotection in the SNc 
and the functional changes of the nigrostriatal system could be illustrated. The 
experimental design is schematically shown in Fig 2.3.  
 
2.2.2 Animals 
Male Spraque-Dawley rats were supplied by Harlan (UK). Rats weighing 
210-230g were housed in groups of 3 or 4 at 21±1ºC on a 12-hour light/ dark cycle 
(lights on 07:00 and off 19:00). Only male rats were housed in the procedure room. 
An acclimatization period of 7 days after deliver from supplier was utilized. The 
weight of every rat was monitored regularly. Standard rat diet and drinking water was 
available ad libitum. All animal experiments were carried out in accordance with the 
Home Office Animals (Scientific Procedures) Acts, UK, 1986.  
 
2.2.3 Surgery: Implantation of guide cannulae for intranigral focal injection 
Anaesthesia was induced, in a Perspex anaesthesia chamber, utilising 5% 
isoflurane with a 2L/min oxygen flow rate. Rats were placed in the stereotaxic frame  
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Rats came in 
to the animal 
facility 
Surgery of 
Implantation of 
cannulae 
Infusion of 
6-OHDA or 
vehicle 
Injection of 
mGluR ligands 
Last 
injection at 
8th day 
Postmortem 
procedures 
10 days 7 days 1 hour 7 days 1 hour 
Snap frozen of 
striata 
Snap frozen 
Immunohistochemistry (IHC) 
Immunofluroscent (IF) staining 
Fixation of 
hindbrains by 
PFA 
HPLC 
Cryoprotection in 
30% sucrose 
5-7 days 
48 hours 
Fig 2.3: The experimental schedule of the study of focal injection of mGluRs 
ligands 
1st focal 
Injection of 
mGluRs 
Ligands 
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on a heated mat controlled by a rectal thermal probe. During the surgery, anaesthesia 
was maintained utilising 1-3% isoflurane with a 1-1.5L/min oxygen flow rate. 
Subcutaneous injections of 25µl Marcain (Astrazeneca, UK) for local analgesia was 
administered beneath the scalp at four different sites around incision site. To prevent 
dehydration during surgery, 5ml of 4% glucose in 0.18% saline (Baxter, UK) was 
intraperitoneally administered. A 2-2.5cm midline incision was then made along the 
shaved scalp and the skin was retracted to expose the parietal bones for drilling. The 
muscle and connective tissue was scrapped away to provide a suitable surface on the 
skull for anchoring the cannulae. Bregma was located according to the following 
diagram (Fig 2.4). 
Using bregma as a reference point, a burr hole was drilled using a dental drill 
just above the SNc at the following coordinate, anterioposterial: -3.0mm and 
mediolateral: +2.5mm, relative to bregma; dorsoventral: -7.6mm, ventral to dura, 
according to the anatomical atlas by Paxinos and Watson (Paxinos and Watson, 1986). 
The coordinate utilised in this study for the SNc had been previously used in other 
studies in our laboratory and other institutions (Datla et al, 2001; Evans et al, 1975; 
Lin and Lipski, 2001; Vernon et al, 2005, 2007 a & b and 2008). Before the 
implantation of the guide cannulae, three cheese-head screws (0.32 cm diameter and 
0.625 cm length) were inserted into the skull around the cannulae site so as to help 
secure the cannulae in position. Afterward, a 26-gauge stainless steel guide cannulae 
(Plastics One, USA) was stereotaxically implanted unilaterally just above the left SNc 
via the drilled hole. Internal cannulae (33-gauge) for injection extend 1mm below the 
tips of guide cannulae allowing injection into the SNc. The indwelling cannulae were 
kept patent by inserting 32-gauge stainless steel dummy cannulae (Plastics One, USA), 
which was cut to the same length as the guide cannulae. The amount of resin 
anchoring cannulae was limited to approximately 2.5cm in diameter 
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Fig 2.4: Bregma is the crossing point of the three different skull plates as 
labelled in the figure. ((Paxinos and Watson, 1986) 
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which was large enough to anchor the cannulae in place yet small enough not to 
irritate the animal. Post-surgery animals were placed in a temperature controlled 
recovery chamber for 30-60 minutes, when fully conscious animals were placed into 
individual cage. A mashed diet was provided immediately. Three days after surgery 
the weight of rats increased back to the level before surgery. Those rats which failed 
to gain weight after surgery were removed from the study.  
 
2.2.4 Schedule of Drug administration: Focal Infusion of mGluR ligands directly 
to the SNc and the induction of the lesioning of the nigrostriatal system by 
6-OHDA 
All injections were made on the conscious rats. Tested compounds and toxins were 
infused via the internal cannulae inserted into the implanted cannulae. The unilateral 
lesions of the left SNc were made by infusing of 12µg 6-hydroxydopamine 
hydrobromide free base (6-OHDA) in 4µl 0.1% ascorbic acid/ 0.9% saline solution 
via 33-gauge stainless steel internal cannulae inserted into guide cannulae. The 
internal cannulae were attached to a flexible tubing (lumen size: 0.5mm in diameter; 
Portex, UK) connected to a 25µl 700 series Hamilton microinjector. Mounted in a 
KDS micropump (KD Scientific Inc., USA) programmed with an injection rate at 
2µl/min. After the 2 min injection, in order to prevent reflux of the injected solution, 
the injection cannula was left in place for a further 2-minute equilibration period.  
In order to study the focal neuroprotective properties of mGluR ligands the test 
ligands were infused directly to the left SNc via the implanted cannulae by a similar 
procedure to the infusion of 6-OHDA. The dosing procedure was initiated 10 days 
post cannulae implantation. The stock solution of ligands was serially diluted on the 
day of injection. (S)-DCPG (stock concentration 50mM), 
(RS)-a-Methylserine-O-phosphate (MSOP; stock concentration 50mM) and 
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L-(+)-2-amino-4-phosphonobutyric acid (L-AP4; stock concentration 5mM) dissolved 
in 0.9% NaCl saline to produce a stock solution (pH 7.4) which were serially diluted 
in sterile saline to produce the desired concentrations for intranigral injection. Stock 
solutions were stored in the -80ºC freezer used within 3 months according to the 
manufacturers’ instruction (Tocris, UK). According to manufacturer’s instructions 
(Tocris, UK) it was recommended that PHCCC, the neuromodulator of mGluR4, 
should be dissolved in the dimethyl sulfoxide (DMSO) as a stock concentration of 
100mM whilst the working solution was serially diluted by 0.9% NaCl. However, in 
initial studies the small amount of DMSO in the injection medium resulted in 
bleeding through the guide cannulae in some animals. This was deemed unsatisfactory 
and in further experiments, PHCCC was dissolved in 1.5M NaOH, neutralized by 
1.5M HCl with the neutralized product diluted with 0.9% NaCl. The stock 
concentration was 100mM.  
The first injection of mGluR ligands was given one hour prior to the infusion of 
12µg 6-OHDA in 4µl via cannulae. The experimental rats then received daily 
unilateral injection of the test compounds via the cannulae for 7 consecutive days.  
For control groups, rats received the drug vehicle injections either saline or DMSO 
containing vehicle for 7 consecutive days. The rats were sacrificed by decapitation 
one hour after the last injection.  
 
2.2.5 Brain tissue preparation for analysis of integrity and functionality of the 
nigrostriatal tract 
2.2.5.1 Post-mortem procedure and the preparation of striata for the measurement of 
monoamines content 
At the end of study period, rats were killed by gradually increasing level of CO2 
in an enclosed chamber. The brain was quickly removed onto a chilled platform from 
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the decapitated rats. For the cannulated rats, the caps of resin with guide cannulae 
were removed carefully in order to prevent mechanical damage by the bending 
cannulae. Using a rodent brain matrix, each brain was then cut coronally at -4.16 mm 
from bregma of the level of infundibular stem to produce a fore- and hindbrain block 
containing striatum and SNc respectively. Visual verification of cannulae placement 
was performed at this stage of the dissection. The track of cannulae with hemorrhage 
could be observed at the stereotaxic levels close to the SNc (approximately about 
-4.16). Any rats with misplaced cannulae were removed from the study. In this study, 
there were about 4% of rats discarded due to the misplacement of cannulae. From the 
forebrain block, left and right striata were quickly dissected out using the corpus 
callosum as a guide, snap frozen on dry ice and stored at -80ºC until biochemical 
analysis of monoamine content. The striata were assessed no later than two weeks 
after dissection.  
 
2.2.5.2 Tissue preservation and sectioning  
Hindbrain blocks were fixed in 4% paraformaldehyde (PFA) in PBS (pH 7.4) for 
5-7 days subsequently. Blocks were cryoprotected in 30% sucrose in PBS for 48 hours 
until blocks were observed to have sunk. Blocks were then snap frozen in isopentane 
pre-chilled on dry ice, stored at -80ºC until subsequent cryostat sectioning. On the day 
of sectioning blocks were equilibrated in the cryostat (Bright Instrument, UK) for 2 
hours before sectioning. After embedding the brain block in mounting medium, 
coronal sections were cut on cryostat maintained at -22ºC, throughout the rostral to 
caudal extent of the SNc (-4.8 to 6.30 mm from bregma, Paxinos and Watson, 1986). 
Again during cryostat sectioning, validation of the cannulae tract was carried out by 
visual observation. Another 5% of samples were removed due to the misplacement of 
cannulae. 20µm sections were collected for free floating immunostaining whilst 15µm 
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sections were for the fluorescent immunostaining. All sections were stored in PBS 
(pH 7.4) containing 0.05% sodium azide (NaN3) as a preservative until the 
immunostaining. At each of the five different anatomical levels throughout the SNc 
(A-E), 6 sections sequentially were collected into PBS with NaN3 and reserved 
individually in the wells of 24-well plates. The immunostaining was performed in the 
24-well plates. Alternate sections were immunostained for TH and NeuN respectively; 
i.e. the first, third and fifth sections were stained for TH whilst the second, fourth and 
sixth sections were stained for NeuN.  
 
2.2.6 Histological analysis: Avidin-Biotinylated enzyme Complex (ABC) 
Immunohistochemistry  
Generally, in order to identify different cell types, cell-type specific proteins 
were detected by means of immunohistochemistry. Firstly, specific proteins expressed 
on the cellular membrane or in cytosol were detected by primary antibodies (Ab) 
directed to the specific antigen. The primary antibodies were then targeted with 
specific secondary antibodies that were conjugated with biotin. Finally, the 
immuno-detection was amplified by combining biotin with the avidin-biotinylated 
horseradish peroxidase complex (ABC). Avidin binds to biotin irreversibly, therefore 
attaching the ABC complex to the secondary antibody. The peroxidase on the ABC 
complex converts the 3’3-diaminobenzidine (DAB) substrate to be a brown product 
which precipitated adjacent to the horseradish peroxidase (Fig 2.5). 
Residues of NaN3 were removed from the stored free-floating tissue sections by 
washing three times in PBS (pH 7.4) for 5 min. The endogenous peroxidases activity 
in tissue sections was deactivated by incubating sections in 3% hydrogen peroxide 
solution in PBS for 30min, so as to reduce background staining. Residue of hydrogen 
peroxide was then removed by three washes with 0.1% Triton X-100 in PBS for 5 min  
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Fig 2.5: The schematic principle of immunohistochemistry. The target 
protein (red triangle) in or on the cells is detected by the primary antibody 
(blue). Afterward, the secondary antibody (green) binds to the primary antibody 
in order to amplify the immuno-signal. The fluorescent or other staining tag on 
the secondary antibody will be developed to illustrate this immunocomplex to 
indicate the expression of target protein in the cells.  In this study, the biotin 
conjugated on the secondary antibody will bind to the horseradish peroxidase 
which will develop the signal with the DAB substrate. For the fluorescent 
staining, the fluorescent molecules conjugated will develop the signal as 
exposed under the fluorescent microscope (figure sourced from Abcam, Inc.).  
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each. Triton was utilized to increase tissue permeability to the detection antibodies. 
Non-specific binding was blocked by incubating the sections with normal sera from 
same species of animals in which secondary antibody was generated. The standard 
blocking medium contained 5% normal sera diluted in PBS with 0.1% triton X-100 
for 60 minutes. Subsequently, without further washes in PBS, sections were incubated 
at room temperature overnight with primary antibodies diluted in PBS/0.1% Triton 
X-100 containing 5% normal sera (Table 2.1 for Ab concentration). Tissue sections 
were then washed in PBS/0.1% Triton X-100 3 times on the following day. Sections 
were then incubated with biotinylated secondary antibody diluted in the blocking 
medium for an hour (Table 1 for Ab concentration). After 3 washes in PBS/Triton 
X-100 for 5 min, sections were then incubated in the avidin-biotin complex (ABC) for 
one hour. This solution was prepared 45 minutes prior to the incubation according to 
the manufacturer’s instructions (Vector labs, UK). Complex of the immunoproteins 
was visualized by utilizing a 3’3-diaminobenzidine (DAB) substrate kit. The DAB 
substrate solution was prepared according to the manufacturer’s instructions. DAB 
was diluted into the buffer provided at a final concentration of 5nmol/ml. 1% 
hydrogen peroxide was added just before use. The color development was quenched 
by washing the developed sections in distilled water briefly. Immuno positive cells 
were stained with a brown precipitate. Stained sections were then mounted onto the 
gelatin-coated slides and dehydrated through a series of graded ethanol solutions. 
After de-fatting with xylene, sections were cover slipped using DPX mounting 
medium.  
The same protocol was adopted for all the immunohistochemical staining in this 
study. However, different antibodies were utilized for different target marker proteins 
for different cell types summarized in Table 2.1.  
In this study, tyrosine hydroxylase (TH) the rate-limiting enzyme in monoamine  
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 Primary antibodies  Biotinylated 
Secondary antibodies 
(Vectorlabs, UK) 
Normal Sera (5%; 
Vector labs, UK) 
TH neuron Rabbit anti-rat TH  
(1:2000) (Chemicon, UK) 
Goat anti-rabbit IgG  
(1:200) 
Goat 
General 
neuron  
Mouse anti-rat NeuN (1:2000) 
(Chemicon, UK) 
Horse anti-mouse IgG  
(1:200) 
Horse 
Astrocyte Mouse anti-rat GFAP (1:2000) 
(Sigma, USA) 
Horse anti-mouse IgG  
(1:200) 
Horse 
General 
microglia 
Mouse anti-rat CD11b (OX42) 
(1:1000) (Serotex, UK)  
Horse anti-mouse IgG  
(1:200) 
Horse 
Activated 
microglia  
Mouse anti-rat RT1b (OX6) 
(1:1000) (Serotex, UK) 
Horse anti-mouse IgG  
(1:200) 
Horse 
α-synuclein Mouse anti-rat α-synuclein 
(1:200) (BD, USA) 
Horse anti-mouse IgG  
(1:200) 
Horse 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1: The usage of primary and secondary antibodies, and sera used in 
the immunohistochemistry. 
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synthesis was utilised as the cellular marker for monoaminergic neurons, although in 
the substantia nigra there are only dopaminergic neurons. Therefore, rabbit anti-rat 
TH Ab, biotinylated goat anti-rabbit IgG and normal goat serum were utilized. As a 
marker of all neuronal types NeuN, a neuronal specific nuclear protein, was utilized. 
Thus, in NeuN staining, all neuronal nuclei in the SNc were marked to indicate the 
change of the total number of neurons. In order to elucidate the proliferation and 
morphological changes of astrocytes, an Ab specifically directed against Glial 
Fibrillary Acidic Protein (GFAP) was utilised. Microglia were detected by the CD11b 
protein expressed on the membrane. Anti-CD11b monoclonal antibody, clone OX42 
(Serotec, UK), was adopted for targeting the general (unactivated and activated 
microglia) microglia. In order to determine whether the microglia were activated, the 
class II major histocompatibility complex (MHC) protein, RT1B, expressed on the 
surface was targeted by the monoclonal anti-RT1B, clone OX6 (Serotec, UK). OX42 
was for the morphological illustration whilst OX6 was for quantitative analysis. For 
the monoclonal antibodies for NeuN, OX42 and OX6, biotinylated horse anti-mouse 
IgG was used meanwhile normal horse serum (NHS) was diluted in PBS with Triton 
X-100 for nonspecific binding sites blocking.  
 
2.2.7 Image capture of immunostained tissue sections and analysis  
Quantitative counting of the number of TH-, NeuN-, OX6 and 
GFAP-immunoreative (IR) cells in the SNc was then preformed manually, utilising an 
analogue JVC camera (JVC, Japan) attached to the Nikon Eclipse E800 microscope at 
x 200 magnification. The image of contralateral and ipsilateral sides of sections was 
analyzed using Image Pro Plus v 5.0 image analysis software (Media Cybernetics, 
Finchampstead, UK).  
For the quantification of TH-IR neurons, each level of the SNc was delineated 
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from the VTA by reference to the brain landmarks including the medial terminal 
nucleus (MTN) (Iravani et al, 2002). Only dopaminergic neurons in this defined area 
of interest (AOI) were counted. This AOI was consistently applied to all sections on 
the same level for manual counting of TH-IR cells. Only cells that were intact, 
displaying a robust soma and staining with axonal processes were counted. For each 
animal, sections displaying the five different levels of the SNc defined by the AOI 
were counted according to the description in Carman et al. 1991. A minimum of three 
sections from each animal were counted for each level, these counts were further 
pooled to give a total mean cell count for the contralateral and ipsilateral hemispheres 
in each animal, and then the mean was taken across the treatment group. In order to 
ease the comparison between different treatment groups, the cell counts were also 
converted to the percentage decrease of TH cells by this computation equation: 
(contralateral count - ipsilateral counts)/contralateral counts x 100%. Blinded analysis 
of TH-IR cells was performed by covering the original slide identification with 
stickers with random numbers (starting from 1) so as to prevent bias. The original 
labels of groups and rats were unknown during the manual counting. After the 
quantification, the original labels were revealed so as to allow statistical analysis.  
The adjacent sections of those stained with anti-TH were then immunostained 
with anti-NeuN. The AOI from the original TH sections on the same level were 
applied to the NeuN sections. Only cells displaying round and intact neuronal nuclei 
were counted. Similarly, only neuronal nuclei in the SNc highlighted by the AOI were 
counted, whilst those in other parts of brain hemispheres, especially the VTA, were 
excluded. A minimum three sections from each animal which are adjacent to the 
TH-stainned sections were counted for each stereotaxic level. All counting was 
performed in the blind fashion as mentioned above. The total amount of neurons was 
expressed as the mean count NeuN-IR cells of the contralateral and ipsilateral 
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hemisphere in each animal, and then mean across the treatment group. The percentage 
decrease of NeuN-IR cells was calculated using the equation mentioned above.  
The manual counting of GFAP-IR cells was carried out in the same manner. 
Only the intact cell bodies with plenty of processes presenting an asterisk-like cell 
shape were counted. A minimum 10 sections from each animal was counted which 
was then pooled to give a mean number of astrocytes for each animal and then 
meaned across the treatment group. All counting was performed in the same blind 
fashion as above. The percentage increase of GFAP-IR cells was calculated as the 
following equation: (Ipsilateral counts-Contralateral counts)/ contralateral counts X 
100%. For the quantification of activated microglia OX-6-IR cells were quantified. 
Only OX6-IR microglia presented with intact cell bodies and network-like processes 
were counted. All counting was performed in the same blind fashion. A minimum 10 
sections from each animal was counted which was then pooled to give a mean number 
of activated microglia for each animal and then meaned across the treatment group. 
The fold increase of OX6-IR cells was calculated as the following equation: 
Ipsilateral counts/contralateral counts. Aside from the quantitative analysis of 
different cell types, contralateral and ipsilateral images of TH & NeuN 
immunopositive cells were captured by using a JVC analogue camera attached to 
Nikon Eclipse E800 microscope at x 40 final magnifications. For GFAP- and OX42- 
and OX6-IR cells, images were captured at x 400 magnifications.  
 
2.2.8 Biochemical analysis of the integrity of the nigrostriatal tract: measurement 
of the concentrations of striatal monoamines by HPLC 
The monoamine content in striata was analyzed by high performance liquid 
chromatography with electrochemical detection (HPLC-ECD). The snap frozen striata 
were weighed, thawed and homogenized in 500µl of ice-cold homogenization buffer 
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(50mM trichloroacetic acid, 0.5mM EDTA and 8mM sodium metabisulfite, pH 2.0) 
containing 5nmol/ml 3,4 dihydroxynezylamine hydrobromide (DHBA, Sigma, UK) as 
an internal standard to correct for any loss of monoamines during extraction. Striatal 
tissue was homogenized by a sonication probe (Sonicprep, UK) for 20 seconds 
followed by a 10-min extraction of the monoamines on ice. Samples were then 
centrifuged at 13,000rpm at 4ºC for 10min, supernatant was then filtered utilising 
syringe filters (4mm diameter, 0.2mm pore size; Whatman, USA) and supernatant was 
then loaded onto the autosampler of the HPLC system which was set at 5ºC (Gina 50, 
Dionex, UK). The content of dopamine (DA), dihydroxyphenylacetic acid (DOPAC) 
and homovanillic acid (HVA) was analyzed by using a phosphate buffered mobile 
phase (0.1M potassium dihydrogen orthophosphare, 0.1mM EDTA, 3.25mM octane 
sodium sulfate and 18% methanol, pH 2.75) at a flow rate of 1.2ml/min on an Altex 
Ultrasphere 3µm ODS column. The system provided an even flow rate controlled by 
the computer-monitored pump (Dionex, UK). The monoamine level were quantified 
by an electrochemical analytical cell attached to a Coulochem II electrochemical 
detector (ESA analytical, UK) with one electrode set at -0.2mV while the other set at 
+ 0.34mV with respect to the palladium reference electrode.  
All data analysis was performed using PC-based Chromeleon Software (Dionex, 
UK). The specific concentration was adjusted according to the weight of striata and 
expressed as ng monoamine/mg of striatal tissue. The percentage decrease or loss of 
monoamine was calculated by the equation: (Contralateral level -Ipsilateral 
level)/contralateral level x 100. The turnover ratio of dopamine was indicated by sum 
of level of the metabolites, in pmol/mg ([DOPAC]+[HVA]) divided by the 
concentration of DA. Monoamine concentrations were calculated utilizing standard 
which containing DA, DOPAC, HVA, 5-hydroxyindoleacetic acid (5-HIAA) and 
serotonin (5-HT) as the reference. The concentration of all species was 50pmol/ml.  
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2.2.9 Immunofluorescent Staining: localization of the mGluR4 and 8 in different 
cell types in the SNc 
The principle of immunofluoresecent staining is similar to that of general 
immunoperoxidase immunohistochemistry described above. Instead of biotinylated 
secondary antibodies, fluorescent molecules conjugated to secondary antibodies are 
employed with the fluorescent signal being visualized under a fluorescent microscope. 
The excitation filter in microscope is designed to allow specific wavelengths of UV 
light, which could be absorbed by the UV-sensitive groups (fluorochromes) of the 
fluorescent molecule conjugated to the secondary antibodies, to pass. Subsequently, 
the light emitted from specimen passes through the emission filter at selective 
wavelengths of light so as to give a single coloured image through to the eyepieces of 
the microscope. For the double immunofluorecent staining conducted in this study, 
two different fluorescent molecules tagged secondary antibodies were applied. Two 
different colours which overlay could indicate the co-localization of two different 
marker proteins visualizing the two different marker proteins in the same cell.  
In this study, mGluR4 and mGluR8 were located in different cell types in the 
SNc by means of double immunofluorescent staining combined with 
immuno-markers of different cell types, including TH-, GFAP-, OX42- and OX6-IR 
cells. Free-floating sections of 15µm thickness were pre-treated with 0.1% 
borohydrate for 10 minutes in order to diminish background fluorescence. The 
non-specific binding sites were blocked by incubation with 5% normal sera diluted in 
PBS with 0.1% Triton X-100 from animals in which secondary antibodies are raised. 
In this double staining technique, two different secondary antibodies are combined. 
Therefore, two different normal sera were co-incubated during the blocking step. 
After the blocking by the sera-containing PBS/Triton X-100, sections were incubated 
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with mixture of two primary antibodies in 0.1% Triton X-100/PBS overnight. The 
dilution of each different antibody was summarized in Table 2.2. After three washes 
with normal PBS, sections were incubated with the mixture of fluorescent tagged 
secondary antibodies diluted in 5% normal sera in 0.1% Triton X-100/PBS for an hour. 
After a further three washes of normal PBS, sections were counter-stained with 
Hoechst dye which stains the nuclei. Finally, sections were mounted with anti-fading 
medium (Vector labs, UK) and coversliped. Fingernail vanish was applied around 
coverslip to prevent the dehydration.  
In order to localise mGluR4 in the different cell types in the SNc, a rodent 
specific mGluR4 antibody raised in goat or rabbit presented in purified form of IgG 
was employed. mGluR8 was detected by a rodent specific mGluR8 antibody raised in 
guinea pig and presented in a sera form (Chemicon, UK). Except for TH, antibodies 
of GFAP, OX42 and OX6 were mouse monoclonal antibodies. Thus, goat raised 
anti-mouse IgG conjugated with FITC and normal goat serum was utilised. The same 
rabbit anti-TH as in TH immunohistochemistry was utilised. Goat anti-rabbit IgG 
conjugated with Alex Fluor was utilized for the detection of primary antibodies, 
whilst normal goat serum was required for blocking of the non-specific binding sites 
inside cells. Furthermore, the dilution of each antibody used was optimized in a 
preliminary series of experiment. Dilutions were summarized in Table 2.2.  
Fluorescent stained sections were observed under the Nikon Eclipse E1000 
fluorescent microscope (Nikon, Japan). The sections were exposed to the UV light 
transmitted through different filters chosen according to the fluorescent molecules 
tagging the secondary antibodies. Images were captured by the QICAM FAST camera 
and utilising Image Pro Plus (version 5.1) software, different fluorescent images was 
overlay, indicating the co-expression of the mGluR4 or 8 and the different cellular 
markers. Cell bodies were counter-stained by Hoechst Staining indicating the nuclei.  
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Primary antibodies 
 
Secondary antibodies 
Normal Sera 
(5%; Vector 
labs, UK) 
mGluR4 (vs 
TH neuron) 
 
(vs other 
cell types) 
Goat anti-mGluR4 (1:500) 
(Santa Cruz, USA) 
 
Rabbit anti-mGluR4 (1:500) 
(Upstate, USA) 
Texas Red tagged donkey anti-goat 
IgG (1:500) (Santa Cruz, USA) 
 
Cy3 tagged Goat anti-rabbit IgG 
(1:200) (Upstate, USA) 
Donkey 
 
 
Goat 
 
mGluR8 
 
Guinea pig anti-mGluR8 
(1:500) (Chemicon, UK) 
Cy3 tagged donkey anti-guinea pig 
IgG (1:200) (Chemicon, UK) 
Donkey 
 
TH neuron 
 
Rabbit anti-TH (1:1000) 
(Chemicon, UK) 
Alex Fluor tagged Goat anti-rabbit 
IgG (1:200) 
Goat 
 
Astrocyte 
 
Mouse anti-GFAP (1:1000) 
(Sigma, UK) 
FITC tagged goat anti-mouse IgG 
(1:200) (Chemicon, UK) 
Goat 
 
General 
microglia 
Mouse anti-CD11b (OX42) 
(1:500) (Serotec, UK) 
FITC tagged goat anti-mouse IgG 
(1:200) (Chemicon, UK) 
Goat 
 
Activated 
microglia 
Mouse anti-RT1b (OX6) 
(1:500) (Serotec, UK) 
FITC tagged goat anti-mouse IgG 
(1:200) (Chemicon, UK) 
Goat 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2: The usage of primary and secondary antibodies, and sera used in the 
immunofluorsecent staining. 
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2.3 Neuroprotective studies utilising peripheral injections of mGluRs 
ligands 
 
2.3.1 Overview 
During the course of these PhD studies DCPG and PHCCC was demonstrated to 
cross the BBB and hence were subsequently administered peripherally in 
neuroprotection studies. One day before the infusion of 6-OHDA to the L-MFB, one 
dose of PHCCC and (S)-DPCG was administered. On the day of 6-OHDA injection 
and the following three consecutive days after surgery, experimental rats received two 
i.p. injections of the mGluR ligands per day. Rats were terminated 9 days after 
6-OHDA lesioning. The striata and hindbrains blocks containing the SNc were 
harvested for further immunohistochemical and HPLC-ECD analysis as detailed 
above (see section 2.2.8). The experiment design was summarized in Fig 2.6.  
 
2.3.2 Surgery: injection of 6-OHDA to the left medial forebrain bundle (L-MFB) 
Induction of anaesthesia was achieved utilising 5% isoflurane with oxygen flow 
rate of 2L/min, whilst maintenance anaesthesia was achieved with 1-3% isoflurane 
with oxygen flowing rate of 1-1.5L/min during the surgery procedure. Rats weighing 
230-250g on the day of surgery were anesthetized and placed on a Kopf stereotaxic 
frame with a temperature-controlled mat. In order to prevent the dehydration during 
the surgery, an i.p. injection of glucose saline (5ml, i.p.; 0.18% sodium chloride and 
4% glucose; Baxter, U.K.) was administered. 0.1ml local anaesthetic, Marcain, was 
injected subcutaneously at four sites around the area of incision. On the shaved scalp, 
a single midline incision about 2-2.5cm was made and the skin was retracted to 
expose the skull. The muscle and other connective tissue on the skull were removed 
by a scalpel until the bregma was clearly visualized. Bregma was located as 
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Fig 2.6: The experimental schedule of the study of systemic injection of mGluRs 
ligands 
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described (section 2.2.3). Taking bregma as the reference point, a burr hole was 
drilled using a dental drill at the level above L-MFB, located according to the 
coordinates: anterior/posterior: -2.2mm, medial/lateral: +1.5mm, taking bregma as the 
reference point whilst dorsoventral: -7.9mm taking dura as the reference point 
(Paxinos and Watson, 1986; Fig 2.7). The stereotaxic frame was mounted with a 500 
serial Hamilton microinjector and lowered to the correct co-ordinates for the L-MFB 
via the drilled hole. 4µl of 6-OHDA (12µg total dissolved in 0.1% ascorbic acid/0.9% 
sodium chloride solution; Sigma, U.K.) was injected into the L-MFB over a 2 minutes 
period followed by another 4 min equilibration to prevent reflux of the 6-OHDA up 
the needle tract. For one of the sham control groups, the Hamilton microinjector was 
placed to the L-MFB for 4 min without injection any solution. In another sham 
control group, Hamilton microinjector was inserted to the L-MFB and 4µl of 
6-OHDA vehicle (0.1% ascorbic acid/0.9% NaCl solution) was injected alone over 4 
min, with the needle being left in place for a further 4 min. After removal of the 
syringe, antibiotic powder was applied on the skull surface and the scalp sutured 
closed. Postoperative care included the individual caging and a mashed diet for the 
first two days after surgery.  
 
2.3.3 Drug treatment 
(S)-DCPG was dissolved in 0.9% NaCl solution with concentration of 30mg/ml 
which was then diluted to 15 and 5mg/ml by 0.9% NaCl saline. PHCCC was diluted 
in 40% DMSO and serially diluted with 0.9% saline to 10, 3 and 1mg/ml. The 
(S)-DCPG and PHCCC were administrated intraperitoneally one day before surgery 
of the intracerebral injection of 6-OHDA into L-MFB. On the day of surgery and for 
the following 3 consecutive days, DCPG or PHCCC was administered twice a day. 
These two injections were separated by 6 hours (9:00 for the first doses; 15:00 for the  
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Fig 2.7: The microinjector for 6-OHDA injection was placed to the left median 
forebrain bundle (L-MFB) according to the coordinate: -2.2mm from Bregma, 
+1.5mm from Bregma and -7.9mm from dura. (Paxinos and Watson, 1986)  
DV: -7.9mm 
ML: 1.5mm 
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second doses). During the dosing procedure, the weight of rats was monitored 
everyday which was the reference for the injected volume. The exact volume for 
injection was adjusted in a ratio of 1ml/kg. For vehicle groups, experimental rats were 
received the DMSO containing vehicle only since there were a limitation in the 
number of animals available for the experiment. In order to show that the DMSO 
containing vehicle administered systemically has no detrimental effect on the extent 
of the 6-OHDA lesion in the SNc, we compared the DMSO vehicle to a saline vehicle 
group from an additional study I carried out that was not associated with these PhD 
studies   
 
2.3.4 Tissue collection 
At the end of the study animals were sacrificed, brains removed and treated as 
before with the hindbrains being fixed in 4% PFA dissolved in PBS. After 
cryo-protection in 30% sucrose in PBS, hindbrain was snap frozen in pre-chilled 
isopantene and stored in -80ºC. 20µm free floating cryostat cut sections from 5 
different stereotatic levels (A-E) were prepared and stored in PBS with 0.1% sodium 
azide (pH 7.4) for the immunohistochemistry. The striata in forebrain were dissected 
on the chilled platform snap frozen in dry ice. The frozen striata were stored in -80ºC 
for the measurement of monoamine content by HPLC as described in section 2.2.8.  
 
2.3.5 Immunohistochemistry and image analysis 
The free-floating immunohistochemistry analysis was conducted by the same 
method described previously (refer to section 2.2.6). The dopaminergic neurons were 
characterized by the TH and NeuN antibodies, while astrocytes and activated 
microglia were detected by GFAP and OX6 antibodies respectively. The antibodies 
and serum utilised is summarized in Table 2.1. TH, NeuN, GFAP and OX6-IR cells 
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were manually counted in the method described in section 2.2.7.  
 
2.3.6 Biochemical analysis of the integrity of the nigrostriatal tract: measurement 
of the striatal monoamines by HPLC 
The striatal level of monoamine level was measured by HPLC with 
electrochemical detection as described previously (section 2.2.8). Briefly, the frozen 
striata was thawed, weighed and homogenized. The monoamine was extracted by the 
homogenizing medium for 10 minutes, followed by centrifugation. Supernatant was 
filtered and load onto the autosampler. DA, DOPAC and HVA were separated by the 
HPLC column with 18% methanol containing phosphate-buffered mobile phase. The 
amount of DA, DOPAC and HVA was analyzed by the electrochemical detector. The 
exact concentration of the monoamines was computed according to external standard.  
 
2.4 Neuroprotective study of mGluRs ligands in Lactacystin lesioned 
model 
To study the neuroprotective effect of mGluRs ligands in the lactacystin PD 
model, mGluRs ligands and lactacystin were infused via the implanted cannulae. Due 
to the poor bioavailability of lactacystin, this ubiquitin-proteasome selective inhibitor 
has to administer directly into the CNS. The inhibition of ubiquitin-proteasome by 
lactacystin consequently induces dopaminergic neuronal death by the accumulation of 
toxic proteins. Pilot studies were utilised to determine the optimal dose of lactacystin 
and exposure period needed to create a partial lesion to the SNc. At the end of the 
studies, rats were sacrificed and brains processed further immunohistochemistry to 
identify cellular markers as well as HPLC determination of the striatal monoamine 
content.  
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2.4.1 Surgery of cannulae implantation and intra-L-MFB injection of lactacystin 
and Intranigral injection of lactacystin and ligands  
Utilising similar surgical procedures as described in section 2.2.3, guide 
cannulae were implanted just above the SNc. After the 10-day recovery period, 
5-7µg/4µl lactacystin was infused to the SNc. Lactacystin was dissolved in DMSO 
(final concentration DMSO: 10%) and then diluted with 0.9% NaCl saline to the 
desired concentration. Lactacystin solutions were prepared freshly before injection. 
The cannulated rats were exposed to different concentrations of lactacystin for 
different time points in order to estimate the optimized condition for the 
neuroprotective study of  (S)-DCPG and PHCCC. (S)-DCPG and PHCCC were 
infused to the left SNc via cannulae 7 days after the administration of lactacystin 
(refer to section 2.2.4). Ligands were injected daily until the end point of the study (14 
days). On the other hand, in order to compare the model of intranigral injection to that 
of intra-L-MFB injection of lactacystin another group were received the surgical 
injection of lactacystin (7µg/4µl) and exposed for 3 weeks. At the end of the study, 
rats were terminated and brain tissue was harvested for further analysis. The dosing 
schedule is detailed in Fig 2.8 and 2.9. 
 
2.4.2 Immunohistochemical analysis of dopaminergic neuron and glial cells and 
the biochemical analysis of striatal dopamine by HPLC 
At the end of each study animals were sacrificed and the brain processed as 
detailed in section 2.2.5. Dopaminergic neurons, microglia and astrocytes were 
identified utilising immunocytochemical techniques on cryostat cut sections as 
previously described (2.2.6) whilst striatal dopamine content was determined by 
HPLC with electrochemical detection as previously described (2.2.8). 
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Fig 2.8: The experimental schedule of the study of lesion of intra-L-MFB 
injection of lactacystin.  
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2.4.3 Characterization of Lewy bodies: Double immunohistochemistry of 
α-synuclein and tyrosine hydroxylase 
One of the advantages of the lactacystin models is that dopaminergic neuronal 
death is associated with the appearance of aggregations of the unwanted proteins in 
form of Lewy bodies (LB) like inclusions. Lewy bodies like inclusions can be 
identified immunohistochemically by one of their major components, α-synuclein. 
Dual immunohistochemistry was utilised, with antibodies against α-synuclein and TH, 
so as to identify protein inclusions within dopaminergic neurons. Dual 
immunohistochemistry was performed with a modification to the method described in 
section 2.2.6. The dopaminergic neurons were firstly labelled with the TH antibody by 
the same method as in section 2.2.6. After the visualization of the TH-IR cells by 
brown DAB substrate peroxidation, the immunohistochemistry for α-synuclein was 
subsequently conducted and hence visualized by the peroxidation of DAB substrate 
with nickel solution (0.1%) enhancement which produces a black staining to 
distinguish the intracellular α-synuclein inclusion within TH-IR brown neurons. The 
antibodies and sera utilised are summarized in Table 2.1.  
 
2.5 Statistical Analysis 
NeuN- and TH-IR cells in both lesioned and contralateral sides of all treatment 
groups was expressed as the mean number of cell count± S.E.M or percentage change 
± S.E.M in relation to the control (unlesioned) side of brain, as indicated in different 
sections. GFAP- and OX6-IR cells were demonstrated as the mean number of cell 
count ± S.E.M or percentage/fold increase ± S.E.M. For the monoamines level, the 
data was presented as the percentage decrease of monoamine ± S.E.M. For the 
turnover ratio of striatal dopamine (T/O), the data was expressed as the turnover level 
± S.E.M. The calculation of turnover was shown below:  
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{[DOPAC (nmol/mg) + [HVA (nmol/mg)]} 
[DA (nmol/mg)] 
In all figures, n values (number of animals in each treatment group) were shown in the 
caption of each figure. The mean values of each group were the average of the mean 
values of each individual rat in the same groups.  
Data was analyzed by a series of statistical analysis. By the one-way analysis of 
variance (ANOVA) among different treatment groups, statistic significance among 
different treatment groups was analyzed under the assumption of random sampling 
and normal distribution. In the analysis of PHCCC vs L-AP4 and MSOP vs ligands, 
the significance was analyzed by the two-way ANOVA. Subsequently, there was the 
post hoc analysis in form of a Bonferroni test made between the lesioned sides of drug 
treatment groups to vehicle group. Unpaired Student’s t tests were made between 
lesioned and contralateral sides in the same groups. Where alternative tests are 
utilised they are indicated in the relevant sections. The significant differences were 
shown by expressing the P value as P<f0.01 (indicated as *, # or †), 0.001 (**, ## or 
††) and 0.0001 (***, ### or †††), which was also annotated in the figures or tables. 
All statistical analysis was performed using Software package of GraphPad Prism 
version 4.00 (GraphPad Software, USA). 
 
2.6 Materials and Sources 
Metabotropic glutamate receptor ligands for focal injection were obtained from 
Tocris Cookson (Bristol, UK) whilst those for peripheral injection were obtained from 
Ascent Scientific (Bristol, UK). Stainless steel cannulae were purchased from Plastics 
One (Roanoke, USA). 6-hydroxydopamine and mouse anti-GFAP antibodies were 
supplied by Sigma-Aldrich Chemical Co. Ltd (Poole, UK). Rabbit anti-TH, guinea 
pig anti mGluR8, mouse anti-NeuN primary antibodies, Cy3 tagged donkey 
anti-guinea pig and FITC tagged goat anti-mouse IgG were purchased from Chemicon 
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Ltd. (Chandlers Ford, UK). Rabbit anti-mGluR4 was obtained from upstate (Herts, 
UK). Another primary antibody of mGluR4 for Mouse anti-CD11b (OX42) and 
mouse anti-RT1b (OX6) IgGs were ordered from Serotec (Kidlington, UK). 
Biotinylated goat anti-rabbit and horse anti-mouse IgG, NGS, NHS, Vectastain Elite 
ABC staining kits and Vectastain VIP kits were obtained from Vector laboratories 
(Peterborough, UK).  Texas Red tagged donkey anti-goat IgG was purchased from 
Santa Cruz biotechnology (CA, USA). Pore filters for HPLC were purchased from 
Whatman (via VWR International, Lutterworth, UK). All other chemicals and 
reagents were supplied by either Sigma-Aldrich Chemical Co. Ltd. (Poole, UK) or 
VWR International Ltd. (Lutterworth, UK) unless otherwise stated in the text.  
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Chapter 3: Neuroprotective effect of the allosteric potentiator of 
mGluR4, PHCCC, on 6-OHDA rat model of PD 
 
3.1. Introduction 
3.1.1 Neuroprotective properties of group III mGluRs  
There is a growing body of evidence that supports the concept that over activity 
of glutamatergic pathways originating from the STN contributes not only to the 
clinical features of PD but may also hasten the demise of the remaining dopaminergic 
neurons in the SNc. Thus drugs which modulate glutamate activity may not only 
modulate the symptoms of the PD but may also potentially slow the disease down. 
This concept was initially tested with NMDA receptor antagonists, which produced 
positive symptom/disease modification in animal models of PD but in humans 
produced unwanted psychological effects due to the wide distribution of NMDA 
receptors. Unlike NMDA receptors, mGluRs have a much more defined CNS 
distribution, mainly being in the basal ganglia, and hence may be a more subtle way 
of modulating glutamate activity without triggering unwanted side effects (Kew, 2004; 
Ossowska et al, 2007; Senkowska and Ossowska, 2003).  
mGluRs can be divided into three distinct sub-groups, with Group I mGluRs 
facilitating glutamates activity whilst Group II and III mGluRs decrease glutamate 
activity. Indeed, recent studies in this group and others have demonstrated that 
antagonism at Group I mGluRs and agonism at Group II & III mGluRs reverses 
behavioural deficits but is also neuroprotectory in many animal models of PD 
(Battaglia et al, 2006; Conn, 2003; Nicoletti et al, 1996; Ossowska et al, 2002; Shen 
and Johnson, 2003; Vernon et al, 2005 and 2007b). Specifically, the mGluR5 
antagonist MPEP has been shown to be neuroprotective in the MPTP mouse and 6-
OHDA rat models of PD (Battaglia et al, 2004; Vernon et al, 2005). Whilst the non-
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selective mGluR2/3 agonist LY379268 and the broad spectrum agonist of Group III 
mGluRs L-(+)-2-amino-4-phosphonobutyric acid (L-AP4), have been shown to 
prevent the dopaminergic neuronal death in the 6-OHDA rat PD model (Murray et al, 
2002, Vernon et al 2005, 2007b).  
However, L-AP4 produced a bell shaped neuroprotective effect in the 6-OHDA 
model, with the highest dose of 50nmol producing no neuroprotection, suggesting that 
at high doses specificity may be lost or receptors may become desensitized (Vernon et 
al, 2007). L-AP4 is a nonselective agonist at Group III mGluRs which comprise of 
mGluR subtype mGluR4, mGluR6, mGluR7 and mGluR8. Except mGluR6, all 
subtypes of Group III mGluRs were found in the basal ganglia (Laurie et al, 1997; 
Messenger et al, 2002). Consequently, recent research has focused on the use subtype 
selective agonists to try and identify which mGluRs subtype are responsible for the 
neuroprotective actions of L-AP4. mGluR4 receptors are located pre-synaptically and 
serve as autoreceptors to decrease glutamate release from glutamatergic nerve endings 
(Valenti et al, 2003; 2005). Indeed, mGluR4 agonists like (1S,3R,4S)-1-aminocyclo-
pentane-1,3,4-tricarboxylic acid (ACPT-1) have been shown to have anti-cataleptic 
effects in the haloperidol mediated Parkinsonian model (Konieczny et al, 2007) and to 
relieve Parkinsonian symptoms in other models (Marino et al, 2005 and Ossowska et 
al, 2007). Although mGluR4 has emerged as a promising drug target, the 
pharmacological use of such agonists may be limited by the fact that mGluR4 
receptors may become saturated by endogenous glutamate, particularly in conditions 
of excessive glutamate release, or that agonist activation may result in mGluR4 
desensitization possibly leading to pharmacological tolerance (Maj et al, 2003). Hence, 
in this study we have taken a different approach in that we have investigated the 
neuroprotective effects of the mGluR4 positive allosteric modulator N-phenyl-7-
(hydroxylimino) cyclopropa-[b] chromen-1a-carboxamide (PHCCC; Fig 3.1).  
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Fig 3.1: The chemical structure of N-Phenyl-7-
(hydroxyimino)cyclopropa[b]chromen-1a-carbox amide, 
PHCCC. (From www.tocris.com) 
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Allosteric modulators are potentially helpful since they amplify receptor 
function independent of the concentration of ambient glutamate and are effective at 
synapses that are tonically activated by glutamate. PHCCC does not potentiate or 
activate any other mGluR subtypes apart from mGluR4, however PHCCC does act as 
a weak partial antagonist at mGluR1b (Maj et al, 2003). In electrophysiological 
studies of the rat striatopallidal synapse in tissue slice preparations PHCCC was found 
to potentiate the effects of the mGluR4 agonist L-AP4 in inhibiting GABAergic 
transmission in the striatopallial synapse (Marino et al, 2003b). Allosteric potentiation 
of mGluR4 by PHCCC has been shown to produce an anti-depressant effect of rat 
models of depression (Stachowicz et al, 2006) whilst PHCCC was also shown to 
inhibit the inflammation and neuropathic pain in animal models of neuropathic pain 
(Goudet et al, 2008).  
PHCCC has also been tested in some animal PD models. PHCCC was found to 
stimulate motor activity in a DA-depletion model of PD induced by reserpine (Marino 
et al, 2003b). In addition PHCCC protected against nigrostriatal toxicity in the MPTP 
mouse model of PD (Battaglia et al, 2006). However, no studies have so far been 
conducted on the neuroprotective effects of PHCCC in the 6-OHDA lesion model. 
 
3.1.2 Aims of this chapter 
1. Investigate whether allosteric modulation of mGluRs in the SNc alone by 
PHCCC is neuroprotective in the 6-OHDA model of PD. This was achieved by 
the focal administration of PHCCC via indwelling cannulae. 
2. Investigate whether allosteric modulation by PHCCC can potentiate the 
neuroprotective effects of a low concentration of the Group III mGluR agonist L-
AP4 and investigate whether such effects are mediated via Group III mGluRs  
3. Investigate the mechanisms for PHCCC neuroprotection by firstly identifying the 
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cellular localization of mGluR4 receptors in the SNc and secondly by 
investigating whether PHCCC modulates microglial or astrocytic activation. 
 
3.2 Experimental Design 
The above aims were investigated by designing the following studies. In the 
focal administration studies indwelling cannulae were implanted supranigrally in rats 
(see section 2.2.3), allowed to recover for 10 days before being utilized in the 
following studies. The implanted cannulae allowed for both drugs and toxin 
administration to the SNc.  
 
3.2.1 Neuroprotective effect of focally injected PHCCC against 6-OHDA–
induced neurotoxicity on nigrostriatal tract 
After the 10 day-recovery period from the implantation of indwelling cannulae, 
the neuroprotective effect of PHCCC against the 6-OHDA-induced neurotoxicity was 
examined. PHCCC exists in a white crystal powder which is not water soluble. 
Current literature had suggested several diluents for PHCCC and the first section of 
this study was to ascertain which diluent was most appropriate. Hence, we examined 
the effect of PHCCC that had been dissolved in two diluents, namely DMSO and 
NaOH with subsequent neutralization with HCl, as described in the literatures 
(Battaglia et al, 2006; Kłak et al, 2007). Doses of PHCCC, 8, 25, 75 and 225nmol 
administered in 4µl, dissolved in DMSO or NaOH, were injected into the SNc for 7 
day consecutive days. One hour after the first administration of PHCCC, 12µg in 4µl 
6-OHDA was also injected into the SNc via the cannulae. For the drug vehicle group, 
the same volume/concentration of DMSO or neutralised NaOH was administered for 
7 days. In order to account for the possible dilution of toxin effects by solvent control 
animals received unilateral intranigral injections of 4µl of PHCCC drug vehicle one 
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hour prior to 6-OHDA lesioning. At the end of the treatment period experimental rats 
were sacrificed and the hindbrain and striata was dissected out. The numbers of 
dopaminergic and total neurons in the SNc was assessed by immunohistochemistry 
utilizing anti-TH and NeuN antibodies on cryostat cut fixed sections (see also section 
2.2.7). Concentrations of striatal dopamine (DA) and its metabolites were measured 
by HPLC. The dosing schedule can be seen in Fig 3.2.  
 
3.2.2 Effects of focally injected PHCCC on nigrostriatal integrity in the sham 
lesioned rat  
In this study the neutralized NaOH was utilized for dissolving PHCCC since 
DMSO in the above studies induced haemorrhage from the indwelling cannulae. After 
the demonstration of the neuroprotection of PHCCC, we went on to investigate the 
effect of the treatment of PHCCC dissolved in neutralized NaOH on the integrity of 
the nigrostriatal tract. PHCCC (225nmol in neutralized NaOH) administered in 4µl 
was administered to the SNc via the implanted cannulae for 7 consecutive days after 
the surgical implantation of the cannulae. Afterwards, rats were sacrificed and the 
brain removed for further analysis (see section 2.2.5). For the quantitative analysis of 
the SNc dopaminergic neurons were visualized by the immunostaining on cryostat cut 
section from the hindbrain with the anti-TH and NeuN followed by the manual 
counting (see section 2.2.6 and 2.2.7). For the biochemical analysis of the 
monoamines striata were dissected out and frozen for later measurement of the levels 
of DA and its metabolites by HPLC (see section 2.2.8). The dosing schedule can be 
seen in Fig 3.3.  
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Fig 3.2: The experimental schedule for the investigation involving focal 
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Fig 3.3: The experimental schedule for the investigation involving of focal 
injection of PHCCC in Sham lesioned rats. 
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3.2.3 Proof of receptor-mediated mechanism of PHCCC’s neuroprotective action  
In order to identify whether the neuroprotection afforded by PHCCC was 
mediated by group III mGluRs, the broad-spectrum group III mGluRs antagonist, 
MSOP, was utilized. 50nmol MSOP was administrated together with the PHCCC 
(75nmol) or alone in a total volume of 4µl in the 6-OHDA model for 7 consecutive 
days as above. Likewise, at the end of the 7-day study period animals were sacrificed, 
brains removed and processed for histological assessment of dopaminergic/total 
neuronal content in the SNc by immunohistochemistry and HPLC determination of 
striatal DA content. Dosing schedule see Fig 3.4.  
 
3.2.4 Investigation of whether PHCCC potentiates the neuroprotective effects of 
L-AP4 in the 6-OHDA model  
PHCCC is a positive allosteric modulator of the mGluR4
 
and the broad spectrum 
group III mGluR agonist, L-AP4, has been shown to be neuroprotectory in PD models. 
To investigate whether allosteric modulation at mGluR4 can potentiate the effect of L-
AP4, PHCCC was combined with a low dose of L-AP4. L-AP4 (2nmol administered 
in 4µl) was administered alone or in combination with 3 doses of PHCCC, 8, 25 and 
75nmol in a total volume of 4µl, into the SNc 7 consecutive days in the 6-OHDA 
model. Previously this group had demonstrated that 2nmol L-AP4 had minimal 
neuroprotective properties on its own in the 6-OHDA model (Vernon et al, 2007b). 
Similarly, the lesion of the SNc was induced by the infusion of 12µg/4µl 6-OHDA 
one hour after the first drug administration. As in the previous studies, the integrity of 
the nigrostriatal system was determined by TH and NeuN immunohistochemistry in 
the SNc (see section 2.2.6) combined with HPLC measurement of the striatal DA 
content and its metabolites (see section 2.2.8).  
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Fig 3.4: The experimental schedule for the investigation involving focal 
injection of MSOP with or without PHCCC/L-AP4 
Animals 
Purchase 
Surgical 
Implantation of 
cannulae 
Last 
injection 
on 8th day 
Postmortem 
procedures 
10 days 7 days 1 hour 7days 1 hour 
Snap frozen of 
striata 
Snap frozen 
Immunohistochemistry (IHC) 
Immunofluroscent (IF) staining 
Fixation of 
hindbrains in PFA 
HPLC 
Cryoprotection in 
30% sucrose 
5-7 days 
48 hours 
1st focal Injection 
of MSOP with or 
without 
PHCCC/L-AP4 
 110 
In order to investigate whether any potentiation of the neuroprotective effects of 
L-AP4 by PHCCC was mediated by group III mGluRs the broad-spectrum antagonist 
MSOP was utilized. In this study 75nmol PHCCC, 2nmol L-AP4 and 50nmol MSOP 
were administered in a total volume of 4µl for 7 consecutive days in the 6-OHDA 
model. The effect of the antagonist MSOP alone or in combination with PHCCC + L-
AP4 was also compared in the 6-OHDA lesion model. As in the previous studies 12µg 
in 4µl 6-OHDA was infused one hour after the first drug administration. The integrity 
of the nigrostriatal tract was analysed by TH and NeuN immunohistochemistry in the 
SNc (see section 2.2.6) and HPLC measurement of striatal concentration of DA and 
its metabolites (see section 2.2.8).  
 
3.2.5 Underlying mechanism of PHCCC neuroprotection against 6-OHDA-
induced neurotoxicity 
In order to identify possible mechanisms to account for the neuroprotective 
effects of PHCCC in SNc we then carried out receptor localization studies to ascertain 
which cell types possess mGluR4, where PHCCC acts as an allosteric enhancer. This 
was achieved by carrying out dual immunofluorescent staining with a specific 
antibody for mGluR4 in conjunction with markers for dopaminergic neurons (TH), 
astrocytes (GFAP) and microglia (OX6/OX42) in control and 6-OHDA lesioned SNc 
(see section 2.3.5). Once we had identified mGluR4 on all cell types, we then 
investigated whether PHCCC treatment modulated astrocytic and microglial 
activation in response to 6-OHDA toxicity. This was achieved by 
immunohistochemical detection of astrocytes (GFAP) and microglia (OX6/O42) in 
fixed cryostat cut section from vehicle and PHCCC treated 6-OHDA lesioned animals.  
 
3.2.6 Statistical analysis 
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NeuN- and TH-IR cells in both lesioned and contralateral sides of all treatment 
groups was expressed as the mean number of cell count± S.E.M or percentage change 
± S.E.M in relation to the control (unlesioned) side of brain, as indicated in different 
sections. GFAP- and OX6-IR cells were demonstrated as the mean number of cell 
count ± S.E.M or percentage/fold increase ± S.E.M. For the monoamines level, the 
data was presented as the percentage decrease of monoamine ± S.E.M. For the 
turnover ratio of striatal dopamine (T/O), the data was expressed as the turnover level 
± S.E.M. The calculation of turnover was shown below:  
{[DOPAC (nmol/mg) + [HVA (nmol/mg)]} 
[DA (nmol/mg)] 
In all figures, n values (number of animals in each treatment group) were shown in the 
caption of each figure. The mean values of each group were the average of the mean 
values of each individual rat in the same groups.  
Data was analyzed by a series of statistical analysis. By the one-way analysis of 
variants (ANOVA) among different treatment groups, statistic significance among 
different treatment groups was analyzed under the assumption of random sampling 
and normal distribution. In the analysis of PHCCC vs L-AP4 and MSOP vs PHCCC, 
L-AP4 and combined treatment of PHCCC and L-AP4, the significance was analyzed 
by the two-way ANOVA. Subsequently, there was the post hoc analysis in form of a 
Bonferroni test made between the lesioned sides of drug treatment groups to vehicle 
group. Where alternative tests are utilised they are indicated in the relevant sections. 
The significant differences were shown by expressing the P value as P<0.01 
(indicated as *, # or †), 0.001 (**, ## or ††) and 0.0001 (***, ### or †††), which was 
also annotated in the figures or tables. All statistical analysis was performed using 
Software package of GraphPad Prism version 4.00 (GraphPad Software, USA). 
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3.3 Result  
3.3.1 The effects of focally administered 6-OHDA 
The 6-OHDA model of PD was generated by the infusion of 12µg 6-OHDA in 
4µl injection volume (containing 0.1% ascorbic acid/0.9% NaCl) directly into the SNc 
via an indwelling cannulae. Infusion of 6-OHDA into the SNc induced a marked loss 
of TH-IR cells in the lesioned side of brains when compared to that in Sham-operated 
animals 7 days after lesion induction (Lesioned side: 37.67±2.30 cells, P<0.0001 vs 
unlesioned side: 91.22±2.32 cells; lesion size: 58.46±2.51%; Fig. 3.5A). Sham 
lesioning itself with 6-OHDA vehicle had no significant effect on the number of TH-
IR cells at 7 days post lesion (Lesioned side: 91.23±2.32 cells, P=0.1727 vs 
unlesioned side: 100.29±5.02 cells; lesion size: 9.01±1.23%; Fig. 3.5A). In order to 
illustrate whether 6-OHDA induced cytotoxicity to TH-IR cells rather than simply 
stimulate a decrease in the cellular expression of TH in dopaminergic neurons, 
secondary immunostaining was performed with the general neuronal marker, NeuN. 
In the 6-OHDA lesioned side of the brain numbers of NeuN-IR cells were decreased 
compared to Sham controls (Lesioned side: 33.91±2.99 cells, P<0.0001 vs unlesioned 
side: 93.22±4.78 cells; lesion size: 63.81±2.19%; Fig 3.5B). Sham lesioning with 6-
OHDA vehicle had no significant effect on the number of NeuN-IR cells at 7 days 
post lesion (Lesioned side: 99.20±3.43 cells, P=0.2037 vs unlesioned side: 
106.72±3.44 cells; lesion size: 6.65±1.99%; Fig. 3.5A). Therefore, these findings 
indicated that intranigral infusion of 6-OHDA induced dopaminergic cell death rather 
than changing TH expression. The lost of TH and NeuN-IR density were illustrated in 
Fig 3.5C, in which 6-OHDA induced a decrease of the density in the lesioned SNc. 
Likewise infusion of 6-OHDA into the SNc produced a reduction in the 
concentrations of striatal DA (6-OHDA: 82.64±1.70% loss, P<0.0001 vs Sham: 
10.08±1.65% loss; Table 3.1) and its metabolites, DOPAC (6-OHDA: 70.69±1.85%  
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Table 3.1: Infusion of 12µg 6-OHDA in 4µl to the left SNc and exposed for 7 days induced 
the % decrease of DA, DOPAC and HVA, and increase of turnover of dopamine (TO). 
Sham group received the 0.01% ascorbic acid vehicle for 7 consecutive days. Data were 
shown as mean percentage change of monoamine level ±SEM in lesioned side when 
compared to contralateral side. N numbers in brackets: Sham (6) and 6-OHDA (6). *** 
P<0.0001, when compared to Sham, analysed by Student’s t-test. 
Group 
58.41±3.04 *** 70.69±3.22 *** 82.64±2.1*** 6-OHDA 
10.83±2.07   6.40±2.65 10.08±1.65 Sham 
HVA (% loss) DOPAC (% loss) DA (% loss) 
0.54±0.02*** 0.19±0.02 6-OHDA 
0.18±0.02 0.13±0.02 Sham 
Ipsilateral Contralateral 
TO   
Group 
A                                                   B
C
6-OHDA (Ipsil; TH)
Sham (Ipsil; TH)
Sham (Ipsil; NeuN)
6-OHDA (Ipsil; NeuN)
SNc SNc
VTA
MTN
SNcSNc
6-OHDA (Cont; TH)
Sham (Cont; TH)
Fig 3.5: Effects of sham and 6-OHDA lesioning on the number of TH and 
NeuN-IR cells in the SNc
Infusion of 12 µg 6-OHDA in 4 µl into the left SNc resulted in a significant loss of both A) NeuN 
and B) TH-IR cells at 7 days post-lesion, whereas in sham-lesioned animals no significant NeuN 
and TH-IR cell loss observed. Sham group received the ascorbic acid (0.1%) vehicle for 7 
consecutive days. Data were expressed as the mean number of cells ± SEM or the mean 
percentage loss of cells on the lesioned side of the brain compared to the unlesioned side ± SEM 
in lesioned side when compared to contralateral side. *** P<0.0001 6-OHDA vs. sham-lesioned 
animals (Student’s t test). The n numbers of Sham and 6-OHDA are 6. C) Representative 
photomicrographs of both contralateral (Cont) and ipsilateral (Ipsil) TH-IR cells of SNc from the 
sham and 6-OHDA groups and NeuN-IR cells of ipsilateral SNc of both groups. Both cell types 
were lost under the condition of 6-OHDA. All images were taken at x 40 magnification, scale bar 
= 250 µm. The substantia nigra pars compacta (SNc), ventral tegmental area (VTA) and medial 
terminal nucleus (MTN) were highlighted.
SNc
SNc
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Group 
58.41±3.04 *** 70.69±3.22 *** 82.64±2.1*** 6-OHDA 
10.83±2.07   6.40±2.65 10.08±1.65 Sham 
HVA (% loss) DOPAC (% loss) DA (% loss) 
0.54±0.02*** 0.19±0.02 6-OHDA 
0.18±0.02 0.13±0.02 Sham 
Ipsilateral Contralateral 
TO   
Group 
Table 3.1: Infusion of 12µg 6-OHDA in 4µl to the left SNc and exposed for 7 days induced the % 
decrease of DA, DOPAC and HVA, and increase of turnover of dopamine (TO). Sham group received 
the 0.01% ascorbic acid vehicle for 7 consecutive days. Data were shown as mean percentage change 
of monoamine level ±SEM in lesioned side when compared to contralateral side. N numbers in 
brackets: Sham (6) and 6-OHDA (6). *** P<0.0001, when compared to Sham, analysed by Student’s 
t-test. 
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loss, P<0.0001 vs Sham: 6.40±2.65% loss; Table 3.1), and HVA (6-OHDA: 
58.41±3.97% loss, P<0.0001 vs Sham: 10.83±2.07% loss; Table 3.1) at 7 days post 
lesioning when compared to the Sham-operated animals. 6-OHDA lesioning also 
induced an increase in the turnover of DA relative to the sham-operated animals (6-
OHDA: 0.54±0.02, P<0.0001 vs Sham: 0.18±0.002; Table 3.1).  
 
3.3.2 Neuroprotective effect of focally administered PHCCC dissolved in DMSO 
against 6-OHDA-induced neurotoxicity  
To study the neuroprotective effect of PHCCC, three different concentrations of 
PHCCC was administered daily via the implanted cannulae for 7 consecutive days in 
the 6-OHDA lesioned animals. Administration of the DMSO vehicle did not produce 
further loss of TH- and NeuN-IR neurons in the 6-OHDA lesioned rats (TH: 
60.96±2.06% loss, P=0.1302, vs 6-OHDA: 56.71±1.56% loss; NeuN: 57.63±3.17% 
loss, P=0.3051 vs 6-OHDA: 52.36±3.70% loss; Fig 3.6A-B). Furthermore, DMSO+6-
OHDA did not induce further loss of striatal DA or its metabolites after 6-OHDA 
lesioning (DA: 55.63±2.29% loss, P=0.4156 vs DA in 6-OHDA alone: 52.61±2.72%; 
DOPAC: 39.31±2.28% loss, P=0.1526 vs DOPAC in 6-OHDA alone: 51.05±7.23%; 
HVA: 36.35±4.65% loss, P=0.0688 vs HVA in 6-OHDA alone: 48.55±3.77%; TO: 
1.10±0.08, P=0.0642 vs TO in 6-OHDA alone: 0.87±0.08; Table 3.2A and B). There 
was a concentration dependent protection of TH-IR neurons in the SNc by PHCCC 
against 6-OHDA toxicity (F6.65, P<0.01). The subsequent post hoc t-test analysis 
revealed that PHCCC doses 75 and 225nmol produced significant neuroprotection of 
the SNc TH-IR cells (25nmol: 49.05±3.85% loss, P=0.051; 75nmol: 35.30±4.57% 
loss, P<0.0001; and 225nmol: 35.81±3.10%loss, P<0.0001, vs DMSO+6-OHDA: 
60.96±2.06% loss; Fig 3.6A) which was mirrored by the reduction of NeuN-IR cell 
loss (F9.52, P<0.001; 25nmol: 49.75±2.29% loss, P=0.0715; 75nmol: 39.38±2.15%  
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A
B
Fig 3.6: Neuroprotective Effect of PHCCC dissolved in DMSO 
on the number of TH and NeuN-IR cells in the SNc
Sub-chronic intranigral administration of PHCCC (25, 75 and 
225nmol) dissolved in DMSO for 7 days significantly attenuated the 
6-OHDA induced loss of A) TH and B) NeuN-IR cells in a 
concentration dependent manner. 6-OHDA/DMSO group received 
the DMSO vehicle whilst the 6-OHDA received an normal saline 
vehicle for 7 days. Data shown were mean percentage loss of cells ±
SEM in lesioned side when compared to contralateral side, n values 
in brackets: 6-OHDA (6), DMSO/6-OHDA (6), 25nmol PHCCC (6), 
75nmol PHCCC (6) and 225nmol PHCCC (6). *** P<0.0001 
PHCCC vs. DMSO/6-OHDA (One-way ANOVA followed by 
Student’s t test). 
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Fig 3.7: Representative photomicrographs of nigral TH-IR cells 
from 6-OHDA lesioned animals treated with PHCCC dissolved 
in DMSO 
Panels A-D, low power (x40; Scale bar = 250μm) representative 
photomicrographs to illustrate that sub-chronic intranigral 
administration of PHCCC in DMSO vehicle for 7 consecutive days 
produced has neuroprotective effect on the integrity of the 
nigrostriatal system with a higher density of TH-IR cells in the 
SNc. 6-OHDA/DMSO received a DMSO vehicle for 7 consecutive 
days. Only ipsilateral SNc images were shown in this section. A) 
DMSO/6-OHDA (n=6), B) 25nmol PHCCC (n=6), C) 75nmol 
PHCCC (n=6) and D) 225nmol PHCCC (n=6) in the 6-OHDA 
model.
A B
C D
SNc
SNc
SNcSNc
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Group 
24.54±1.83* 27.53±3.25** 18.74±2.62 *** PHCCC  225 
36.13±4.89 30.69±5.65** 31.78±4.26 *** PHCCC  75 
38.70±4.14 32.91±5.23 52.99±3.37 PHCCC  25 
36.35±4.65 39.31±2.28 55.63±2.29 DMSO+6-OHDA 
48.55±3.77 51.05±7.23 52.61±2.72 6-OHDA 
HVA (% loss) DOPAC (% loss) DA (% loss) 
0.61±0.10** 0.56±0.05 PHCCC  225 
0.73±0.05** 0.45±0.06 PHCCC  75 
0.75±0.05* 0.38±0.02 PHCCC  25 
1.10±0.08 0.45±0.03 DMSO + 6-OHDA 
0.87±0.08 0.54±0.03 6-OHDA 
Ipsilateral Contralateral 
TO   
Group 
Table 3.2A: Subchronic intra-SNc administration of PHCCC (25, 75 and 225nmol) 
dissolved in DMSO for 7 consecutive days provided reversal effect of the 6-OHDA-
induced depletion of dopamine (DA). 6-OHDA/DMSO received the DMSO vehicle whilst 
6-OHDA received the normal saline vehicle for 7 consecutive days. Data were shown as 
mean percentage decrease of monoamines level±SEM in lesioned side when compared to 
contralateral side. N numbers in brackets: 6-OHDA (6), DMSO+6-OHDA (6), 25nmol 
PHCCC (6), 75nmol PHCCC (6) and 225nmol PHCCC (6). * P<0.01, ** P<0.001, *** 
P<0.0001, when compared to DMSO+6-OHDA, analysed by one-way ANOVA followed by 
Student’s t-test. 
Table 3.2B: Subchronic intra-SNc administration of PHCCC (25, 75 and 225nmol) 
dissolved in DMSO for 7 consecutive days provided reversal effect of the 6-OHDA-
induced increase of DA turnover ratio. 6-OHDA/DMSO received the DMSO vehicle 
whilst 6-OHDA received the normal saline vehicle for 7 consecutive days. Data were 
shown as mean turnover ratio ± SEM. N values in brackets: 6-OHDA (6), DMSO+6-
OHDA (6), 25nmol PHCCC (6), 75nmol PHCCC (6) and 225nmol PHCCC (6). * P<0.01 
and ** P<0.001, when compared to DMSO+ 6-OHDA; analysed by one-way ANOVA 
followed by Student’s t-test. 
 119 
loss, P<0.0001; and 225nmol: 30.15±1.76% loss, P<0.0001, vs DMSO+6-OHDA: 
57.63±3.17% loss; Fig 3.6B). Photomicrographs depict the global loss of TH-IR cells 
in the SNc due to 6-OHDA toxicity, whilst increasing concentration of PHCCC 
preserved TH-IR cells density in the SNc (Fig 3.7). Similarly, PHCCC produced a 
dose dependent preservation of striatal DA concentration (F7.95, P<0.001; 25nmol: 
52.99±3.37% loss, P=0.5324; 75nmol: 31.78±4.26% loss, P<0.0001 and 225nmol: 
18.74±2.62% loss, P<0.0001, vs DMSO+6-OHDA: 55.63±2.29% loss; Table 3.2A), 
DOPAC (F3.44, P<0.05; 25nmol: 32.91±5.23% loss, P=0.2882; 75nmol: 30.69±5.65% 
loss, P<0.001; and 225nmol: 27.53±3.25% loss, P<0.001, vs DMSO+6-OHDA: 
39.31±2.28% loss; Table 3.2A) and HVA (F2.25; P<0.05; 25nmol: 38.70±4.14% loss, 
P=0.7138, 75nmol: 36.13±4.89% loss, P=0.9743; and 225nmol: 24.54±1.83% loss, 
P<0.05, vs DMSO+6-OHDA: 36.35±4.65% loss; Table 3.2A) against the toxic actions 
of 6-OHDA. In addition, PHCCC administration normalized the increase in striatal 
DA turnover induced by 6-OHDA toxicity (F8.20, P<0.0001; 25nmol: 0.75±0.05, 
P<0.01; 75nmol: 0.73±0.05, P<0.001 and 225nmol: 0.61±0.10, P<0.001, vs 
DMSO+6-OHDA: 1.1±0.08; Table 3.2B). Although there was no significant lesion 
induced by DMSO, haemorrhage from the cannulae was observed during the dosing 
procedure. Consequently, we then proceeded to try and find an alternative diluent that 
did not cause haemorrhage. 
 
3.3.3 Neuroprotective effect of focally injected PHCCC dissolved in neutralized 
NaOH against 6-OHDA-induced neurotoxicity 
To study the putative neuroprotective effect afforded by PHCCC dissolved in a 
aqueous solvent 6-OHDA-lesioned animals were administered with the intranigral 
injections of 8, 25 and 75nmol PHCCC dissolved in originally in NaOH and 
subsequently neutralised with HCl to form NaCl, administered once daily for a period 
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of 7 days starting with the first injection one hour prior to 6-OHDA (see section 2.2.4). 
The 6-OHDA lesion was characterized by the loss of TH (61.40±1.67% loss, 
P<0.0001; Fig 3.8A) and NeuN-IR (61.34±1.53% loss, P<0.0001, Fig 3.8B) cells 
whilst striatal DA (82.69±5.15% loss, P<0.001, Table 3.3A), DOPAC (70.68±4.16% 
loss, P<0.001; Table 3.3A) and HVA (58.41±3.62% loss, P<0.001, Table 3.3A) were 
significantly depleted. Intranigral administration of PHCCC dose dependently 
significantly attenuated the 6-OHDA-induced loss of TH-IR cells in the lesioned SNc, 
when compared to the unleisoned side of the brain (F18.73, P<0.0001; 8nmol: 
45.08±3.17% loss, P<0.001; 25nmol: 35.71±2.46% loss, P<0.0001; and 75nmol: 
22.94±0.96% loss, P<0.0001; vs 6-OHDA: 61.40±1.67% loss; Fig 3.8A). Despite this 
robust neuroprotection PHCCC did not completely protect against 6-OHDA-induced 
neurotoxicity. To illustrate the histological neuroprotection following PHCCC 
treatment, representative photomicrographs of TH-IR cell bodies from PHCCC 
treated and untreated animals are shown in Fig 3.9. A similar concentration dependent 
neuroprotection was observed with PHCCC against 6-OHDA-induced toxicity when 
considering total neuronal counts (NeuN-IR; 8nmol: 44.30±4.11% loss, P<0.01; 
25nmol: 34.52±2.05% loss, P<0.0001; and 75nmol: 30.05±2.51% loss, P<0.0001; vs 
6-OHDA: 61.34±1.53% loss; Fig 3.8A). 
Subchronic intranigral administration of PHCCC also significantly attenuated 
the 6-OHDA-induced depletion of striatal DA concentrations in the lesioned striatum 
(F25.46, P<0.0001). Post-hoc analysis revealed that the striatal DA depletion was not 
reduced in a classical dose dependant manner but more in a “all or nothing” response, 
with the 8 and 25nmol doses of PHCCC failing to provide any neuroprotection whilst 
75nmol PHCCC provided a similar marked preservation of the striatal DA  
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Fig 3.8: Neuroprotective effect of PHCCC on the number of TH and
NeuN-IR cells in the SNc
Sub-chronic intranigral administration of PHCCC (8, 25 and 75nmol) 
dissolved in neutralized NaOH and 2nmol L-AP4 significantly attenuated the 
6-OHDA induced loss of A) TH and B) NeuN-IR cells, whereas the 
neuroprotective effect of L-AP4 is potentiated by PHCCC (25 and 75nmol). 
6-OHDA group received the neutralized NaOH vehicle for 7 consecutive days. 
Data shown were mean percentage loss of TH and NeuN-IR cells ± SEM in 
lesioned side when compared to contralateral side, n values in brackets: 6-
OHDA (7), 2nmol L-AP4 (6), 8nmol PHCCC (6), 25nmol PHCCC (6), 
75nmol PHCCC (6), 8nmol PHCCC + L-AP4 (6), 25nmol PHCCC + L-AP4 
(6) and 75nmol PHCCC + L-AP4 (6). * P<0.01, **P<0.001 and ***P<0.0001 
PHCCC or L-AP4 vs. 6-OHDA. ### P<0.0001 PHCCC+L-AP4 vs L-AP4 in 
the same concentration (Two-way ANOVA followed by Bonferroni test). 
A
B
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concentrations (8nmol: 74.31±3.00% loss, P=0.2603; 25nmol: 71.77±4.93% loss, 
P=0.1574; and 75nmol: 15.43±2.40% loss, P<0.0001; vs 6-OHDA: 82.69±5.15% loss; 
Table 3.3A). Similarly, only the higher concentration of PHCCC preserved the striatal 
level of DOPAC (8nmol: 67.78±3.95% loss, P=0.6271; 25nmol: 66.93±3.87% loss, 
P=0.5274; and 75nmol: 13.01±1.93% loss, P<0.0001; vs 6-OHDA: 70.68±4.16% loss; 
Table 3.3A). Interestingly the 6-OHDA-induced loss of HVA was concentration-
dependently reversed by PHCCC (8nmol: 42.27±3.74% loss, P<0.01; 25nmol: 
38.58±6.07% loss, P<0.01; and 75nmol: 20.41±2.68% loss, P<0.0001; vs 6-OHDA: 
58.41±3.62% loss; Table 3.3A). 6-OHDA administration induced a significant 
increase in DA turnover in the lesioned striata, however 25 and 75nmol PHCCC 
completely normalized the 6-OHDA increased DA turnover whilst 8nmol PHCCC 
failed to reserve the turnover increase (8nmol: 0.45±0.04, P=0.7726; 25nmol: 
0.25±0.03, P<0.01; and 75nmol: 0.27±0.03; P<0.01; vs 6-OHDA: 0.44±0.03; Table 
3.3B). From this observation, the neuroprotective effect of PHCCC was demonstrated 
in which high concentration of PHCCC could protect significantly also the depletion 
of striatal DA.  
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Fig 3.9: Representative photomicrographs of nigral TH-IR cells from 6-
OHDA lesioned animals treated with PHCCC dissolved in neutralized 
NaOH with or without L-AP4
Panels A-H, low power (x40; Scale bar = 250μm) representative 
photomicrographs of contralateral (Cont) and ipsilateral (Ipsil) SNc to 
illustrate that sub-chronic intranigral administration of PHCCC and L-AP4 
produced neuroprotective effect on the integrity of the nigrostriatal system. 
The combined treatment of them enhanced the neuroprotection. 6-OHDA 
group received the neutralized NaOH vehicle for 7 consecutive days. A) 6-
OHDA alone (n=7), B) 8nmol PHCCC (n=6), C) 25nmol PHCCC (n=6), D) 
75nmol PHCCC (n=6), E) 2nmol L-AP4 (n=6), F) 8nmol PHCCC +L-AP4 
(n=6), G) 25nmol PHCCC + L-AP4 (n=6) and H) 75nmol PHCCC + L-AP4 
(n=6), in 6-OHDA model. 
SNc
SNc
SNc
SNc
(continued)
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Table 3.3A: Subchronic intra-SNc administration of 75nmol PHCCC dissolved in 
neutralized NaOH for 7 consecutive days provided reversal effect of the 6-OHDA-induced 
depletion of dopamine (DA), DOPAC and HVA. However 8 and 25 nmol PHCCC failed to 
prevent the % decrease of DA and DOPAC. Interestingly, 8 and 25nmol PHCCC could 
prevent the 6-OHDA induced % decrease of HVA. L-AP4 treated in same way provided a 
weak reverse of 6-OHDA induced depletion of DA only. Combined treatment of PHCCC 
and L-AP4 reversed the 6-OHDA induced decrease of monoamine. Additionally, 25 and 
75nmol PHCCC potentiated the reversal effect of L-AP4 on the 6-OHDA induced decrease 
of monoamine. 6-OHDA received the neutralized NaOH vehicle for 7 consecutive days. 
Data were shown as mean percentage loss of monoamines level ± SEM in lesioned side when 
compared to contralateral side. N values in brackets: 6-OHDA (7), 8nmol PHCCC (6), 
25nmol PHCCC (6), 75nmol PHCCC (6), 2nmol L-AP4 (6) and 8nmol PHCCC + L-AP4 
(6), 25nmol PHCCC + L-AP4 (6) and 75nmol PHCCC + L-AP4 (6). * P<0.01, ** P<0.001, 
*** P<0.0001, when compared to 6-OHDA; ## P<0.001, ### P<0.0001, when compared to 
the L-AP4; analysed by Two- way ANOVA followed by Bonferroni test.  
10.29±1.40 ***, ## 12.45±1.96 ***, ### 10.26±1.71***,### PHC 75 + AP4 2 
13.16±2.21 ***, ## 16.11±1.90 ***, ### 16.95±2.42***,### PHC 25 + AP4 2 
39.25±3.04* 54.24±4.32* 58.54±4.18*** PHC 8 + AP4 2 
49.67±4.73 66.95±6.43 70.25±3.67* AP4 2 
20.41±2.68 *** 13.01±1.93*** 15.43±2.70*** PHC 75 
38.58±6.07* 66.93±3.87 71.77±4.93 PHC 25 
42.27±3.74* 67.78±3.95 74.31±3.00 PHC 8 
58.41±3.62** 70.68±4.16 82.69±5.15 6-OHDA 
HVA (% loss) DOPAC (% loss) DA (% loss) Group 
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Ipsilateral Contralateral 
TO Group 
0.34±0.02* 0.18±0.01 AP4 2 
0.44±0.03 0.24±0.02 6-OHDA 
0.45±0.04 0.22±0.01 PHC 8 
0.18±0.01**, ## 0.22±0.03 PHC 75 + AP4 
0.22±0.02**, # 0.24±0.01 PHC 25 + AP4 
0.34±0.07* 0.22±0.01 PHC 8 +AP4 
0.27±0.03* 0.17±0.02 PHC 75 
0.25±0.03* 0.22±0.04 PHC 25 
Table 3.3B: Subchronic intra-SNc administration of PHCCC (8, 25 and 75nmol) dissolved 
in neutralized NaOH for 7 consecutive days provided reversal effect of the 6-OHDA-
induced increase of DA turnover (TO) ratio dopamine. L-AP4 treated in same way 
provided a weak reverse of 6-OHDA induced increase of DA turnover ratio. 25 and 
75nmol PHCCC potentiated reductive effect on LAP4 on 6-OHDA induced increase of 
TO. 6-OHDA received the neutralized NaOH vehicle for 7 consecutive days. Data were 
shown as mean turnover ratio ±SEM. N value in brackets: 6-OHDA (7), 225nmol PHCCC 
alone (6), 8nmol PHCCC (6), 25nmol PHCCC (6), 75nmol PHCCC (6), 2nmol L-AP4 (6) 
and 8nmol PHCCC + L-AP4 (6), 25nmol PHCCC + L-AP4 (6) and 75nmol PHCCC + L-
AP4 (6). * P<0.01 and ** P<0.001, when compared to 6-OHDA # P<0.01 and ## P<0.001 
when compared to the same treatment without L-AP4; analysed by Two- way ANOVA 
followed by Bonferroni test. 
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3.3.4 Effect of focally injected PHCCC alone in Sham-lesioned SNc  
The effect of PHCCC administration alone on the integrity of the nigrostriatal 
system was investigated by the injection of 225nmol PHCCC to the left SNc in the 
Sham lesioned animals daily for 7 days. PHCCC administration had no significant 
effect on the numbers of TH-IR cells (7.11±1.45% loss, P=0.7036 vs Sham: 
7.58±1.53%; Fig 3.10A) or the numbers of NeuN-IR cells in the Sham lesioned SNc 
when compared to the unlesioned SNc (7.03±1.19% loss, P=0.9642 vs Sham: 
6.78±1.33%; Fig 3.10A). In Fig 3.10B, there was no loss of nigral TH-IR cells, 
illustrating an intact structure of the SNc. Likewise, PHCCC administration into the 
SNc for 7 days failed to produce any changes in concentrations of striatal DA 
(7.44±1.59% loss, P=0.5115; Table 3.4), DOPAC (10.06±1.51% loss, P=0.1328; Table 
3.4), HVA (6.31±1.21% loss, P=0.9408; Table 3.4) and turnover ratio (T/O) 
(0.13±0.02, P=0.2630; Table 3.4) in the Sham lesioned striata when compared to the 
unlesioned striata. The observations above demonstrate that 7-day sub-chronic 
treatment of PHCCC into the left SNc does not produce any functional and 
histochemical modification of the nigrostriatal system itself. In addition, subchronic 
administration of a high dose of PHCCC (225nmol) did not produce any overt general 
behavioural abnormalities by daily observation.  
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A
B
Fig 3.10: Effect of PHCCC on the number of TH, NeuN GFAP and OX6-IR 
cells in the SNc of the naïve rodents
A) The subchronic treatment of PHCCC (225nmol) dissolved in neutralized 
NaOH focally to the SNc for 7 days did not reduce the loss of TH and NeuN-IR 
cells. Sham group received the neutralized NaOH vehicle for 7 consecutive days. 
Data were mean percentage loss of cells ± SEM in lesioned side when compared 
to contralateral side, n values of sham-lesioned and PHCCC alone groups are 6. B)
Representative photomicrographs of TH (contralateral and ipsilateral) from the 
Sham and PHCCC alone treated animals (x40 magnification; Scale bar = 250μm) 
and GFAP and OX6-IR cells from PHCCC alone treated animals (x400 
magnification; scale bar = 25µm). PHCCC did not induced loss of TH-IR cells 
and the activation of the GFAP and OX6-IR cells morphologically.
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6.31±0.98 10.06±0.16 7.44±0.60 PHC alone 
6.20±0.78 6.99±1.12 8.65±0.77 Sham 
HVA (% loss) DOPAC (% loss) DA (% loss) Group 
0.13±0.02 0.14±0.02 PHCCC alone 
Ipsilateral Contralateral 
 
Group 
0.15±0.02 0.17±0.01 Sham 
TO 
Table 3.4: Infusion of 225nmol PHCCC to the left SNc and exposed for 7 days did not 
induce the % decrease of DA, DOPAC and HVA, and increase of turnover of dopamine 
(TO). Data were shown as mean percentage change of monoamine level ±SEM in lesioned 
side when compared to contralateral side, or mean TO ±SEM in both sides. N numbers in 
blankets: Sham (6) and 6-OHDA (6). *** P<0.0001, when compared to Sham, analysed by 
Student’s t-test. 
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3.3.5 PHCCC enhances the neuroprotective effects of L-AP4 
In the previous studies we demonstrated that allosteric modulation of mGluR4 is 
neuroprotective in the 6-OHDA model. However it is not know whether PHCCC can 
potentiate the effects of group III mGluRs agonists. Previously we demonstrated that 
the broad-spectrum group III mGluRs agonist L-AP4 produced a concentration 
dependent neuroprotection against 6-OHDA (Vernon et al, 2007b). In this section of 
study our aim was to determine whether PHCCC could potentiate the neuroprotective 
effects of the sub-maximal dose of L-AP4 (2nmol). L-AP4 was administered into the 
SNc alone or in combination with 8, 25 or 75nmol PHCCC as above in a total volume 
of 4µl, one hour before 6-OHDA administration and subsequently daily for 7 days. 
Intranigral administration of 2nmol L-AP4 alone produced a small attenuation of 6-
OHDA-induced loss of TH- (48.56±1.47% loss, P<0.0001 vs 6-OHDA: 61.40±1.67% 
loss; Fig 3.8A) and NeuN-IR (49.89±1.88% loss, P<0.0001 vs 6-OHDA: 
61.34±1.53% loss; Fig 3.8B) cells. When administered in combination, 8nmol of 
PHCCC with 2nmol L-AP4 failed to show any enhanced neuroprotection in the 
numbers of TH and NeuN-IR neurons when compared to that provided by 8nmol 
PHCCC alone (TH-IR: PHCCC+L-AP4: 42.36±3.34% loss, vs PHCCC alone: 
45.08±3.17% loss, P=0.6434, vs L-AP4: 48.56±1.47% loss, P=0.0723; and NeuN-IR: 
PHCCC+L-AP4: 48.98±4.63% loss, vs PHCCC alone: 44.30±4.11% loss P=0.3712, 
vs L-AP4: 48.89±1.88% loss, P=0.5581; Fig 3.8A-B). However, at the higher doses of 
PHCCC, 25 and 75nmol, combination with 2nmol L-AP4 caused a significant 
potentiation of the neuroprotective effects against 6-OHDA toxicity compared to 
when PHCCC was given alone when analyzed by two-way ANOVA (F69.20, P<0.0001) 
with post hoc Bonferroni analysis: TH-IR (25nmol PHCCC+L-AP4: 18.36±1.88% 
loss vs PHCCC alone: 35.71±2.46% loss, P<0.0001, vs L-AP4: 48.56±1.47% loss, 
P<0.001 and 75nmol PHCCC+L-AP4: 11.42±1.15% loss vs PHCCC alone: 
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22.94±2.46% loss, P<0.0001, vs L-AP4: 48.56±1.47% loss, P<0.001; Fig 3.8A) and 
NeuN-IR (25nmol PHCCC+L-AP4: 28.45±2.63% loss vs PHCCC alone: 
34.52±2.05% loss, P<0.0001, vs L-AP4: 49.89±1.88% loss, P<0.0001 and 75nmol 
PHCCC+L-AP4: 21.99±1.77% loss vs PHCCC alone: 30.05±2.51% loss, P<0.0001, 
vs L-AP4: 49.89±1.88% loss, P<0.001; Fig 3.8B). The representative 
photomicrographs are illustrated in Fig 3.9. A further increase in the density of TH-IR 
cells was detected in the SNc with the combined presence of 2nmol L-AP4 with 
PHCCC in different concentration.  
Subchronic administration of 2nmol L-AP4 alone also significantly attenuated 
the 6-OHDA-induced depletion of striatal DA in the lesioned striatum (2nmol L-AP4: 
70.25±3.67% loss, P<0.01 vs 6-OHDA: 82.69±5.15%, Table 3.3A). When in 
combination with 2nmol L-AP4 8nmol PHCCC did not further attenuate the loss of 
striatal DA compared to PHCCC alone (8nmol PHCCC+L-AP4: 58.54±4.18% loss, 
P=0.0852, vs 8nmol: 74.31±3.00% loss, vs L-AP4: 70.25±3.67% loss, P=0.0756; 
Table 3.3A). However, a combination of either 25 or 75nmol PHCCC with 2nmol L-
AP4 further attenuated the 6-OHDA-induced loss of striatal DA concentrations when 
compared to the neuroprotective effects of 2nmol L-AP4 or PHCCC alone (25nmol 
PHCCC+L-AP4: 16.95±2.42% loss, vs PHCCC alone: 71.77±4.93% loss, P<0.0001, 
vs L-AP4: 70.25±3.67% loss, P<0.0001; and 75nmol PHCCC+L-AP4: 10.26±1.71% 
loss vs PHCCC alone: 15.43±2.40% loss, P<0.0001; vs L-AP4: 70.25±3.67% loss, 
P<0.0001; Table 3.3A). Similarly, combination of PHCCC with L-AP4, except 8nmol, 
further attenuated the loss of striatal DOPAC (8nmol PHCCC+L-AP4: 54.24±4.32% 
loss, vs PHCCC alone: 67.78±3.95% loss, P<0.01, vs L-AP4: 66.95±6.43% loss, 
P=0.1804; 25nmol PHCCC+L-AP4: 16.11±1.90% loss, vs PHCCC alone: 
66.93±3.87% loss, P<0.0001, vs L-AP4: 66.95±6.43% loss P<0.0001; 75nmol 
PHCCC+L-AP4: 12.45±1.96% loss, vs PHCCC alone: 13.01±1.93% loss, P<0.0001, 
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vs L-AP4: 66.95±6.43% loss, P<0.0001; Table 3.3A) and HVA (8nmol PHCCC+L-
AP4: 39.25±3.04% loss, vs PHCCC alone: 42.27±3.74% loss, P=0.2136, vs L-AP4: 
49.67±4.73% loss, P=0.1028; 25nmol PHCCC+L-AP4: 13.16±2.21% loss, vs PHCCC 
alone: 38.58±6.07% loss, P<0.0001, vs L-AP4: 49.67±4.73% loss, P<0.001; 75nmol 
PHCCC+L-AP4: 10.29±1.40% loss, vs PHCCC alone: 20.41±2.68% loss, P<0.0001, 
vs L-AP4: 49.67±4.73% loss, P<0.001; Table 3.3A) when compared to both L-AP4 
and PHCCC alone. Conversely, PHCCC, except 8nmol, failed to potentiate the 
reductive effect on striatal DA turnover by L-AP4 (8nmol PHCCC+L-AP4: 0.34±0.07, 
vs PHCCC alone: 0.45±0.04 P<0.01, vs L-AP4: 0.34±0.02 P=0.1722; 25nmol 
PHCCC+L-AP4: 0.22±0.02, vs PHCCC alone: 0.25±0.03 P<0.001, vs L-AP4: 
0.34±0.02 P<0.01; 75nmol PHCCC+L-AP4: 0.18±0.01, vs PHCCC alone: 0.27±0.03 
P<0.001, vs L-AP4: 0.34±0.02 P<0.001; Table 3.3B). Although we observed the 
increase of neuroprotection when PHCCC co-administered with 2nmol L-PA4, the 
degree of further neuroprotection is possibly due to the additive effect of both ligands. 
Therefore, although PHCCC was proved to be the positive allosteric modulator of 
mGluR4, this effect could not be reflected in the study of the neuroprotective effect of 
PHCCC.  
 
3.3.6 Receptor mediated mechanism of PHCCC neuroprotection 
To assess whether the enhancement of neuroprotective effects of L-AP4 by PHCCC 
was due to allosteric modulation at mGluR4 similar studies to above were carried out 
but in the presence of group III mGluR antagonist MSOP. Daily administration of 
50nmol MSOP alone in 4µl to the SNc via the cannulae for 7 consecutive days had no 
neuroprotective effect against 6-OHDA toxicity observed in term of the TH- 
(54.11±3.03% loss, P=0.1931 vs Sham: 9.01±1.23%; Fig 3.11A) and NeuN-IR cells 
(54.97±2.39% loss, P=0.1197 vs Sham: 6.65±1.99%; Fig 3.11B). Furthermore, MSOP  
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A
B
Fig 3.11: Blocking effect of MSOP on the neuroprotective effect of PHCCC, 
L-AP4 or L-AP4+PHCCC on the number of TH and NeuN-IR cells in the 
SNc
The subchronic intranigral administration of MSOP (50nmol) focally to the SNc 
for 7 consecutive days reversed the neuroprotective effect of PHCCC, L-AP4 
and combined in term of increasing number of A) TH and B) NeuN-IR cells. 
However, MSOP only partially reversed the PHCCC and PHCCC+L-AP4, 
whilst it fully reversed the neuroprotection in L-AP4. 6-OHDA group received 
the neutralized NaOH vehicle for 7 consecutive days. Data shown were mean 
percentage loss cells ± SEM in lesioned side when compared to contralateral side, 
n values in brackets: 6-OHDA (7), 50nmol MSOP (6), 2nmol L-PA4 (6), 2nmol 
L-AP4 + MSOP (6), 75nmol PHCCC (6), MSOP + 75nmol PHCCC, and 75nmol 
PHCCC+L-AP4 (6) and with MSOP (6). ** P<0.001 and ***P<0.0001 vs. 6-
OHDA. # P<0.01, ## P<0.001 and ### P<0.0001 vs the same treatment of 
PHCCC without MSOP (Two-way ANOVA followed by Bonferroni test). 
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20.41±2.68 *** 13.01±1.93*** 15.43±2.70*** PHC 75 
49.67±4.73 66.95±6.43 70.25±3.67* AP4 2 
44.49±3.85 *, ##, † 58.16±3.28  **, ### 69.25±2.51 *, ###, † MSOP +PHC +AP4 
32.31±2.61 *, ## 49.42±3.94 ***, ### 56.08±3.14 **, ###  MSOP +PHC 75 
56.69±3.82 55.88±1.98 75.85±2.22# MSOP +AP4 
47.27±5.45 60.91±4.07 76.37±3.33 MSOP 
55.96±2.34 72.27±3.44 79.11±3.16 6-OHDA 
10.29±1.40 *** 12.45±1.96 *** 10.26±1.71*** PHC 75+AP4 
HVA (% loss) DOPAC (% loss) DA (% loss) Group 
Table 3.5A: Subchronic intra-SNc administration of 50nmol MSOP for 7 consecutive 
days blocked the reversal effect of PHCCC (75nmol) and PHCCC (75nmol) +L-AP4 
(2nmol) partially, but L-AP4 (2nmol) fully, on the 6-OHDA-induced depletion of DA. 
MSOP did not produce any reversal effect on the depletion of DA. 6-OHDA group 
received the neutralized NaOH vehicle. Data were shown as mean percentage loss of 
monoamine levels ±SEM in lesioned side when compared to contralateral side. N 
numbers in brackets: 6-OHDA (7), 50nmol MSOP (6), 2nmol L-AP4 + MSOP (6), MSOP 
+ 75nmol PHCCC, and 75nmol PHCCC+L-AP4+ MSOP (6). AP4 2, PHC 75, and PHC 
75+AP4 groups are same as in Table 3.3A. * P<0.01, ** P<0.001 and *** P<0.0001 vs 6-
OHDA. # P<0.01, ## P<0.001 and ### P<0.0001 vs the same treatment group without 
MSOP. † P<0.01, when compared the MSOP+PHCCC+L-AP4 to the MSOP+PHCCC, 
analysed by Two-way ANOVA followed by Bonferroni test.  
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0.18±0.01** 0.22±0.03 PHC 75 + AP4 
0.27±0.03* 0.17±0.02 PHC 75 
0.34±0.02* 0.18±0.01 AP4 2 
0.43±0.02 0.18±0.02 MSOP 
0.44±0.02 ###, † 0.21±0.01 MSOP + PHCCC + AP4 
0.37±0.01# 0.17±0.01 MSOP + PHCCC 
0.45±0.01## 0.23±0.01 MSOP + AP4 
Ipsilateral Contralateral 
0.44±0.03 0.24±0.02 6-OHDA 
TO Group 
Table 3.5B: Subchronic intra-SNc administration of 50nmol MSOP for 7 consecutive 
days blocked the reversal effect of PHCCC (75nmol) and PHCCC (75nmol) +L-
AP4(2nmol) partially, but L-AP4(2nmol) fully, on the 6-OHDA-induced increase of DA 
turnover ratio. MSOP did not produce any reversal effect on the turnover of DA. 6-
OHDA group received the neutralized NaOH vehicle. Data were shown as mean 
turnover ratio ±SEM. N numbers in brackets: 6-OHDA (7), 50nmol MSOP (6), 2nmol L-
AP4 + MSOP (6), MSOP + 75nmol PHCCC, and 75nmol PHCCC+L-AP4+ MSOP (6). 
AP4 2, PHC 75, and PHC 75+AP4 groups are same as in Table 3.3B. * P<0.01 and ** 
P<0.001 vs 6-OHDA; # P<0.01, ## P<0.001 and ### P<0.0001 vs the same treatment 
group without MSOP. † P<0.01, when compared the MSOP+L-AP4+PHCCC to the 
MSOP+ PHCCC group analysed by Two-way ANOVA followed by Bonferroni test.  
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did not reverse the 6-OHDA-induced reduction of striatal DA and the metabolites 
(DA: 76.37±3.33% loss, P=0.5722 vs 10.08±1.65%; DOPAC: 60.91±4.07% loss, 
P=0.0551 vs 6.40±2.65%; HVA: 47.27±5.45% loss, P=0.1331 vs 10.83±2.07%; and  
T/O: 0.43±0.03, P=0.1887 vs 0.18±0.02; Table 3.5A and B). In the combination 
treatment group of MSOP and L-AP4, the reduction of the 6-OHDA-induced 
percentage loss of TH and NeuN-IR cells by L-AP4 was totally blocked by MSOP 
(TH: 54.74±2.72% loss, P<0.01 vs L-AP4: 48.56±1.47% loss; NeuN: 56.59±2.66% 
loss, P<0.01 vs L-AP4: 49.89±1.88% loss; Fig 3.11A). However, similar blocking 
effects of MSOP on L-AP4 induced preservation of 6-OHDA-induced reduction of 
DA (75.85±2.22% loss, P=0.1522, vs L-AP4: 70.25±3.67% loss; Table 3.5A), 
DOPAC (55.88±1.98% loss, P=0.1308 vs L-AP4: 66.95±6.43% loss; Table 3.5A), 
HVA (56.69±3.82% loss, P=0.2756 vs L-AP4: 49.67±4.73% loss; Table 3.5A) were 
not observed. However, the effect of L-AP4 on T/O was reversed by MSOP 
(0.45±0.01, P<0.001, vs L-AP4: 0.34±0.02; Table 3.5B). These could be due to only a 
small degree of reversal of 6-OHDA-induced loss of striatal monoamines by L-AP4. 
Therefore the blocking effect of MSOP became not significant. However, MSOP 
could only partially block the neuroprotective effect of 75nmol PHCCC against 6-
OHDA-induced toxicity in term of numbers of TH and NeuN-IR cells (TH: 
36.62±2.54% loss, P<0.001 vs 75nmol PHCCC: 22.94±0.96% loss; NeuN: 
38.81±2.40% loss, P<0.01; vs 75nmol PHCCC: 30.05±2.51% loss; Fig 3.11A-B). 
Such a partial blocking effect of MSOP was also detected at the level of PHCCC 
preservation of the striatal monoamines loss induced by 6-OHDA (DA: 56.08±3.14% 
loss, P<0.0001 vs PHCCC alone: 15.43±2.40% loss; DOPAC: 49.42±3.94% loss, 
P<0.0001 vs PHCCC alone: 13.01±1.01% loss, HVA: 32.31±2.61% loss, P<0.001, vs 
PHCCC alone: 20.41±2.68% loss; and TO: 0.37±0.01, P<0.01, vs PHCCC alone: 
0.27±0.03; Table 3.5A and B). These findings suggested that neuroprotection by 
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PHCCC is only partially mediated by group III mGluRs.  
Whereas MSOP only partially blocked the neuroprotective effects of PHCCC 
alone against 6-OHDA toxicity MSOP almost entirely blocked the neuroprotective 
effects when PHCCC was administered in combination with L-AP4 in the SNc (TH: 
MSOP+PHCCC+L-AP4: 48.35±4.58% loss, P<0.0001 vs MSOP+PHCCC: 
36.62±2.54% loss; NeuN: MSOP+PHCCC+L-AP4: 48.22±2.09% loss, P<0.0001 vs 
MSOP+PHCCC: 38.81±2.40% loss, Fig 3.11A-B). Similarly, MSOP almost 
completely blocked the effects of combined PHCCC & L-AP4 treatment at the striatal 
DA level (MSOP+PHCCC+L-AP4: 69.25±2.51% loss, P<0.0001 vs MSOP+PHCCC: 
56.08±3.14% loss; Table 3.5A), DOPAC (MSOP+PHCCC+L-AP4: 58.16±3.28% loss, 
P<0.0001 vs MSOP+PHCCC: 49.42±3.94% loss; Table 3.5A), HVA 
(MSOP+PHCCC+L-AP4: 44.49±3.85% loss, P<0.0001 vs MSOP+PHCCC: 
32.31±2.61% loss; Table 3.5A) and T/O (MSOP+PHCCC+L-AP4: 0.44±0.02, 
P<0.0001 vs MSOP+PHCCC: 0.37±0.01; Table 3.5B). In Fig 3.12, we demonstrated 
that the co-administrated MSOP reversed the protection of the integrity of TH-IR cells 
in the SNc by PHCCC.  
 
3.3.7 Localization of mGluR4  
Although the neuroprotective effect of PHCCC was achieved partly through the 
allosteric modulation of mGluR4, we do not know which cell types express mGluR4. 
This information could also give vital information as to the potential mechanisms of 
neuroprotection. Expression studies of the localization of mGluR4 on different cell 
types including dopaminergic neurons (TH), astrocytes (GFAP) and microglia (OX6) 
were investigated by the double immunofluorescent staining. Consistent with previous 
studies, mGluR4 were detected on TH-IR cells (Fig 3.13; Valenti et al, 2005). The 
expression level of this receptor were not different on individual TH-IR neurons after  
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Fig 3.12: Representative photomicrographs of nigral TH-IR cells from 6-OHDA lesioned 
animals treated with L-AP4, PHCCC and L-AP4 in saline vehicle with or without MSOP 
Panels A-E, low power (x40; scale bar = 250µm) representative photomicrographs of 
contralateral (Cont) and ipsilateral (Ipsil) SNc to illustrate that MSOP reversed the 
neuroprotective effect of PHCCC, L-AP4 and combined treatment on the number of TH-IR cells. 
A) 6-OHDA alone (n=7), B) 50nmol MSOP (n=6), C) 50nmol MSOP + L-AP4 (n=6), D) 50nmol 
MSOP + 75nmol PHCCC (n=6) and E) 50nmol MSOP+75nmol PHCCC + L-AP4 (n=6), in 6-
OHDA model. For comparison, images of L-AP4, 75nmol PHCCC and 75nmol PHCCC+L-AP4 
could be referred to Fig 3.9.  
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Fig 3.13: Localization of mGluR4 on different cell types in the SNc 
Immunofluorescent images of both mGluR4-IR (red) and cell markers (TH, GFAP and OX6; 
green) –IR cells are illustrated at high power magnification (x400; Scale bar = 25µm). The merged 
images illustrated the co-localization of receptors and cell markers. The overlay stained cells was 
indicated by white arrows. Counter-staining by DAPI dye indicated the nuclei of the stained cells.  
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treatment with 6-OHDA, however with the global loss of TH-IR neurons in this 
model there was an overall loss of mGluR-IR neurons after 6-OHDA lesioning as 
observed previously by Gu et al, 2003. Consequently, PHCCC may firstly bring about 
its neuroprotective effects by allosteric modulation of mGluR4 on dopaminergic 
neurons but are such receptors present on microglia and astrocytes? In cell culture 
studies, the expression of mGluR4 has been detected on microglia (Fig 3.13; Taylor et 
al, 2003), but no studies have been carried out in vivo. Indeed, double 
immunofluorescent staining in the current study revealed the presence of mGluR4-IR 
on both astrocytes and microglia thus giving support to the concept that PHCCC may 
secondarily also mediate its neuroprotective effects via allosteric modulation of 
mGluR4 on these cell types. The localization study of mGluR4 in TH, GFAP and 
OX6-IR cells indicated the possible neuroprotective mechanism is via the direct 
modulation of dopaminergic neuronal mGluR4 and modulation of the glial mGluR4. 
 
3.3.8 Glial mediated mechanism of the neuroprotection by focally injected 
PHCCC 
Apart from neuronal loss and a decrease in functionality of the nigrostriatal tract, 
6-OHDA-induced neurotoxicity was associated with the activation and infiltration of 
glial cells, a phenomenon also observed by Teismann et al (2003). In the Sham-
operated group there was a weak and statistically insignificant proliferation of the 
GFAP-IR cells in the Sham lesioned SNc (120.30±5.29 cells, P=0.0936 vs 
107.50±3.93 cells; activation %: 10.21±3.16%; Fig 3.14A). 7 days after exposure to 
12µg 6-OHDA, there was a significant up-regulation of the number and activation 
state of the GFAP-IR cells in the lesioned SNc compared to Sham operated rats 
(lesioned side: 193.2±8.32 cells vs Sham: 110.30±4.85 cells, P<0.0001; activation %: 
42.86±1.34%; Fig 3.14A). Morphologically, unactivated GFAP-IR cells were depicted  
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A
B
Fig 3.14: Effect of sham and 6-OHDA lesioning on the number of 
astrocytes in the SNc
Infusion of 12 µg 6-OHDA in 4 µl into the left SNc results in a 
significant increase of A) GFAP-IR cells at 7 days post-lesion, 
whereas in sham-lesioned animals no significant GFAP-IR cell 
increase observed. Sham group received the ascorbic acid (0.1%) 
vehicle for 7 consecutive days. Data were expressed as the mean 
GFAP-IR cells ± SEM or mean percentage increase of GFAP-IR cells 
± SEM in lesioned side when compared to contralateral side. *** 
P<0.0001 6-OHDA vs. sham-lesioned animals (Student’s t test). 
Sham and 6-OHDA treatment groups for SNc injection n=6. B) 
Representative photomicrographs (x 400 magnification, scale bar = 
25µm) of GFAP-IR cells from the sham-lesioned and 6-OHDA 
lesioned SNc. 6-OHDA activated the GFAP-IR cells in term of the 
morphology and number. 
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with a small cell body with small thin processes, in which the intensity of GFAP 
immunoreactive signal was weak (Fig 3.14B). However, 6-OHDA activated GFAP-IR 
cells were depicted by large cell bodies with thickened and more numerous processes, 
in which the intensity of GFAP signal was much stronger (Fig 3.14B). Similarly 6-
OHDA lesioning in the SNc produced a marked microglial activation and 
proliferation as visualized by OX6 immunostaining. Sham lesioning produced a small 
but significant increase in the number of OX6-IR cells, possibly due to insertion of 
the injection needle or drug vehicle administration (lesioned: 19.29±1.45 P<0.0001 vs 
contralateral: 5.43±0.83, Fig 3.15A), where as 6-OHDA administration produced a 
marked increase in the number of OX6-IR cells in the SNc compared to Sham 
lesioned (6-OHDA: 43.6±4.15, P<0.0001 vs Sham: 19.29±1.45; activation fold: 
7.26±0.89 fold increase when compared to the contralateral side of brains; Fig. 3.15A). 
Morphologically, the unactivated microglia had a small soma with small spindly 
processes. In comparison, the activated microglia demonstrated as a ‘spider-like’ 
phenotype with more bulky processing and larger cell bodies (Fig 3.15B).  
Past research demonstrated that the modulation of mGluR4 influences glutamate 
release onto dopaminergic neurons in the SNc (Valenti et al, 2005). However, the 
neuroprotective action of PHCCC could also rely on the glial cells as mGluR4 was 
detected in astrocytes and microglia. In this study, we investigated whether PHCCC 
treatment could modify the glial response following 6-OHDA-induced neurotoxicity. 
As previously described, astrocytes, characterized by GFAP-IR, are activated by 6-
OHDA (Rodrigues et al, 2001). However, treatment with PHCCC was associated with 
a decreased number of GFAP-IR cells after 6-OHDA administration (F31.2, P<0.0001). 
Post hoc Student’s t test revealed that PHCCC produced a concentration-dependent 
reduction of 6-OHDA induced activation of astrocytes (8nmol: 31.72±1.44% increase, 
P<0.0001, 25nmol: 21.67±1.98% increase, P<0.0001, and 75nmol:23.09±1.97%  
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A
B
Fig 3.15: Effect of sham and 6-OHDA lesioning on the number 
of activated microglia in the SNc
Infusion of 12 µg 6-OHDA in 4 µl into the left SNc results in a 
significant increase of A) OX6-IR cells at 7 days post-lesion, 
whereas in sham-lesioned animals no significant OX6-IR cell 
increase observed. Sham group received the ascorbic acid (0.1%) 
vehicle for 7 consecutive days. Data were expressed as mean 
number of OX6-IR cells or the fold increased of OX6-IR cells ±
SEM in lesioned side when compared to contralateral side. Sham 
and 6-OHDA treatment groups for SNc injection n=6. ** P<0.001 
and *** P<0.0001 6-OHDA vs. sham-lesioned animals (Student’s t 
test). B) Representative photomicrographs (x 400 magnification, 
scale bar = 25µm) of OX6-IR cells from the sham-lesioned and 6-
OHDA lesioned SNc. 6-OHDA activated the OX6-IR cells in term 
of number and morphology.
6-OHDA (focal SNc)Sham (focal SNc)
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Fig 3.16: Preventive effect of PHCCC on 6-OHDA induced increase of 
number of GFAP-IR cells which is reversed by MSOP 
A) Subchronic intranigral administration of PHCCC (8, 25 and 75nmol) and 
2nmol L-AP4 for 7 consecutive days eliminated the 6-OHDA induced 
increasing number of GFAP-IR cells in the SNc. Furthermore, PHCCC (25 and 
75nmol) potentiated the preventive effect of L-AP4 on the increased number of 
GFAP-IR cells. n values in blanket: 6-OHDA (7), 2nmol L-AP4 (6), 8nmol (6), 
25nmol (6), 75nmol (6), 8nmol PHCCC + L-AP4 (6), 25nmol PHCCC + L-
AP4 (6) and 75nmol PHCCC + L-AP4 (6). **P<0.001 and ***P<0.0001 vs. 6-
OHDA. # P<0.01 and ## P<0.001 vs L-AP4 alone. B) Subchronic intranigral 
administration of 50nmol MSOP reversed the preventive effect of L-AP4, 
PHCCC and PHCCC+L-AP4 on 6-OHDA-induced increased of number of 
GFAP-IR cells. 6-OHDA group received the neutralized NaOH vehicle for 7 
consecutive days. All data shown were mean percentage increase of GFAP-IR 
cells ± SEM in leisoned side when compared to contralateral side. n values in 
brackets: 6-OHDA (7), 50nmol MSOP (6), 2nmol L-PA4 (6), 2nmol L-AP4 + 
MSOP (6), 75nmol PHCCC (6), MSOP + 75nmol PHCCC, and 75nmol 
PHCCC+L-AP4 (6) and with MSOP (6). * P<0.01 and *** P<0.0001 vs. 6-
OHDA. # P<0.01, ## P<0.001 and ### P<0.0001 vs the same treatment of 
PHCCC without MSOP. All data were analyzed by Two-way ANOVA 
followed by Bonferroni test. 
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increase, P<0.0001, vs 6-OHDA: 42.86±1.09% increase; Fig 3.16A). Furthermore, the 
combination of increasing concentrations of PHCCC with L-AP4 produced a further 
reduction in the number of GFAP-IR cells (F97.95, P<0.0001; 8nmol+L-AP4: 
22.24±2.13% increase, vs PHCCC alone: 31.72±1.44% increase, P<0.001, vs L-AP4: 
38.23±1.95% increase, P<0.0001; 25nmol+L-AP4: 9.63±1.28% increase, vs PHCCC 
alone: 21.67±1.98% increase, P<0.0001, vs L-AP4: 38.23±1.95% increase, P<0.001; 
75nmol+L-AP4: 17.02±2.04% increase, vs PHCCC alone: 23.09±1.97% increase, 
P<0.0001; vs L- AP4: 38.23±1.95% increase, P<0.001; Fig 3.16A). Moreover, MSOP 
co-treatment blocks the suppression of astrocytic activation after 6-OHDA by PHCCC 
(MSOP+PHCCC: 40.30±3.14% increase, P<0.001, vs PHCCC: 23.09±1.97% increase; 
Fig 3.16B). Such blocking effect could also be found when MSOP was co-
administered with PHCCC and L-AP4 on the 6-OHDA-activated GFAP-IR cells 
(MSOP+PHCCC+L-AP4: 45.66±3.78% increase, P<0.0001 vs PHCCC+L-AP4: 
17.02±2.04% increase; Fig 16B).  
Similarly, we have previously demonstrated that 6-OHDA administration is 
associated with an infiltration and activation of microglia (Rodrigues et al, 2001). L-
AP4 alone had no effect on the number of OX6-IR cells after 6-OHDA lesioning (L-
AP4: 9.11±1.06 folds increase, P=0.1653 vs 6-OHDA: 7.29±0.67 folds increase; Fig 
3.17A). Instead it induced an increase of OX6-IR cells. Although the mGluR4 
activation prevents the microglial activation, this dose is possibly too low to prevent 
the microglial activation. However, we cannot explain the further increase of activated 
microglia. While treatment with either 25 or 75nmol PHCCC decreased the 6-OHDA  
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Fig 3.17: Preventive effect of PHCCC on 6-OHDA-induced increase of 
number of OX6-IR cells reversed by MSOP 
A) Subchronic intra-SNc administration of PHCCC (25 and 75nmol), but not 
2nmol L-AP4, prevented the 6-OHDA induced increase of OX6-IR cells. 
However, PHCCC did not potentiate the preventive effect of L-AP4 on the 6-
OHDA induced increase of OX6-IR cells. n values in blanket: 6-OHDA (7), 
2nmol L-AP4 (6), 8nmol PHCCC (6), 25nmol PHCCC (6), 75nmol PHCCC (6), 
8nmol PHCCC+L-AP4 (6), 25nmol PHCCC+L-AP4 (6) and 75nmol PHCCC+L-
AP4 (6). * P<0.01 vs. 6-OHDA (2-way ANOVA followed by Bonferroni test). B) 
The blocking effect of MSOP on the prevention in PHCCC treatment groups. n 
values in brackets: 6-OHDA (7), 50nmol MSOP (6), 2nmol L-PA4 (6), 2nmol L-
AP4 + MSOP (6), 75nmol PHCCC (6), MSOP + 75nmol PHCCC, and 75nmol 
PHCCC+L-AP4 (6) and with MSOP (6). * P<0.01 vs. 6-OHDA. # P<0.01 vs the 
same treatment without MSOP. 6-OHDA group received the neutralized NaOH 
vehicle for 7 consecutive days. All data shown were mean increased folds of 
OX6-IR cells ± SEM in lesioned side when compared to contralateral side and 
analyzed by 2-way ANOVA followed by Bonferroni test.  
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induced proliferation of activated microglia (OX6-IR; 8nmol: 7.75±0.46 folds 
increase, P=0.6066; 25nmol: 4.96±0.46 folds increase, P<0.01; 75nmol: 4.88±0.51 
folds increase, P<0.01; vs 6-OHDA: 7.29±0.67 folds increase; Fig 3.17A). 
Interestingly, the combination of PHCCC and L-AP4 did not potentiate the effects of 
PHCCC alone on the suppression of microglial activation in fact it made it worse.  
(F18.37, P<0.0001; 8nmol+L-AP4: 7.62±0.46 folds increase, vs PHCCC alone: 
7.75±0.46 folds increase, P=0.1328, vs L-AP4: 9.11±1.06 folds increase, P=0.1192; 
25nmol+L-AP4: 6.09±0.48 folds increase, vs PHCCC alone: 4.96±0.46 folds increase, 
P=0.0712, vs L-AP4: 9.11±1.06 folds, P=0.0816; 75nmol+L-AP4: 6.67±0.51 folds, vs 
PHCCC alone: 4.88±0.51 folds increase, P=0.09321, vs L-AP4: 9.11±1.06 folds 
increase, P=0.0771; Fig 3.17A). Furthermore, MSOP blocked the reductive effect of 
PHCCC on the 6-OHDA-activated microglia (MSOP+PHCCC: 8.19±0.99 folds 
increase, P<0.01 vs PHCCC: 4.88±0.51 folds increase, Fig 3.17B). Such blocking 
effect of MSOP could also be found when MSOP was co-administered with 75nmol 
PHCCC and L-AP4 on the 6-OHDA-activated microglia (MSOP+PHCCC+L-AP4: 
9.72±1.18 folds increase, P<0.01 vs PHCCC+L-AP4: 6.67±0.51 folds increase, Fig 
3.17B).  
 
3.4 Discussion and conclusion 
In this study we have clearly demonstrated the implantation of indwelling 
cannulae themselves causes very little damage to the nigrostriatal tract. In contrast, 
the infusion of 6-OHDA induced a significant loss of the dopaminergic neurons in the  
SNc, resulting in a depletion of striatal DA and its metabolites reminiscent of the 
neuropathological and biochemical changes in early diagnosed PD. The toxic effects 
of 6-OHDA may be mediated by the induction of oxidative stress, altered iron 
metabolism, increased glutamate release and the inhibition of mitochondrial complex 
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I and IV, resulting in the apoptosis of the dopaminergic neurons (Gorman et al, 2005; 
Glinka and Youdim, 1995). In this study the close agreement between the TH and 
NeuN-IR data would indicate that 6-OHDA produces toxicity to dopaminergic 
neurons rather than change in TH expression. 
Furthermore, 6-OHDA induced marked astrogliosis in the SNc was consistent 
with the previous study (Rodrigues et al, 2004). Interestingly, the mechanical damage 
by cannulation and the subsequent injection of drug vehicle induced only a small 
increase in astrocytes. The activated astrocytes had larger cell bodies with thicker and 
longer processes, indicating activation. In addition, the degree of GFAP expression 
was also increased after 6-OHDA administration again indicating activation. This was 
supported by a study by Sheng et al. (1993). However, the role of activated astrocytes 
in 6-OHDA toxicity is not clear. According to certain studies, activated astrocytes play 
a role to defend against foreign or intrinsic toxins (Tritsch and Bergles, 2007). 
Activated astrocytes synthesize and release neuroprotective and neurotrophic factors, 
such as glial cell-derived neurotrophic factor (GDNF) and brain-derived neurotrophic 
factor (BDNF). Such neurotrophic factors are neuroprotective in some in vivo rats and 
in vitro PD studies (Aoi et al, 2000; Kordower, 2003; Onyango et al, 2005). 
Furthermore, astrocytes scavenge increased extracellular glutamate concentrations 
which could induce the cell death of dopaminergic neurons (Yao et al, 2005). 
However, the synthesis and release of pro-inflammatory factors from activated 
astrocytes could also implicate a neurotoxic role. Aside from the astrogliosis, the 
infiltration and activation of the microglia was also demonstrated by an increase in 
OX6-IR in these studies which is consistent with studies in 6-OHDA and MPTP PD 
models (Mihara et al. 2008; Rogers et al. 2007). In addition, activated microglia have 
been detected in several brain areas in PD, raising the possibility that the activation 
may be detrimental (Reynolds et al, 2008 a and b; Schwarz et al, 1998). Interestingly, 
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Sham lesioning produced a moderate activation of microglia in the SNc, suggesting 
the implantation and/or injection of vehicle was sufficient to induce the activation of 
microglia whereas 6-OHDA induced a marked activation of microglia. Therefore, in 
these studies 6-OHDA lesioning produced a partial lesion model with astrocytic and 
microglial activation; a suitable test best for the early preclinical testing of the 
neuroprotective effects of mGluRs modulation.  
 
3.4.1 Neural mechanism of PHCCC on the mGluR4 
From the biochemical and immunohistochemical analysis in the current study 6-
OHDA-induced neurotoxicity was attenuated by focally administered PHCCC in a 
concentration-dependent manner. Furthermore, at some concentrations PHCCC 
potentiated the neuroprotective effect of L-AP4 against 6-OHDA-induced 
neurotoxicity, whilst at other concentration the effects were additive. Activation of 
group III mGluRs has been demonstrated to produce anti-Parkinsonian effects in 
haloperidol and MPTP PD models (Konieczny et al, 2007; Lopez et al, 2007). 
Additionally, the broad spectrum group III mGluRs agonist, L-AP4, and the mGluR4-
specific agonist, ACPT-1, has been shown to reverse the haloperidol-induced 
behavioural abnormality (Lopez et al, 2007). Similarly, the activation of group III 
mGluRs has been shown to alleviate the reserpine-induced akinesia in rodents 
(MacInnes et al, 2004). Furthermore, the activation of group III mGluRs, specifically 
mGluR4 but not mGluR8, in the striatopallidal synapses in the BG inhibits the first 
GABAergic neurons then result in the activation of the second GABAergic neurons 
(pallidus to STN) but down regulation of glutamatergic transmission (Valenti et al, 
2003). Asides from the anti-Parkinsonian properties, our group has demonstrated that 
activation of group III mGluRs by the broad-spectrum agonist, L-AP4, protects the 
dopaminergic neurons in the SNc against 6-OHDA-induced neurotoxicity (Vernon et 
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al, 2005 and 2007b). The activation of mGluR4 decreases cytosolic levels of cAMP 
via the binding of Gi protein to adenylate cyclase, resulting in the deactivation of 
protein kinase A (PKA). The deactivation of PKA by mGluR4 activation increases the 
activity of the potassium channel and hence inhibits the neural transmission and 
promotes cell survival (Cain et al, 2008 and Maiese et al, 1996). In addition, PHCCC 
activates the extracellular signal-regulated kinase 1/2 (ERK1/2) which also regulates 
glutamate-mediated neural plasticity and glutamate excitotoxicity (Canudas et al, 
2004; Ferraguti et al, 1999). Therefore, the neuroprotective potential of PHCCC relies 
on the mGluR4 activation which inhibits the glutamate neurotransmission and even 
the excitotoxicity. Indeed, the significance of the anti-Parkinsonian and dopaminergic 
neuroprotective properties of regulating group III mGluRs has also been summarized 
in certain review articles (Feeley Kearney and Albin, 2003; Ossowska et al, 2007).  
As reported previously, PHCCC is the positive allosteric modulator of mGluR4 
(Maj et al, 2003; Marino et al, 2003b). To confirm the allosteric modulating property 
of PHCCC, it was administered with a low concentration of L-AP4 (2nmol). In the 
current study, we showed that the activation of mGluR4 by PHCCC also provide a 
similar degree of neuroprotection to L-AP4, as observed also in previous studies in 
this group (Vernon et al, 2007b). Indeed, the allosteric modulation of mGluR4 in the 
presynaptic terminals in the STN-SNc synapse prevents glutamate release onto 
dopaminergic neurons in the SNc (Valenti et al, 2003 and 2005). Consequently, the 
excitotoxic-induced apoptosis could be modulated by PHCCC. Hypothetically, the 
cellular protection of dopaminergic neurons by allosteric modulation on mGluR4 
could help to preserve the integrity of the nigrostriatal functionality. As described 
previously in this group, 10nmol L-AP4 provided maximum neuroprotection for the 
dopaminergic neurons in the SNc against the 6-OHDA-induced neurotoxicity in 
which the loss of TH-IR neurons was reduced from about 65% to 30% (Vernon et al, 
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2007b). In the same model we demonstrated that 2nmol L-AP4 provided a higher 
degree of neuroprotection for the dopaminergic neurons with the co-administration of 
25 and 75nmol PHCCC rather than 10nmol L-AP4 alone (~20% for 25nmol 
PHCCC+2nmol L-AP4 vs ~30% for 10nmol L-AP4 from Vernon et al, 2007). 
50nmmol L-AP4 failed to provide any significant neuroprotection possibly because of 
initiation of internalization of mGluR4 (Vernon et al, 2007b). This unwanted effect 
could be avoided by administration of PHCCC alone or in combination with a low 
dose of L-AP4, implying that highly selective allosteric modulators could provide a 
safer and reliable therapy for PD without the unwanted effect induced by the higher 
concentration L-AP4. Additionally, PHCCC is lipid soluble which guarantees its 
interaction with allosteric sites in the transmembrane domains of the receptors. This 
property of allosteric modulators may also impart good brain penetration unlike many 
other mGluR ligands which are poorly BBB penetrant (Gao and Jacobson, 2006; 
Marino and Conn, 2006). The utilization of allosteric modulators may provide a more 
specific treatment with hopefully fewer side effects. High lipid solubility of such 
modulators also leads to high bioavailability and high efficacy. Furthermore, some 
groups claimed that the binding of allosteric modulators to the transmembrane 
domains of the receptors prevents receptor internalization thus preventing drug 
desensitisation since there are not directly activate the receptor (Marino and Conn, 
2006). Therefore, allosteric modulators have recently become the focus of drug 
development in many neurological diseases, including PD. In this study, 2nmol L-
AP4 alone produced only a weak neuroprotection, consistent with previous 
observations by this group (Vernon et al, 2007b).  
Such allosteric potentiation of PHCCC could not be demonstrated successfully 
in the current study. When PHCCC was administered together with L-AP4, the 
neuroprotection as assessed by the number of TH-IR cells was potentiated at the 
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higher doses of PHCCC (25 and 75nmol) however, when considering the 
neuroprotection at the NeuN-IR level the effects of PHCCC combined with L-AP4 
appeared to be more additive rather than potentiation. Importantly, no loss of 
neuroprotective effect with PHCCC was observed at high doses, even when combined 
with L-AP4. Hence, allosteric modulation at mGluR4 by PHCCC potentiates/adds to 
the neuroprotective effect of a low concentration of L-AP4 and may avoid 
desensitisation of the receptor which is observed at higher dose of L-AP4. Moreover, 
surprisingly only the high concentration of PHCCC prevented 6-OHDA induced loss 
of striatal levels of monoamines illustrated in the current study. Such findings were 
consistent with the previous study by Valenti and colleagues in which a relatively low 
concentration of PHCCC (30µM) failed to affect the excitatory postsynaptic current 
(EPSC) in the nigral dopaminergic neurons (Valenti et al, 2005). Therefore, the 
restoration of striatal DA might rely on high concentration of PHCCC (> 25nmol, see 
section 3.3.3). 
After demonstrating the neuroprotective effect of PHCCC we then investigated 
whether such mechanisms are receptor mediated utilising the broad spectrum group 
III mGluRs antagonist MSOP. Surprisingly, MSOP only partially blocked the 
neuroprotective actions of PHCCC, indicating that another mechanism in addition to 
allosteric modulation of mGluR4 may be involved in the neuroprotective effects of 
PHCCC. This partial effect of MSOP was also observed when PHCCC was combined 
with L-AP4. Indeed, PHCCC has been previously reported to act as a weak antagonist 
of mGluR1b, whilst antagonism at mGluR1 has been shown to have anti-Parkinsonian 
effects (Dekundy et al, 2006). Furthermore the blockade of group I mGluRs by the 
specific antagonists, including MPEP and LY 367385, prevent the Parkinsonian 
behavioural abnormalities and dopaminergic neuronal degeneration (Vernon et al, 
2005; and Phillips et al, 2006). Accordingly, any neuroprotection is possibly due to 
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two mechanisms, firstly due to the antagonism of group I mGluRs by PHCCC and 
secondly due to the allosteric modulation of mGluR4 by PHCCC making them more 
responsive to exogenously released glutamate. This could potentially be investigated 
by the co-administration of a mGluR1b agonist with PHCCC and MSOP to see 
whether this treatment prevents the neuroprotective effects of PHCCC. Interestingly, 
MSOP produced a greater reversal of the neuroprotective effects of L-AP4 and 
PHCCC in combination than PHCCC treatment alone. Suggesting that in the presence 
of a higher concentration of mGluR4 agonist, i.e. above basal glutamate levels, 
PHCCC may function mainly as a modulator at mGluR4. Whereas, PHCCC alone 
may mainly act as mGluR1b antagonist combined with mGluR4 potentiation through 
basal glutamate levels. The data concerning whether the neuroprotective effects of 
PHCCC were potentiated by the presence of L-AP4 were far from clear with some 
potentiation observed at the higher doses of PHCCC when considering the numbers of 
TH-IR cells but this was not supported by the data from the NeuN cell counts. To 
clarify whether L-AP4 can potentiate the effects of PHCCC further studies should be 
carried out using a very low concentration of L-AP4 (lower than 2nmol in the current 
study) which provides no neuroprotection alone. The allosteric potentiation could be 
elucidated if there is the synergistic neuroprotection could be observed when 
compared to PHCCC administered alone in this 6-OHDA PD model.  
 
3.4.2 Involvement of glial cells in PHCCC neuroprotection 
Typically, the underlying mechanism of PHCCC neuroprotection is associated 
with the allosteric modulation of mGluR4 at presynaptic (the glutamatergic neurons) 
neurons of the subthalamonigral tract, resulting in the modulation glutamate release 
and excitation (Valenti et al, 2003 and 2005). However, excitotoxicity mediated by 
glutamate in PD models, such as 6-OHDA, may only be a minor factor in neuronal 
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loss (Olanow, 2007). Therefore, the strong neuroprotective effect of PHCCC may not 
only rely on the regulation of glutamate transmission, but also it may depend on other 
mechanisms, possibly glial cells. The involvement of glial cells is implicated by the 
mGluR4 expression on both astrocytes and microglia in the current study which is 
consistent with other studies utilising glial cell cultures (Taylor et al, 2003 and Yao et 
al, 2005). Although the decreased astrocytic response associated with PHCCC 
treatment, with or without L-AP4, could simply represent the neuroprotective effects 
of these compounds which would result in diminished astrocytic triggers, the presence 
of mGluR4 on astrocytes does raise the possibility that mGluR4 activation may 
modulate astrocytic activity directly. Astrocytes can play a dual role in tissue damage, 
firstly a role in repair/neuroprotection by the release of growth factors and the 
removal of toxins (Chen et al, 2006 and Cunningham and Su, 2002). However, 
secondly astrocytes can play a potentially damaging role in the inflammatory response 
through the release of inflammatory factors (Gabryel et al, 2004). Hence, further cell 
culture studies are required before we clarify whether mGluR4 stimulation can 
directly modify astrocytic responses. 
Furthermore, neuroprotective effects of intranigral administration of PHCCC 
was associated with reduced microglial activation by 6-OHDA and effect was blocked 
by MSOP co-administration. Although again such effects could simply reflect the 
preservation of dopaminergic neurons and the removal of activational triggers, the 
presence of mGluR4 receptors on microglia raises the possibility that PHCCC may 
have some direct effect on the innate inflammatory response. Activated microglia 
release pro-inflammatory factors such as TNFα, IL1β and IL6 which induce 
dopaminergic apoptosis (Carvey et al, 2005). Indeed, the prevention of 6-OHDA 
induced activation of microglia by minocycline prevents SNc dopaminergic neuronal 
degeneration (He et al, 2001).  Therefore, the prevention of microglial activation and 
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the subsequent release of pro-inflammatory factors by PHCCC could contribute to the 
neuroprotective process. Indeed, in an in vitro microglial culture study, group III 
mGluRs agonist, L-AP4, prevents LPS-induced microglial activation (Taylor et al, 
2003).  
 
3.4.3 Conclusion  
In the current study, we successfully demonstrated the neuroprotective 
properties of PHCCC, a positive allosteric modulator of mGluR4, in the 6-OHDA PD 
model. Therefore, PHCCC is capable of preventing the degeneration of nigrostriatal 
tract in 6-OHDA lesion model. With the maintenance of the integrity of nigrostriatal 
tract, the Parkinsonian symptom could possibly be prevented.  
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Chapter 4: Neuroprotective effect of the mGluR8 agonist, (S)-DCPG, 
in the 6-OHDA rat model of PD 
4.1 Introduction  
4.1.1 Neuroprotective potential of group III mGluRs 
The neuroprotective effects of broad spectrum group III agonist L-AP4 in the 6-
OHDA model indicated that the activation of group III mGluRs may be one of the 
promising targets for developing better PD drug treatments (Vernon et al. 2007b). 
However, L-AP4 has a similar affinity for both mGluR4 and 8 receptors, mRNA for 
both of which has been reported to be present in the SNc (Messenger et al, 2002). L-
AP4 has also been shown to have a lower affinity for mGluR7 (Naples and Hampson, 
2001). Hence, studies by Vernon and colleagues (2007b) were unable to say by which 
mGluR L-AP4 was producing its neuroprotection. In order to investigate which group 
III mGluRs mediate the neuroprotective effects of L-AP4 this thesis has set out to 
examine the neuroprotective effects of more selective mGluR ligands. In the previous 
chapter we utilised the mGluR4 neuromodulator PHCCC which was neuroprotective 
in the 6-OHDA model of PD. To investigate the potential role of mGluR8 activation 
in L-AP4 neuroprotection we have utilised the selective mGluR8 agonist, (S)-3,4-
Dicarboxyphenylglycine ((S)-DCPG), described in this chapter (Fig 4.1).  
 
4.1.2 Hypothesis for neuroprotection by mGluR8 
Similar to mGluR4, mGluR8 are reported to be located presynaptically 
functioning as autoreceptors that control the presynaptic release of the 
neurotransmitters (Zhai et al, 2002). This hypothesis is supported by the anti-
convulsant and anxiolitic effect of activating mGluR8 presynaptically by (S)-DCPG 
(Lee et al, 2003; Moldrich et al, 2003; Schmid and Fendt, 2006). However, there are 
no reports about the anti-Parkinsonian and neuroprotective properties of (S)-DCPG in  
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Fig 4.1: The chemical structure of (S)-3,4-Dicarboxyphenylglycine, 
(S)-DCPG. (From www.tocris.com) 
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animal models of PD. Interestingly, intrapallidal administration of (S)-DCPG failed to 
prevent catalepsy induced by haloperidol (Ossowska et al. 2007). However, utilising 
Fluro-Jade staining to detect degenerating neurons, the activation of mGluR8 by (S)-
DCPG prevented the death of cerebral neurons exposed to NMDA (Folbergrová et al, 
2008). Since mRNA for mGluR8, and potentially the corresponding receptors protein, 
has been located in the rat SNc (Messenger et al, 2002) we therefore hypothesize that 
the activation of mGluR8 in the SNc could contribute to the neuroprotective effects of 
L-AP4 in animal models of PD. To investigate this we have utilised the mGluR8 
selective agonist (S)-DCPG in the 6-OHDA lesion model.  
 
4.1.3 Dicarboxyphenylglycine (DCPG) 
(R,S)-DCPG was first developed by Thomas and co-workers as an AMPA 
receptor antagonist and mGluR8 agonist (Thomas et al, 1997; 2001). The same group 
also discovered that (S)-DCPG specifically modulates afferent terminal in the 
peripheral nervous system via the activation of mGluR8 (Thomas et al, 2001). In 
addition, the systemic administration of (R,S)-DCPG relieved the amphetamine-
induced hyperactivity, implying that the systemic activation of mGluR8 or blockade 
of AMPA could modulate the extrapyramidal activity (Ossowska et al. 2004) 
 
4.1.4 Aims of this chapter 
The specific aims of this chapter were as followed:  
1. Investigate whether activation of mGluR8 in the SNc alone by (S)-DCPG is 
neuroprotectory in the 6-OHDA model of PD. This was achieved by the focal 
administration of (S)-DCPG via indwelling cannulae. 
2. Investigate whether neuroprotective actions by focal (S)-DCPG administration 
are mediated via Group III mGluRs  
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3. Investigate the mechanisms for (S)-DCPG neuroprotection by firstly 
identifying the cellular localization of mGluR8 receptors in the SNc and 
secondly by investigating whether (S)-DCPG modulates microglial or 
astrocytic activation. 
 
4.2 Experimental design 
4.2.1 The effect of (S)-DCPG treatment alone in the sham lesioned rats 
To investigate the effect of (S)-DCPG alone on the SNc dopaminergic neurons, 
(S)-DCPG (50nmol) was administered intranigrally once daily in a total volume of 
4µl via the indwelling cannulae for 7 consecutive days 10 days after the surgery of 
implantation of cannulae (section 2.2.3). At the end of experiment, the hindbrains and 
striata were removed for further analysis (section 2.2.4). The integrity of the 
dopaminergic neurons in the nigrostriatal pathway were analysed by 
immunohistochemistry with TH and NeuN antibodies (see section 2.2.6 and 7). 
Meanwhile, concentrations of dopamine (DA) and its metabolites were measured by 
HPLC (section 2.2.8). The dosing schedule is illustrated in Fig 4.2.  
 
4.2.2 Neuroprotective effect of focally injected (S)-DCPG in the 6-OHDA-model 
of Parkinson’s disease.  
The neuroprotective potential of (S)-DCPG was analysed by the daily intranigral 
sub-chronic treatment with either 0.4, 2, 10 or 50nmol (S)-DCPG in a total injection 
volume of 4µl 0.9% NaCl saline solution (pH=7.4) via the indwelling cannulae for 7 
consecutive days. 12µg 6-OHDA was infused into the SNc via the indwelling 
cannulae one hour after the first injection of (S)-DCPG. In order to account for the 
possible dilution of toxin effects by solvent, control animals received unilateral 
intranigral administration of 4µl (S)-DCPG drug vehicle one hour prior to 6-OHDA.  
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5-7 days 
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Fig 4.2: The experimental schedule for the study of focal administration of 
(S)-DCPG Sham lesioned animals 
1st focal 
Injection of 
(S)-DCPG or 
vehicle 
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At the end of the study period rats were sacrificed and the brain removed for 
further analysis. The toxic effects of 6-OHDA on the nigrostriatal dopaminergic 
neurons were analysed by immunohistochemistry with TH and NeuN antibodies 
(section 2.2.6 and 7). The concentration of striatal DA and its metabolites were 
analysed by HPLC (section 2.2.8). The dosing schedule is illustrated in Fig 4.3.  
 
4.2.3 Proof of mGluR group III receptor mediated mechanism for the 
neuroprotective effect of (S)-DCPG in the 6-OHDA model. 
To investigate whether the neuroprotective effects of (S)-DCPG are mediated 
via mGluR8 50nmol of the broad spectrum group III mGluRs antagonist MSOP was 
administered daily with or without 50nmol (S)-DCPG in a total injection volume of 
4µl. One hour after the first dosing of the MSOP with or without (S)-DCPG, 12µg 6-
OHDA was infused to induce the lesion of the dopaminergic neurons. 7 days after the 
lesion induction, the brain tissue was removed for further analysis. The toxic effects 
of 6-OHDA on the nigrostriatal dopaminergic neurons was investigated by 
immunohistochemistry with TH and NeuN antibodies in SNc tissue sections (section 
2.2.7). Concentrations of striatal monoamines were analysed by HPLC (section 2.2.8). 
The dosing schedule is shown in Fig 4.4.  
 
4.2.4 Mechanisms of (S)-DCPG neuroprotection against 6-OHDA-induced 
toxicity 
 In order to investigate possible mechanisms by which (S)-DCPG produces its 
neuroprotective effects the localization of mGluR8 was examined by double 
immunofluorsecent staining with specific markers for dopaminergic neurons (TH), 
astrocytes (GFAP) and microglia (OX-6) (see section 2.2.9).  After confirming the 
expression of mGluR8 on microglia and astrocytes, the effect of (S)-DCPG  
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administration on the degree of astrocytic (GFAP) and microglial (OX-6) activation  
after 6-OHDA toxicity was then investigated by immunohistochemical techniques 
(section 2.2.6 and 7). Furthermore, MSOP was utilized to investigate whether 
blockade of group III mGluRs had any effect on the glial modulation produced by (S)-
DCPG.  
 
4.2.5 Statistical analysis 
NeuN- and TH-IR cells in both lesioned and contralateral sides of all treatment 
groups was expressed as percentage loss ± S.E.M in relation to the control 
(unlesioned) side of brain, as indicated in different sections. GFAP- and OX6-IR cells 
were demonstrated as percentage/fold increase ± S.E.M. For the monoamines level, 
data was presented as percentage decrease of monoamine ± S.E.M. For the turnover 
ratio of striatal dopamine (T/O), data was expressed as the turnover level ± S.E.M. 
The calculation of turnover was shown below:  
{[DOPAC (nmol/mg) + [HVA (nmol/mg)]} 
[DA (nmol/mg)] 
In all figures, n values (number of animals in each treatment group) were shown in the 
caption of each figure. The mean values of each group were average of the mean 
values of each individual rat in the same groups.  
Data was analyzed by a series of statistical analysis. By the one-way analysis of 
variants (ANOVA) among different treatment groups, statistic significance among 
different treatment groups was analyzed under the assumption of random sampling 
and normal distribution. In the analysis of MSOP vs (S)-DCPG, the significance was 
analyzed by the two-way ANOVA. Subsequently, there was the post hoc analysis in 
form of a Bonferroni test made between the lesioned sides of drug treatment groups 
and the vehicle group. Unpaired Student’s t tests were made between lesioned and 
 167 
contralateral sides in the same groups. Where alternative tests are utilised they are 
indicated in the relevant sections. The significant differences were shown by 
expressing the P value as P<0.01 (indicated as *, # or †), 0.001 (**, ## or ††) and 
0.0001 (***, ### or †††), which was also annotated in the figures or tables. All 
statistical analysis was performed using Software package of GraphPad Prism version 
4.00 (GraphPad Software, USA). 
 
4.3 Result 
4.3.1 Effect of intranigral sub-chronic administration of (S)-DCPG alone on the 
integrity of the nigrostriatal system 
To investigate the effects of (S)-DCPG administered alone on the integrity of 
nigrostriatal system, (S)-DCPG (50nmol) was administered daily to the left SNc in 
sham lesioned animals for 7 consecutive days. Immunohistochemical analysis 
revealed that (S)-DCPG administration had no effect on the numbers of TH-IR cells 
(DCPG alone: 6.92±0.71%, P=0.8793 vs Sham: 7.11±0.97%, Fig 4.5A) or NeuN-IR 
(DCPG alone: 5.87±1.04%, P=0.5581 vs Sham: 6.72±0.94%, Fig 4.5A) neurons when 
comparing the vehicle and (S)-DCPG-alone groups. Representative photomicrographs 
of the TH-IR and NeuN-IR neurons in the SNc are shown in the Fig 4.5B. The density 
of TH-IR neurons in the SNc was not decreased when 50nmol (S)-DCPG was 
administered to the SNc. Consistent with the lack of effect of (S)-DCPG on the 
integrity of dopaminergic neurons, (S)-DCPG administration for 7 days had no effect 
on striatal DA (9.31±1.14% loss, P=0.7034 vs Sham: 8.48±1.23% loss; Table 4.1), 
DOPAC (10.74±4.54% loss, P=0.4186 vs Sham: 6.65±1.68% loss; Table 4.1) and 
HVA (7.22±1.94% loss, P=0.4138 vs Sham: 9.42±1.69% loss; Table 4.1) between the 
vehicle and (S)-DCPG-only groups observed. Furthermore, no significant increase of 
the striatal DA TO was detected when compared to the vehicle (0.21±0.02, P=0.1284  
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Fig 4.5: Effect of (S)-DCPG on the number of TH, NeuN, GFAP and OX6-IR 
cells in the SNc of Sham lesioned rat 
A) Subchronic administration of (S)-DCPG (50nmol) dissolved in saline focally to the 
SNc for 7 days did not reduce the loss of TH and NeuN-IR cells. Sham groups 
received saline vehicle for 7 days. All data were mean percentage loss of cells in 
lesioned side when compared to contralateral side ± SEM, n values of sham-lesioned 
and PHCCC alone treatment groups are 6. B) Representative photomicrographs of TH 
(x40; scale bar=250µm), GFAP and OX6-IR cells (x400; scale bar=50µm) from the 
Sham and (S)-DCPG alone treated animals. (S)-DCPG did not induced loss of TH-IR 
cells or the activation of the OX6-IR cells morphologically. However, (S)-DCPG 
itself may activate the GFAP-IR cells morphologically. 
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7.22±1.05 
9.42±1.69 
HVA (% loss) 
10.74±1.64 
6.65±1.68 
DOPAC (% loss) 
9.31±1.31 
8.48 ±1.23 
DA (% loss) 
DCPG only 
Sham 
Group 
Ipsilateral Contralateral 
 
Group 
0.21±0.02 
0.17±0.02 
0.15±0.02 
0.18±0.02 
TO 
DCPG only 
Sham 
Table 4.1: Subchronic intra-SNc administration of 50nmol (S)-DCPG dissolved in 
neutralized NaOH for 7 consecutive days did not affect the level of monoamines and 
the turnover of dopamine in striata. Data were shown as mean percentage change of 
monoamines level in lesion side when compared to contralateral side ±SEM or mean 
TO ±SEM. N numbers in brackets: Sham (6) and 6-OHDA (6). Data were analyzed 
by Student’s t test.  
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vs Sham: 0.17±0.02; Table 4.1). From the observation above, the 7-day sub-chronic 
administration of (S)-DCPG itself to the SNc did not induce any functional and 
cellular modification of the nigrostriatal system. Interestingly, (S)-DCPG treated 
alone induced the enlargement of astrocytic cell bodies, increased GFAP expression 
and the number of astrocytic processes (Fig 4.6B).  
 
4.3.2 Neuroprotective effects of sub-chronic SNc focal administration of (S)-
DCPG against 6-OHDA induced neurotoxicity 
Similar to the description in Chapter 3, administration of 12µg 6-OHDA to the 
SNc induced a significant decrease in the number of TH (56.94±2.49%, P<0.0001; 
Fig 4.6A) and NeuN-IR cells (66.94±2.49%, P<0.0001; Fig 4.6B) 7 days after lesion 
induction. The similar loss of TH and NeuN-IR cells confirms the actual loss of 
dopaminergic neurons rather than a decrease in TH expression. Similarly infusion of 
12µg 6-OHDA into the SNc induced a significant reduction in concentrations of 
striatal DA (91.01±2.15% loss, P<0.0001; Table 4.1A), DOPAC (73.58±8.77% loss, 
P<0.01; Table 4.1A) and HVA (85.15±7.01% loss, P<0.0001; Table 4.1A) compared 
to the unlesioned side of the brain. Administration of 6-OHDA also induced an 
increase of striatal DA TO (0.54±0.08, P<0.0001, vs unlesioned side: 0.17±0.02; 
Table 4.2A) in the lesioned side of the brain compared to the unlesioned side.  
To investigate the neuroprotective potential of (S)-DCPG it was administered 
daily in either of the following concentrations 0.4, 2, 10 or 50nmol to the left SNc via 
the indwelling cannulae. Sub-chronic treatment with (S)-DCPG significantly reversed 
the 6-OHDA induced loss of TH-IR neurons as revealed by one-way ANOVA (F106, 
P<0.0001). Post hoc analysis revealed that the neuroprotection afforded by (S)-DCPG  
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Fig 4.6: Neuroprotective Effect of (S)-DCPG dissolved in saline on the 
number of TH and NeuN-IR cells in the SNc. 
Sub-chronic intranigral treatment with (S)-DCPG (0.4, 2, 10 and 50nmol) 
significantly attenuated the 6-OHDA induced loss of A) TH and B) NeuN-IR 
cells in a concentration dependent manner. 6-OHDA group received saline 
vehicle for 7 consecutive days. C) A consistent of neuroprotective effect of 
(S)-DCPG in 5 different stereotaxic levels (A-E). All data shown were mean 
percentage loss cells ± SEM in lesioned side when compared to contralateral 
side. n values in brackets: 6-OHDA (6), 0.4nmol (S)-DCPG (6), 2nmol (S)-
DCPG (6), 10nmol (S)-DCPG (6) and 50nmol (S)-DCPG (6). * P<0.01, **  
P<0.001 and ***P<0.0001 (S)-DCPG vs. 6-OHDA; analyzed by One-way 
ANOVA followed by Student’s t-test. 
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39.16±3.16 *** 48.72±3.32 * 52.36±2.65 *** DCPG 0.4 
  9.63±0.86 *** 
  9.83±1.73 *** 
17.59±2.67 *** 
85.15±7.01 
HVA (% loss) 
29.33±4.18 *** 
10.38±1.56 *** 
25.75±5.32 *** 
73.58±8.77 
DOPAC (% loss) 
24.29±2.68 *** 
28.57±2.37 *** 
10.45±1.78 *** 
91.01±2.15 
DA (% loss) 
DCPG 50 
DCPG 10 
DCPG 2 
6-OHDA 
Group 
Table 4.2A: Subchronic intra-SNc administration of (S)-DCPG (0.4, 2, 10 
and 50nmol) dissolved in neutralized NaOH for 7 consecutive days provided 
reversal effect of the 6-OHDA-induced depletion of dopamine (DA), DOPAC 
and HVA. Data were shown as mean percentage change of monoamines level 
in lesion side when compared to contralateral side ±SEM. N numbers in 
bracket: Sham (6), 6-OHDA (6), (S)-DCPG alone (6), 0.4nmol (6), 2nmol (6), 
10nmol (6) and 50nmol (6). * P<0.01, *** P<0.0001, when compared to 6-
OHDA; analyzed by One-way ANOVA followed by Student’s t test.  
Ipsilateral Contralateral 
Group 
0.16±0.01 ** 0.19±0.02 DCPG 0.4 
0.19±0.02 * 
0.12±0.02 ** 
0.18±0.03 * 
0.54±0.08 
0.15±0.01 
0.12±0.004 
0.15±0.02 
0.17±0.02 
TO 
DCPG 50 
DCPG 10 
DCPG 2 
6-OHDA 
Table 4.2B: Turnover ratio (TO) in the striata of different treatment groups. 
Subchronic intra-SNc administration of (S)-DCPG (0.4, 2, 10 and 50nmol) 
dissolved in neutralized NaOH for 7 consecutive days provided reversal 
effect of the 6-OHDA-induced increase of DA turnover ratio. Data were 
shown as mean DA turnover ±SEM. N numbers in brackets: 6-OHDA (6), 
0.4nmol (S)-DCPG (6), 2nmol (S)-DCPG (6), 10nmol (S)-DCPG (6) and 
50nmol (S)-DCPG (6). * P<0.01 and ** P<0.001, when compared to 6-OHDA, 
analyzed by One-way ANOVA followed by Student’s t test.  
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was concentration-dependent (0.4nmol: 39.95±1.36%, P<0.001; 2nmol: 22.28±1.34%, 
P<0.0001; 10nmol: 14.57±1.51%, P<0.0001 and 50nmol: 11.54±1.17%, P<0.0001; vs 
6-OHDA: 56.32±2.46%, Fig 4.6A). This phenomenon was mirrored by (S)-DCPG 
attenuating the 6-OHDA induced loss of NeuN-IR cells (F115.5, P<0.0001; 0.4nmol: 
52.18±1.78%, P<0.01; 2nmol: 22.43±1.37%, P<0.0001; 10nmol: 13.61±1.17%, 
P<0.0001; and 50nmol: 9.63±1.42%, P<0.0001; vs 6-OHDA: 66.94±2.49%; Fig 4.6B). 
Furthermore, the consistency between NeuN and TH staining indicates that the 
neuroprotection afforded by (S)-DCPG is via dopaminergic neuronal protection 
instead of the maintenance of the cytosolic expression of tyrosine hydroxylase. 
Moreover, there was the same concentration-dependent reduction of loss of TH-IR 
neurons among 5 different stereotaxic levels (level A to E), illustrating that the 
neuroprotection with (S)-DCPG occurs throughout the entire structure of the SNc (Fig 
4.6C). Photomicrographs in Fig 4.7 depict typical TH immunostaining in the SNc and 
the concentration dependent preservation of TH-IR neuronal number by (S)-DCPG.  
Similarly, sub-chronic treatment with (S)-DCPG for 7 days attenuated the 6-
OHDA induced loss of DA level when analysed by one-way ANOVA (F54.46, 
P<0.0001). Post hoc Student’s t test revealed that the 6-OHDA induced loss of striatal 
DA was attenuated by (S)-DCPG in a concentration dependent manner although the 
degree of striatal DA loss was attenuated the most by (S)-DCPG (0.4nmol: 
52.36±2.65% loss, P<0.0001; 2nmol: 10.45±1.78% loss, P<0.0001; 10nmol: 
28.57±2.37% loss, P<0.0001; and 50nmol: 24.29±2.68% loss, P<0.0001; vs 6-OHDA: 
91.01±2.15% loss, Table 4.2A). The reduction of DOPAC (0.4nmol: 48.72±3.32% 
loss, P<0.01; 2nmol: 25.75±5.32% loss, P<0.0001; 10nmol: 10.38±1.56% loss, 
P<0.0001; and 50nmol: 29.33±4.18% loss, P<0.0001; vs 6-OHDA: 73.58±8.77% loss, 
Table 4.2A) and HVA (0.4nmol: 39.16±3.16% loss, P<0.0001; 2nmol: 17.59±2.67% 
loss, P<0.0001; 10nmol: 9.83±1.73% loss, P<0.0001; and 50nmol: 9.63±0.86% loss,  
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Fig 4.7: Representative photomicrographs of nigral TH-IR cells from 6-
OHDA lesioned animals treated with (S)-DCPG or drug vehicle 
Panels A-E, low power (x40; scale bar=250µm) representative 
photomicrographs of contralateral (Cont) and ipsilateral (Ipsil) SNc to 
illustrate that sub-chronic intranigral treatment with (S)-DCPG produced 
neuroprotective effect on the cellular integrity of the nigrostriatal system. A) 
6-OHDA alone (n=6), B) 0.4nmol (S)-DCPG (n=6), C) 2nmol (S)-DCPG 
(n=6), D) 10nmol (S)-DCPG (n=6) and E) 50nmol (S)-DCPG (n=6) in the 
6-OHDA model. 
SNc
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SNc
SNc
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P<0.0001; vs 6-OHDA: 85.15±7.01% loss; Table 4.2A) induced by 6-OHDA were 
also reversed by (S)-DCPG. Furthermore, the increase in DA TO induced by 6-OHDA 
was reduced by the sub-chronic treatment with (S)-DCPG (0.4nmol: 0.16±0.01, 
P<0.001; 2nmol: 0.18±0.03, P<0.01; 10nmol: 0.12±0.02, P<0.001; 50nmol: 0.19±0.02, 
P<0.01; vs 6-OHDA: 0.54±0.08; Table 4.2B). Taking these results together, (S)-
DCPG provided a significant neuroprotection of dopaminergic neurons in the SNc 
against the 6-OHDA-induced toxicity.  
 
4.3.3 Receptor mediated mechanisms for the neuroprotective effects of focally 
injected (S)-DCPG against 6-OHDA-induced neurotoxicity 
After demonstrating the neuroprotective potential of (S)-DCPG, it was important 
to ascertain whether the neuroprotective action of (S)-DCPG is mediated via mGluR8. 
This was investigated by administering 50nmol MSOP with or without 50nmol (S)-
DCPG in the 6-OHDA model. Firstly, MSOP alone did not have any effect against the 
toxic actions of 6-OHDA when considering the number of TH and NeuN IR cells (TH: 
56.42±2.26% loss, P=0.3550 vs TH IR in 6-OHDA: 60.61±3.50%; and NeuN: 
53.59±3.75% loss, P=0.2026 vs NeuN IR in 6-OHDA: 60.32±3.30%; Fig 4.8A-B). 
Additionally, MSOP alone also failed to have any effect on the 6-OHDA-induced 
depletion of monoamine, except DOPAC, and increase of DA TO (DA: 84.71±2.66% 
loss, P=0.1351 vs DA in 6-OHDA: 70.07±2.73%; DOPAC: 32.14±5.06% loss, P<0.01 
vs DOPAC in 6-OHDA: 52.40±4.35%, HVA: 23.77±4.88% loss, P=0.1518 vs 
33.73±4.28% and TO: 0.33±0.03, P<0.01 vs TO in 6-OHDA: 0.51±0.03; Table 4.3A 
and 4.3B), suggesting that group III mGluRs antagonism does not influence 6-
OHDA-induced neurotoxicity in the nigrostriatal tract. However, when given in the 
combination of MSOP + (S)-DCPG, the neuroprotective effect of (S)-DCPG in term 
of the cellular protection of TH-IR cells (MSOP+(S)-DCPG: 53.34±2.56% loss,  
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Fig 4.8: Blocking effect of MSOP on the neuroprotective effect of 
(S)-DCPG on the number of TH and NeuN-IR cells in the SNc in 
the 6-OHDA lesioned rats
The subchronic intranigral administration of 50nmol MSOP for 7 
consecutive days blocks the neuroprotective effect of (S)-DCPG on the 
number of TH and NeuN-IR cells in the SNc of 6-OHDA lesioned rats. 
6-OHDA received saline vehicle for 7 consecutive days. Data shown 
were mean percentage loss of A) TH and B) NeuN-IR cells in the 
lesioned side when compared to contralateral side ± SEM, n values in 
brackets: 6-OHDA (7), 50nmol MSOP (6), 50nmol (S)-DCPG (6) and 
50nmol (S)-DCPG+ 50nmol MSOP (7). *** P<0.0001 vs. 6-OHDA.
### P<0.0001 vs the same treatment without MSOP (Two-way 
ANOVA followed by Bonferroni test). 
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23.77±4.88 32.14±5.06 * 84.71±2.66  MSOP 50 
78.07±2.55 ### 
  9.63±0.86 *** 
33.73±4.28 
HVA (% loss) 
64.47±6.10 ### 
29.33±4.18 *** 
52.40±4.35 
DOPAC (% loss) 
80.03±4.29 ### 
24.29±2.68 *** 
70.07±2.73 
DA (% loss) 
MSOP50+DCPG 50 
DCPG 50 
6-OHDA 
Group 
Ipsilateral Contralateral 
Group 
0.33±0.03 # 
0.19±0.02 * 
0.33±0.03 
0.51±0.03 
0.15±0.01 
0.15±0.01 
0.09±0.01 
0.08±0.01 
TO 
MSOP50+DCPG 50 
DCPG 50 
MSOP 50 
6-OHDA 
Table 4.3A: Subchronic intra-SNc administration of 50 nmol (S)-DCPG dissolved in 
neutralized NaOH for 7 consecutive days blocked the reversal effect of (S)-DCPG on the 
6-OHDA-induced depletion of dopamine (DA), DOPAC and HVA. Data were shown as 
mean percentage decrease of monoamines level in lesion side when compared to 
contralateral side ±SEM. N numbers in brackets: 6-OHDA (7), 50nmol (S)-DCPG (6), 
50nmol MSOP (6) and 50nmol (S)-DCPG + MSOP (7). * P<0.01, *** P<0.0001, when 
compared to 6-OHDA; ### P<0.0001, when compared with same treatment group 
without MSOP; analyzed by Two-way ANOVA followed by Bonferroni test.  
Table 4.3B: Subchronic intra-SNc administration of 50 nmol (S)-DCPG dissolved in 
neutralized NaOH for 7 consecutive days blocked the reversal effect of (S)-DCPG on the 
6-OHDA-induced increase of turnover dopamine (TO). Data were shown as mean 
turnover of dopamine in lesion side when compared to contralateral side ±SEM. N 
numbers in bracket: 6-OHDA (7), 50nmol (S)-DCPG (6), 50nmol MSOP (6) and 50nmol 
(S)-DCPG + MSOP (7). * P<0.01, when compared to 6-OHDA; # P<0.01, when 
compared with same treatment group without MSOP; analyzed by Two-way ANOVA 
followed by Bonferroni test.  
 178 
P<0.0001 vs (S)-DCPG alone: 11.54±1.27% loss; Fig 4.8A) and NeuN-IR neurons 
was blocked by MSOP administration (MSOP+(S)-DCPG: 52.97±3.49% loss, 
P<0.0001 vs (S)-DCPG alone: 9.63±1.42% loss; Fig 4.8B). Furthermore, there was no 
significant difference between the degree of dopaminergic neuronal loss observed in 
the 6-OHDA and MSOP+(S)-DCPG groups (TH: 53.34±2.56%, P=0.4295 vs TH in 6-
OHDA: 60.61±3.50%; NeuN: 52.97±3.49%, P=0.0516 vs NeuN in 6-OHDA: 
60.32±3.30%; Fig 4.8A-B), implying that the neuroprotective effect of (S)-DCPG was 
completely blocked by MSOP. The visual illustration of the loss of dopaminergic 
neurons in the SNc is illustrated in Fig 4.9. Furthermore, MSOP also blocked the 
neuroprotective  effects of (S)-DCPG against 6-OHDA-induced depletion of striatal 
DA (MSOP+(S)-DCPG: 80.03±4.29% loss, P<0.0001 vs (S)-DCPG alone: 
24.29±2.68% loss,; Table 4.3A), DOPAC (MSOP+(S)-DCPG: 64.47±6.10% loss, 
P<0.0001 vs (S)-DCPG alone: 29.33±4.18% loss; Table 4.3A) and HVA (MSOP+(S)-
DCPG: 78.07±2.55% loss, P<0.0001 vs (S)-DCPG alone: 9.63±0.86% loss; Table 
4.3A). Moreover, MSOP prevented the normalization of 6-OHDA-induced increase of 
DA turnover by (S)-DCPG (MSOP+(S)-DCPG: 0.33±0.03, P<0.01 vs (S)-DCPG 
alone: 0.19±0.02; Table 4.3B). Taken together these findings indicate that the 
neuroprotection afforded by (S)-DCPG is mGluR8 mediated.  
 
4.3.4 Localization of mGluR8 in cell types in the SNc 
The mRNA of mGluR8 was originally detected in the substantia nigra of rats 
(Messenger et al, 2002) but no mGluR8 localisation studies in the SNc have been 
carried out. In order to elucidate the proposed neuroprotective mechanisms for (S)-
DCPG, mGluR8 expression in different cell types in the SNc was investigated by 
double immunofluorescent staining. Such studies clearly revealed that mGluR8 
receptors are not only expressed on SNc dopaminergic neurons (TH-IR) but mGluR8  
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Fig 4.9: Representative photomicrographs of SNc TH-IR cells 
from 6-OHDA lesioned animals treated with (S)-DCPG with or 
without MSOP
Panels A-D, low power (x40; scale bar=250µm) representative 
photomicrographs of contralateral (Cont) and ipsilateral (Ipsil) to 
illustrate that MSOP reversed the neuroprotective effect of (S)-
DCPG on the cellular integrity of the SNc. 6-OHDA group received 
saline vehicle for 7 consecutive days. A) 6-OHDA alone (n=7), B) 
50nmol (S)-DCPG (n=6), C) 50nmol MSOP (n=6) and D) 50nmol 
(S)-DCPG + MSOP (n=6), in 6-OHDA leisoned rats. 
SNc
SNc
SNc
SNc
A (Ipsil)
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receptors were also detected on SNc astrocytes (GFAP-IR) (Fig 4.10) which is 
consistent with the previous reports about the expression of group III mGluRs on  
astrocytes in vitro (Yao et al, 2005). Expression of mGluR8 receptors was also 
detected on both total (OX42-IR) and activated microglia (OX6-IR) cells (Fig 4.10). 
However, only a small number of unactivated microglia in the SNc region expressed 
mGluR8 in the unlesioned animals. In contrast in the 6-OHDA lesioned animals most 
of the activated microglia (OX6-IR) expressed mGluR8. Quantitative analysis of the 
number of cells expressing mGluR8 was not carried out but qualitatively it was clear 
that 6-OHDA lesioning produced a decrease in the number of dopaminergic neurons 
expressing mGluR8, which mirrored the loss of TH-IR cells, whilst expression on 
microglia and astrocytes increased as these cells were recruited into the lesioned area. 
Microglia in other brain regions, such as geniculate bodies and VTA, also expressed 
mGluR8 (images not shown).  
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Fig 4.10: Localization of mGluR8 in different cell types in the SNc  
Immunofluorescent images of both mGluR8-IR (red) and cell markers (TH for 
dopaminergic neurons, GFAP for astrocyte, OX42 for total microglia and OX6 for 
activated microglia; green) -IR cells are illustrated at high power magnification 
(x400; scale bar= 250µm). The merged images (yellow) illustrated the co-
localization of receptors and cell markers. The overlay stained cells was indicated 
by white arrows. Counter-staining by DAPI dye (blue) indicated the nuclei of the 
stained cells.  
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4.3.5 SNc Glial responses to 6-OHDA toxicity and the effect of SNc focally 
administered (S)-DCPG  
6-OHDA administration into the SNc stimulated an up-regulation in the numbers 
GFAP-IR cells in the SNc compared to the unlesioned side of brain (6-OHDA: 
42.73±3.87% increase, P<0.001 vs Sham: 9.72±1.44% increase, Fig. 4.11A). 
Morphologically, the GFAP-IR cells had thickened astrocytic processes and a higher 
expression of cytosolic GFAP characteristic of activated astrocytes which is consistent 
with previous studies utilising the 6-OHDA lesion model (Gomide et al, 2005a & b; 
Raicević et al, 2005; Rodrigues et al, 2001 and 2004). (S)-DCPG administration at 
any of the doses tested failed to modulate neither the 6-OHDA-induced up-regulation 
of numbers of activated astrocytes (0.4nmol: 42.71±4.38% increase, P=0.3973; 2nmol: 
38.20±4.78% increase, P=0.4148; 10nmol: 39.21±1.97% increase, P=0.4375; 50nmol: 
39.20±4.78% increase, P=0.5783, vs 6-OHDA: 42.73±3.87% increase, Fig 4.11).  
To study the role of mGluR8 in the 6-OHDA-induced inflammatory response, 
the pathophysiological changes of microglia exposed to a 6-OHDA insult were 
investigated. From this study, the infusion of 12µg 6-OHDA dramatically increased 
the number of activated microglial cells (OX6-IR; 6-OHDA: 7.63±0.62 fold increase, 
P<0.0001 vs Sham: 3.80±0.33 fold increase; Fig 4.12A). Such microglial activation 
by 6-OHDA is consistent with the previous literature (Rodrigues et al, 2001). With the 
sub-chronic administration of (S)-DCPG, the microglial activation by 6-OHDA was 
diminished by all doses of (S)-DCPG (0.4nmol: 5.08±1.14 fold increase, P=0.6786; 
2nmol: 4.26±0.47 fold increase, P<0.01; 10nmol: 4.36±0.43 fold increase, P<0.01; 
50nmol: 4.39±0.37 fold increase, P<0.01 vs 6-OHDA: 7.63±0.62 fold increase; Fig 
4.12A). Maximal attenuation of the microglial response was even obtained at the 
relatively low dose of 2nmol (S)-DCPG which seems to correlate with the degree of 
TH-IR cell preservation. Therefore, (S)-DCPG strongly modulated the 6-OHDA- 
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Fig 4.11: Absence of the preventive effect of (S)-DCPG on 6-
OHDA-induced increased number of GFAP-IR cells.
Subchronic intranigral administration of (S)-DCPG (0.4, 2, 10 and 
50nmol) for 7 consecutive days did not eliminate the 6-OHDA-
induced increase of GFAP-IR cells number. 6-OHDA received 
saline vehicle for 7 consecutive days. Data shown were mean 
percentage increase of GFAP-IR cells in lesioned side when 
compared to contralateral side ± SEM. n values in brackets: Sham 
(6), 6-OHDA alone (6), 0.4nmol (S)-DCPG (6), 2nmol (S)-DCPG 
(6), 10nmol (S)-DCPG (6), and 50nmol (S)-DCPG (6). Data were 
analyzed by One-way ANOVA followed by Student’s t test. 
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Fig 4.12: Preventive effect of (S)-DCPG on 6-OHDA-induced increasing number of 
OX6-IR cells which reversed by MSOP. 
A) Subchronic intranigral administration of (S)-DCPG (0.4, 2, 10 and 50nmol) for 7 
consecutive days eliminated the 6-OHDA-induced increase of OX6-IR cells number. Sham 
(n=6), 6-OHDA (n=6), 0.4 DCPG (n=6), 2 DCPG (n=6), 10 DCPG (n=6) and 50 DCPG 
(n=6). B) Subchronic treatment of 50nmol MSOP reversed the reductive effect of (S)-
DCPG on the number of OX6-IR cells. 6-OHDA group received saline vehicle for 7 
consecutive days. 6-OHDA (n=7), 50nmol MSOP (n=6), 50nmol (S)-DCPG (n=6) and 
50nmol (S)-DCPG+ 50nmol MSOP (n=7). The (S)-DCPG group in B was same as the 
50nmol (S)-DCPG in A. All data shown were as increased folds of OX6-IR cells in 
lesioned side when compared to contralateral side ±  SEM. * P<0.01 vs. 6-OHDA. # 
P<0.01 vs the same treatment without MSOP (Two-way ANOVA followed by Bonferroni 
test).  
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induced microglial activation. The (S)-DCPG administration alone did not show any 
effect on microglial activation (Data not shown). Furthermore, the microglial 
modulation by (S)-DCPG was blocked by co-administration of MSOP (MSOP+(S)-
DCPG: 7.96±1.22 fold increase P<0.0001, vs (S)-DCPG alone: 4.37±0.36 fold 
increase; Fig 4.12B).  
 
4.4 Discussion  
In the current study we have demonstrated that focal and systemic 
administration of (S)-DCPG provided a significant neuroprotection of dopaminergic 
neurons in the SNc against the 6-OHDA toxicity and protected against the 
concomitant 6-OHDA induced depletion of striatal DA. The sub-chronic treatment 
alone of (S)-DCPG did not have any detrimental effect on the dopaminergic neurons 
in the SNc. Furthermore, MSOP blocked the (S)-DCPG-mediated neuroprotection 
suggesting that (S)-DCPG neuroprotection was mediated via the activation of 
mGluR8. Furthermore, we demonstrated that mGluR8 receptors are not only located 
on dopaminergic neurons but are also present on astrocytes and microglia. We also 
demonstrated that the neuroprotection produced by (S)-DCPG was also associated 
with a modulation of microglial activation in response to 6-OHDA, tentatively raising 
the possibility that one of the mechanisms of (S)-DCPG neuroprotection is via 
modulation of the inflammatory response.  
 
4.4.1 Neuroprotective actions of (S)-DCPG may not only be due to the regulation 
of glutamate transmission 
Neuroprotection by (S)-DCPG was consistent with the previous reported 
neuroprotective potential of L-AP4 (Vernon et al, 2007b). This finding suggested that 
mGluR8 activation by L-AP4 may partly account for the neuroprotective effects L-
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AP4. Within group III mGluRs, namely mGluR4, 6, 7 and 8, since mGluR6 is not 
expressed in the brain, the neuroprotective effects of L-AP4 must be mediated via the 
activation of mGluR4, 7 or 8. mGluR4 and 8 are stimulated at low concentration of L-
AP4 (1-10µM) whilst mGluR7 are only stimulated by high concentrations L-AP4 
(100 µM) (Schoepp and Johnson, 1989). Furthermore, L-AP4 shares a relatively 
similar affinity for both mGluR4 and 8 (Ki value in mGluR4: 2.01µM; Ki value in 
mGluR8: 2.7µM; Naples and Hampson, 2001). Therefore, the proposed subtypes 
involved in this neuroprotection were mGluR4 and/or mGluR8. Indeed, the mGluR8 
activation by (S)-DCPG provided a high degree of neuroprotection of the 
dopaminergic neurons in the SNc. Interestingly, there is a classic linear concentration 
dependent neuroprotective response from focally administered (S)-DCPG, whilst L-
AP4 produced a ‘bell shaped’ dose response with the highest concentration of L-AP4 
(50nmol) failing to provide any neuroprotection (Vernon et al, 2007b). Such 
difference could be explained by the internalization of mGluR4 activated by L-AP4 in 
a high concentration, which did not occur with (S)-DCPG treatment. Alternately, the 
sub-chronic administration of the highest concentration of L-AP4 could possibly 
induce the internalisation of mGluR4, a phenomenon reported by Mathiesen and 
Ramirez (2006). However, there are no reports about the internalization of mGluR8 
by high concentration of L-AP4. Thus, using subtype specific agonist of mGluR8, 
(S)-DCPG, may provide the neuroprotection without affecting receptor availability. 
Since the neuroprotective effects of (S)-DCPG were blocked by the presence of 
MSOP it would suggest that the neuroprotective effects are due to the selective 
stimulation of mGluR8 by (S)-DCPG.   
Originally, group II/III mGluRs were known as the autoreceptors localized at the 
presynaptic terminals to negatively modulate the release of neurotransmitters, such as 
glutamate and GABA (Mills et al, 2001; Takahashi and Alford, 2002). The therapeutic 
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role of autoreceptor of mGluR4 has been demonstrated in haloperidol PD models 
(Valenti et al, 2003; Lopez et al, 2007). Therefore, the activation of mGluR8 on the 
presynaptic terminal of the STN-SNc synapse was hypothetically the underlying 
mechanism of the neuroprotection reported in this chapter. However, the hypothesis 
that presynaptic mGluR8 modulates glutamatergic output was questioned by Valenti 
and colleagues following the failure of the activation of mGluR8 to inhibit the 
overactive STN-SNc transmission in the rat utilising whole cell patch clamp 
techniques (Valenti et al, 2005). These findings introduced the concept that only 
mGluR4 but not mGluR8 may modulate glutamate release in the overactive indirect 
pathways. On the other hand, although mGluR8 mRNA was found in STN (Testa et al, 
1994; Messenger et al, 2002), the failure of the presynaptic activation of mGluR8 by 
(S)-DCPG in the inhibition of the glutamatergic neurotransmission in the STN-SNc 
synapse may be due to the absence of the protein expression of mGluR8 in the SNc 
(Valenti et al, 2005). Furthermore, the postsynaptic activation of mGluR8 on 
dopaminergic neurons was also shown not to inhibit glutamate excitation (Valenti et al, 
2005). However, in the current study, mGluR8 was detected on dopaminergic neurons, 
the postsynaptic neurons of subthalamonigral tract. A possible explanation for this 
contradiction is that mGluR8 on dopaminergic neurons triggers other cellular 
functions relating to cell survival rather than diminishing the glutamate excitation. 
However, the exact function of mGluR8 in the dopaminergic neurons remains 
unknown. In support of such a hypothesis, the activation of group II and III mGluRs 
was found to be neuroprotective in certain experimental condition. For instance, the 
activation of group II/III mGluRs results in the inhibition of formation of nitric oxide 
(NO) and cyclic GMP (cGMP) in cultured cerebellar granule neurons and striatal 
neurons from rodents (Cartmell et al, 1997 and Wroblewska et al, 2006). Indeed, NO 
and cGMP are recognized as upstream components of the apoptotic pathways that are 
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implicated in models of neurodegeneration, such as 6-OHDA model (Guo et al, 2005). 
In addition, activation of group III mGluRs was shown to activate PDK1/PI3K/AKT 
pathways leading to neuroprotection against the 6-OHDA toxicity (Nakaso et al, 
2008). Therefore, mGluR8 may possibly couple to other Gi-proteins to decrease the 
cGMP level in dopaminergic neurons and inhibit other intracellular signalling 
pathways, such as PKA, for neuroprotection. Hence, rather than modulating glutamate 
transmission in the STN-SNc synapse, the neuroprotection afforded by (S)-DCPG 
may be mediated via the down-regulation of the apoptotic signalling pathways, such 
as NO/cGMP pathway which is activated by 6-OHDA in the dopaminergic neurons.  
 
4.4.2 Modulation of glial activation may contribute to the neuroprotective actions 
of (S)-DCPG in the SNc  
Neuroprotection from focal administration of (S)-DCPG was associated with a 
down regulation of the 6-OHDA-induced activation of microglia. Activated microglia 
with a pro-inflammatory phenotype could compromise the integrity of the 
dopaminergic neurons in the SNc (Taylor et al, 2003). The loss of the neuron-glia 
interaction might be one of the reasons for the 6-OHDA-induced microglial activation 
and resultant neuroinflammation (Minghetti et al, 2005). Moreover, the 
phosphatidylserine exposed on the cytoplasmic membrane of the apoptotic 
dopaminergic neurons induced by 6-OHDA stimulates the microglial activation (Chen 
et al, 2006).  Although the decrease in microglial activation with (S)-DCPG treatment 
in the 6-OHDA lesioned rat may be a direct consequence of neuroprotection i.e. 
decreased distress signals or debris from degenerating neurons, there could also be a 
direct effect of (S)-DCPG on the activational state of the microglia. Previous studies 
have shown that activation of the group III mGluRs inhibits the microglial activation 
in the in vitro cell culture model (Taylor et al, 2003), implying that the direct 
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modulation of microglial group III mGluRs can modulate microglial activation. This 
was then further confirmed by the detection of the mGluR8 expression on microglia 
in the current study. However there are still no conclusive evidence in this study to 
prove the microglial mechanism in the (S)-DCPG neuroprotection, 
Cell culture studies have demonstrated that 6-OHDA induces nNOS and 
inducible NOS (iNOS)-mediated synthesis of NO, which can trigger microglial 
activation (Lin et al, 2007). This indicates that the inhibition of NOSs activity and the 
synthesis of NO may prevent microglial activation. Furthermore, NO released by 
microglia may induce further dopaminergic neurons apoptosis in the SNc (Kaushal 
and Schlichter, 2008; Khazaei et al, 2008; and Kwon et al, 2008). As mentioned above, 
the activation of group III mGluRs inhibits the NO signalling pathway in cerebellar 
neuronal cultures (Canals et al, 2001). Therefore, (S)-DCPG, by activating mGluR8, 
may also prevent NO-mediated microglial activation and NO-mediated apoptosis of 
dopaminergic neurons. Interestingly, 6-OHDA lesioning appeared to up regulate 
mGluR8 expression on activated microglia. However, this finding needs to be further 
confirmed by the quantitative analysis of the protein expression of mGluR8 in 
microglia. It is unclear about the significance and role of the increased expression of 
mGluR8 in microglia.  
Moreover, astrocytes are also involved in neuroinflammation in the 6-OHDA 
PD model (Rodrigues et al, 2001). Indeed, the increase of mRNA level of GFAP was 
detected under the insult of 6-OHDA (Sheng et al, 1993). However, the role of 
astrocytic activation in PD remains unclear. Indeed, astrocytes have been implicated 
in an inflammatory role by the release of the pro-inflammatory cytokines (Gabryel et 
al, 2004; and Wu et al, 2005) whilst other reports suggest a neuroprotective role for 
astrocytes (Basso et al, 2008; Farfara et al, 2008; Liang et al, 2008). In such studies 
activated astrocytes synthesize and release neurotrophic factors, such as brain-derived 
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neurotrophic factors (BDNF), glial cell line-derived neurotrophic factors (GDNF) and 
conserved dopamine neurotrophic factor (CDNF) (Chen et al, 2006; Lindholm et al, 
2007). Moreover, inhibiting mGluR5 and activating group II mGluRs trigger the 
cerebral and hippocampal expression of BDNF in astrocytes (Bond et al, 2000 and 
Legutko et al, 2006). On the other hand, astrocytes also serve as the scavenger of 
excessive glutamate and remove the reactive oxygen and nitrogen species by 
glutathione (Rao et al, 2005; Wu et al, 2008a; Yao et al, 2005). Interestingly, 
astrocytes also take up extracellular iron ions and hence prevent iron mediated 
oxidation (Hoepken et al, 2004). Therefore, the astrocytic activation could also be 
neurorestorative for the SNc in this 6-OHDA PD models. In the current study we 
demonstrated that the neuroprotection from SNc focally injected (S)-DCPG was not 
associated with a modulation of the number of activated astrocytes in response to 6-
OHDA toxicity. However, (S)-DCPG treatment alone or in the 6-OHDA lesioned 
animals was associated with a visual increase in the degree of activation of each 
astrocyte. This manifested itself in increases in the number of cellular processes and 
an increase in GFAP expression. Such astrocytic activation by (S)-DCPG 
hypothetically could provide neuronal support for the dopaminergic neurons in the 
SNc. Although we detected mGluR8 receptors on the astrocytes in the SNc, at the 
present time we do not have evidence to indicate whether (S)-DCPG activation of 
astrocytes produces a pro-inflammatory or neuro-supportive phenotype in the 
astrocytes.   
Taken together, the functional and morphological modification of nigral glia by 
mGluR8 may be one of the underlying mechanisms in the neuroprotection against 6-
OHDA-induced toxicity. The activation of mGluR8 may modulate the activity of the 
activated astrocytes which remove the toxic molecules, such as extracellular 
glutamate, metal ions and other oxidative species, and release the neurotrophic factors, 
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such as GDNF, BDNF and CDNF. In addition, (S)-DCPG was also associated with 
decreased microglial activation, possibly via the activating mGluR8; which could 
influence the neuroinflammatory response and ultimately cell death.  
 
4.4.3 Conclusion 
From the current study, we demonstrated the neuroprotective effect of (S)-
DCPG on the dopaminergic neurons in the SNc against the 6-OHDA neurotoxicity. 
The neuroprotective mechanism of (S)-DCPG may rely of the prevention of the 
microglial activation. Furthermore, the detection of mGluR8 expressed in the 
microglial indicated the possibility of direct deactivation of microglia by (S)-DCPG 
which needs to be further confirmed in future study. Interestingly, the (S)-DCPG 
administered alone induced the astrocytic activation but we are unclear as to whether 
this neuro-supportive or not. Therefore, (S)-DCPG may be a promising therapeutic 
reagent that could successfully slow down the degeneration of nigral dopaminergic 
neurons in clinical PD patients.  
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Chapter 5: Neuroprotective effect of systemically administered 
PHCCC and (S)-DCPG in 6-OHDA PD model of rats.  
5.1 Introduction 
The neuroprotective effects of PHCCC and (S)-DCPG injected focally into the 
SNc against 6-OHDA-induced lesions was demonstrated in chapters 3 and 4 in which 
we also investigate the involvement of astrocytic and microglial mechanism. In order 
to extend these studies we then went on to investigate whether PHCCC and 
(S)-DCPG could maintain their neuroprotective effect in the 6-OHDA lesion model 
with global brain distribution resulting from systemic injection of PHCCC and 
(S)-DCPG. However, rather than SNc administration, the 6-OHDA was infused to the 
left median forebrain bundle (L-MFB) which contains the dopaminergic axonal 
projections from the SNc to striatum. Dopamine transporters (DAT) expressed on the 
dopaminergic axons facilitate 6-OHDA access to the dopaminergic neurons and is 
retrogradely transported to cell bodies in the SNc. Subsequently the accumulated 
6-OHDA could induce the intracellular oxidative stress and finally cell death of the 
dopaminergic neurons under the mechanisms discussed previously in chapter 3. The 
retrograde lesion produced by intra-MFB infusion of 6-OHDA produces a slower rate 
of dopaminergic degeneration when compared to direct SNc administration but 
without any mechanical damage to the SNc.  
 
5.1.1 Bioavailability of PHCCC and (S)-DCPG 
The essential criterion for the systemic administration of ligands providing 
anti-Parkinsonian or neuroprotective effects is brain bioavailability. In indirect studies 
looking at their pharmacological actions both PHCCC and (S)-DCPG have been 
shown to cross the blood brain barrier (BBB) (Battaglia et al, 2006; Ngomba et al, 
2008). Furthermore, as mentioned in Chapter 3, the lipid solubility of PHCCC 
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facilitates brain penetration. In addition, systemically administered PHCCC has been 
shown to prevent MPTP induced dopaminergic cell death in the SNc (Battaglia et al, 
2006). Therefore, we would hypothesize that the systemic administration of PHCCC 
would also be neuroprotective against 6-OHDA induced toxicity. Unlike PHCCC, 
there have been pharmacokinetic studies concerning the biodistribution of (S)-DCPG, 
thus confirming that (S)-DCPG crosses the BBB (Robbins et al, 2007). Therefore, the 
systemic administration of (S)-DCPG could also provide a similar neuroprotection for 
the nigral dopaminergic neurons against 6-OHDA toxicity as described in chapter 4.  
 
5.1.2 Aims of this chapter 
The specific aims of this chapter were as followed:  
1. Investigate whether the neuroprotective effects of focally SNc administered 
PHCCC and (S)-DCPG can be replicated following their systemic administration 
in the MFB 6-OHDA lesion model of PD. 
2. Investigate whether the modulation of microglial or astrocytic activation are 
involved in PHCCC and (S)-DCPG neuroprotection following systemic 
administration.  
 
5.2 Experimental design 
5.2.1 Neuroprotective effects of systemically administered PHCCC and 
(S)-DCPG against 6-OHDA-induced toxicity 
After demonstrating neuroprotective effect of SNc focally administered PHCCC 
and (S)-DCPG, we then went on to investigate whether such neuroprotective effects 
against 6-OHDA toxicity could be replicated following the systemic administration of 
(S)-DCPG. This was achieved by the daily intraperitoneal administration of one of 3 
concentrations of PHCCC (1, 3 and 10mg/kg) or (S)-DCPG (5, 15 and 30mg/kg). 
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PHCCC or (S)-DCPG was administered once on the day before 6-OHDA lesioning 
(Refer to chapter 2 section for MFB lesioning), twice on the day of 6-OHDA 
lesioning and twice daily for 3 consecutive days after 6-OHDA lesioning. Control rats 
were received drug vehicle of 10% DMSO containing 0.9% NaCl solution in the same 
regime of PHCCC and (S)-DCPG administration. 6-OHDA was stereotaxically 
injected into the L-MFB so as to avoid any possible direct mechanical damage to the 
SNc and to minimise animal suffering through cannulae implantation. The toxic 
effects of 6-OHDA was assessed by immunohistochemistry with TH and NeuN 
antibodies in tissue section at the level of the SNc to detect dopaminergic neurons (see 
section 2.2.6 and 7). In addition the concentration of DA and its metabolites were 
analysed in the striatum by HPLC (see section 2.2.8). The dosing schedule is 
illustrated in Fig 5.1.  
 
5.2.2 Underlying mechanism of PHCCC and (S)-DCPG neuroprotection against 
6-OHDA-induced neurotoxicity 
As in chapter 3 and 4, the neuroprotection of focally administered PHCCC and 
(S)-DCPG involved the modulation of the astrocytic and microglial activation. In this 
section, we also investigated whether PHCCC and (S)-DCPG treatment modulated 
astrocytic and microglial activation in response to 6-OHDA toxicity. This was 
achieved by immunohistochemical detection of astrocytes (GFAP) and microglia 
(OX6) in fixed cryostat cut section from 6-OHDA, PHCCC and (S)-DCPG treated 
6-OHDA lesioned animals.  
 
5.2.3 Statistical analysis 
NeuN- and TH-IR cells in both lesioned and contralateral sides of all treatment  
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Animals 
Purchase 
Surgical injection of 
6-OHDA to L-MFB 
1st i.p. 
Injection of 
PHCCC or 
(S)-DCPG 
Injection of PHCCC or 
(S)-DCPG 
Postmortem 
procedures 
9 days 
4 days 
7days 1 day 
Snap frozen of 
striata 
Snap frozen 
Immunohistochemistry (IHC) 
Fixation of 
hindbrains in PFA 
HPLC 
Cryoprotection in 30% 
sucrose 
5-7 days 
48 hours 
Fig 5.1: The experimental schedule of the study of systemic injection of 
PHCCC and (S)-DCPG 
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groups was expressed as percentage loss ± S.E.M in relation to the control 
(unlesioned) side of brain, as indicated in different sections. GFAP- and OX6-IR cells 
were demonstrated as percentage/fold increase ± S.E.M. For the monoamines level, 
data was presented as percentage decrease of monoamine ± S.E.M. For the turnover 
ratio of striatal dopamine (T/O), data was expressed as the turnover level ± S.E.M. 
The calculation of turnover was shown below:  
{[DOPAC (nmol/mg) + [HVA (nmol/mg)]} 
[DA (nmol/mg)] 
In all figures, n values (number of animals in each treatment group) were shown in the 
caption of each figure. The mean values of each group were average of the mean 
values of each individual rat in the same groups.  
Data was analyzed by a series of statistical analysis. Before proving that the data 
was collected by means of random sampling and the data was in pattern of normal 
distribution, the statistic significance among different treatment groups was analyzed 
by the one-way analysis of variants (ANOVA) among different treatment groups. Data 
for PHCCC and (S)-DCPG treatment groups were analyzed all together versus the 
6-OHDA control group. Unpaired Student’s t tests were made between lesioned and 
contralateral sides in the same groups. Where alternative tests are utilised they are 
indicated in the relevant sections. The significant differences were shown by 
expressing the P value as P<0.01 (indicated as *, # or †), 0.001 (**, ## or ††) and 
0.0001 (***, ### or †††), which was also annotated in the figures or tables. All 
statistical analysis was performed using Software package of GraphPad Prism version 
4.00 (GraphPad Software, USA). 
 
5.3 Result 
5.3.1 The neurotoxicity of focally administration of 6-OHDA into the L-MFB  
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12µg 6-OHDA infused to L-MFB induced a significant loss of TH-IR cells 
(55.49±3.83% loss, P<0.0001 vs Sham: 6.92±1.17% loss; Fig. 5.2A), which was also 
mirrored by a reduction of NeuN-IR cells (58.31±2.48% loss, P<0.0001 vs Sham: 
4.10±0.95% loss; Fig. 5.2A). The density of TH-IR cells in the SNc was decreased in 
the lesioned SNc, illustrated in Fig 5.2B. Furthermore the intra-L-MFB infusion of 
6-OHDA led to the reduction of the striatal level of DA (87.06±4.27% loss, P<0.0001 
vs Sham: 4.48±0.39% loss; Table 5.1A), DOPAC (51.81±3.51% loss, P<0.0001 vs 
Sham: 5.41±0.33% loss; Table 5.1A) and HVA (48.86±4.07% loss, P<0.0001 vs Sham: 
10.67±0.92% loss; Table 5.1A) significantly when compared to the sham-operated 
group, whereas 6-OHDA induced the proliferation of DA turnover (T/O; 0.19±0.02, 
P<0.0001 vs 0.07±0.01, Table 5.1B).  
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Sham (NeuN)
Sham (NeuN)
Sham (Ipsil; TH)
6-OHDA (Ipsil; TH)
Fig 5.2: Effects of sham and intra-L-MFB infused 6-OHDA lesioning on the 
number of TH and NeuN-IR cell in the SNc 
A) Infusion of 12 µg in 4 µl 6-OHDA into the left MFB results in a significant loss of 
both NeuN and TH-IR cells at 9 days post-lesion, whereas in sham-lesioned animals 
no significant cell loss observed. Sham group received a single injection of 0.1% 
ascorbic acid vehicle to L-MFB. n numbers in brackets: 6-OHDA (7), and Sham-
lesion (7). Data were expressed as the percentage loss of cells ± SEM. *** P<0.0001 
6-OHDA vs. sham-lesioned animals. B) Representative micrographs of TH of both 
contralateral (Cont) and ipsilateral (Ipsil) SNc and NeuN-IR cells from the sham-
lesioned and 6-OHDA lesioned SNc. All images were taken at x 40 magnification; 
scale bar = 250 µm. 
A
B
SNc
SNc SNc
SNc
Sham (Cont; TH)
6-OHDA (Cont; TH)
SNc
SNc
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34.78±2.89 # 32.84±2.41 ## 62.06±3.73 # DCPG 5 
23.30±1.59 ### 37.24±2.82 ### 32.84±3.64 ### DCPG 15 
44.54±3.99 47.17±3.99 78.98±2.79  DCPG 30 
HVA (% loss) DOPAC (% loss) DA (% loss) Group 
10.67±0.92 5.41±0.33 4.48±0.39 Sham MFB 
25.12±2.39 ## 24.29±1.94 # 34.05±2.52 ### PHC 10 
45.01±3.14 35.43±3.02 # 57.19±3.48 ## PHC 3 
52.71±3.82 59.47±5.47 70.84±2.18 # PHC 1 
63.21±4.64 *** 72.37±4.41 *** 80.69±3.28 *** 6-OHDA MFB 
Table 5.1A: Systemic injection of PHCCC (1, 3 and 10mg/kg) and (S)-DCPG (5, 15, 
30mg/kg), for 4 consecutive days produced a significant reversal effect on 6-OHDA 
(L-MFB)-induced depletion of DA, DOPAC and HVA. 6-OHDA group received systemic 
injections of DMSO containing vehicle. Data were shown as mean percentage decrease of 
monoamine levels ± SEM in lesioned side when compared to contralateral side. n values 
in brackets: 6-OHDA (n=7), 1mg/kg PHCCC (n=7), 3mg/kg PHCCC (n=7), 10mg/kg 
PHCCC (n=7), 5mg/kg (S)-DCPG (n=7), 15mg/kg (S)-DCPG (n=7) and 30mg/kg (S)-DCPG 
(n=7). *** P<0.0001, when compared to Sham. # P<0.01, ## P<0.001 and ### P<0.0001, 
when compared to the 6-OHDA; analysed by one-way ANOVA followed by Student’s t-test. 
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0.15±0.03 ## 0.09±0.01 DCPG 5 
0.08±0.01 ### 0.07±0.01 DCPG 15 
0.22±0.03  0.08±0.01 DCPG 30 
Ipsilateral Contralateral 
0.07±0.01 0.08±0.01 Sham MFB 
0.11±0.01 ## 0.05±0.01 PHC 10 
0.12±0.02 # 0.07±0.01 PHC 3 
0.14±0.03 0.07±0.01 PHC 1 
0.19±0.02 *** 0.06±0.004 6-OHDA MFB 
TO Group 
Table 5.1B: Systemic injection of PHCCC (1, 3 and 10mg/kg) and (S)-DCPG (5, 15, 
30mg/kg), for 4 consecutive days produced a significant reversal effect on 6-OHDA 
(L-MFB)-induced increase turnover ratio of dopamine. 6-OHDA group received systemic 
injections of DMSO containing vehicle. Data were shown as mean TO ± SEM in lesioned 
side when compared to contralateral side. n values in brackets: 6-OHDA (n=7), 1mg/kg 
PHCCC (n=7), 3mg/kg PHCCC (n=7), 10mg/kg PHCCC (n=7), 5mg/kg (S)-DCPG (n=7), 
15mg/kg (S)-DCPG (n=7) and 30mg/kg (S)-DCPG (n=7). * P<0.01 and *** P<0.0001, when 
compared to 6-OHDA. # P<0.01, ## P<0.001 and ### P<0.0001, when compared to the 
6-OHDA; analysed by one-way ANOVA followed by Student’s t-test.  
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5.3.2 Neuroprotective effect of systemically administered PHCCC against 
6-OHDA-induced neurotoxicity 
To assess whether the systemically administered PHCCC is still neuroprotective 
in the 6-OHDA model, PHCCC at 1, 3 and 10mg/kg was administered 
intraperitoneally in 6-OHDA L-MFB lesion model. The systemic administration of 
PHCCC attenuated the 6-OHDA induced loss of TH-IR cells in a 
concentration-dependent manner (F136.6, P<0.0001; 1mg/kg: 44.61±2.39% loss, 
P<0.01, 3mg/kg: 23.22±2.49% loss, P<0.0001, 10mg/kg 18.37±2.07% loss, P<0.0001, 
vs 6-OHDA: 55.49±3.83% loss; Fig 5.3A), which was mirrored by a similar 
preservation in NeuN-IR cells (F42.6, P<0.001; 1mg/kg: 41.60±2.18% loss, P<0.001, 
3mg/kg: 20.02±1.59% loss, P<0.0001, 10mg/kg 16.33±2.96% loss, P<0.0001, vs 
6-OHDA: 58.31±2.48% loss; Fig 5.3B). The representative photomicrographs are 
illustrated in Fig 5.4 where the increasing concentration of PHCCC induced an 
increase in the density of TH-IR cells in the SNc. Furthermore, PHCCC in all 
concentrations significantly reversed the 6-OHDA induced loss of striatal DA 
(1mg/kg: 70.84±2.47% loss, P<0.01; 3mg/kg: 57.19±3.48% loss, P<0.001, 10mg/kg 
34.05±2.52% loss, P<0.0001, vs 6-OHDA: 87.06±4.27% loss; Table 5.1A). However 
only 3 and 10mg/kg PHCCC could reverse the 6-OHDA induced loss of striatal 
DOPAC (1mg/kg: 59.47±5.47% loss, P=0.3118; 3mg/kg: 35.43±3.02% loss, P<0.01, 
10mg/kg 24.29±1.94% loss, P<0.01, vs 6-OHDA: 51.81±3.51% loss; Table 5.1A) 
whilst only 10mg/kg PHCCC reversed the 6-OHDA induced loss of striatal HVA 
(1mg/kg: 52.71±3.82% loss, P=0.5139, 3mg/kg: 45.01±3.14% loss, P=0.1637, 
10mg/kg 25.12±2.39% loss, P<0.001, vs 6-OHDA: 48.86±4.07% loss; Table 5.1A). 
Furthermore, 3 and 10mg/kg PHCCC but not 1mg/kg normalized the 6-OHDA 
induced increase in striatal DA T/O (1mg/kg: 0.14±0.03, P=0.2164, 3mg/kg:  
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A
B
Fig 5.3: Neuroprotective effect of systemic administration of PHCCC on the 
number of TH and NeuN-IR cells
Systemic injection (i.p.) of PHCCC (1, 3 and 10mg/kg) and (S)-DCPG (5, 15 and 
30mg/kg) for 4 consecutive days significantly attenuated the 6-OHDA induced 
loss of A) TH and B) NeuN-IR cells in a concentration dependent manner. Sham 
group received the DMSO containing vehicle for 4 consecutive days. The left 
charts on each panel illustrated the aqueous vehicle illustrated a similar reductive 
effect of the 6-OHDA induced TH and NeuN-IR cells loss, which was employed 
from another study, when compared to the 6-OHDA with DMSO containing 
vehicle (n=6). Data shown were mean percentage loss cells ± SEM in lesioned 
side when compared to contralateral side, n numbers in brackets: 6-OHDA (7), 
1mg/kg PHCCC (7), 3mg/kg PHCCC (7), 10mg/kg PHCCC(7), 5mg/kg (S)-
DCPG (7), 15mg/kg (S)-DCPG (7) and 30mg/kg (S)-DCPG (7). * P<0.01, * 
P<0.01, ** P<0.001 and *** P<0.0001when compared to 6-OHDA (One-way 
ANOVA followed by Student’s t test). 
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SNc
SNc
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C (Cont)
D (Cont)
B (Ipsil)
C (Ipsil)
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Fig 5.4: Representative photomicrographs of SNc TH-IR cells from 6-
OHDA lesioned animals treated systemically with (S)-DCPG. 
Panels A-G, low power (x40; scale bar=250µm) representative 
photomicrographs of contralateral (Cont) and ipsilateral (Ipsil) SNc to 
illustrate that systemic treatment with (S)-DCPG has neuroprotective 
effect on the cellular integrity of the SNc. PHCCC and (S)-DCPG 
provided a concentration dependent manner of protection of the SNc 
against the 6-OHDA; however, 30mg/kg (S)-DCPG failed to provide any 
neuroprotection for the TH-IR cells in the SNc against the 6-OHDA. 6-
OHDA group received DMSO containing vehicle. A) 6-OHDA (n=7), B) 
1mg/kg PHCCC (n=7), C) 3mg/kg PHCCC (n=7), D) 10mg/kg PHCCC 
(n=7), E) 5mg/kg (S)-DCPG (n=7), F) 15mg/kg (S)-DCPG (n=7), and G) 
30mg/kg (S)-DCPG (n=7) in 6-OHDA lesioned rats.
SNc
SNc
SNc
SNc
SNc
SNc
E (Cont)
F (Cont)
G (Cont)
E (Ipsil)
F (Ipsil)
G (Ipsil)
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Taken together, these observations demonstrated that the systemically administered 
PHCCC was also neuroprotective in the 6-OHDA model whilst the functionality of 
nigrostriatal tract was preserved.  
 
5.3.3 Neuroprotective effect of systemically administered (S)-DCPG against 
6-OHDA-induced neurotoxicity 
To test whether the neuroprotective effect of (S)-DCPG are maintained after 
systemically administered, one of three different concentrations of (S)-DCPG (5, 15 
and 30mg/kg) were administered intraperitoneally for 4 days (twice per day) after the 
6-OHDA lesioning plus a single dose the day before the stereotaxic infusion of 12µg 
6-OHDA to L-MFB. By one-way ANOVA analysis, it was observed that the systemic 
administration of (S)-DCPG prevented the 6-OHDA induced TH-IR neuronal loss in 
the SNc against 6-OHDA-induced neurotoxicity (F25.65, P<0.0001). However, instead 
of the classical concentration dependent profile, the neuroprotective effect of 
(S)-DCPG had a ‘bell shape’ profile. Post hoc Student’s t test revealed that 5 and 
15mg/kg (S)-DCPG provided neuroprotection at the level of TH-IR neuronal numbers 
(5mg/kg: 38.12±1.84% loss, P<0.01 and 15mg/kg: 31.01±3.54% loss, P<0.001, vs 
6-OHDA: 55.49±3.83% loss; Fig 5.3A). However, 30mg/kg (S)-DCPG failed to 
provide any significant neuroprotection (51.48±3.93% loss, P=0.4786, vs 6-OHDA: 
55.49±3.83% loss; Fig 5.3A). This neuroprotective profile was similarly mirrored in 
NeuN neuronal numbers (F48.08, P<0.0001; 5mg/kg: 34.28±2.08% loss, P<0.0001, 
15mg/kg: 28.70±2.39% loss, P<0.0001, and 30mg/kg: 51.30±3.08% loss, P=0.1019, 
vs 6-OHDA: 58.31±2.48% loss; Fig 5.3B). The data of (S)-DCPG study was 
compared to the 6-OHDA control group. Due to constraints on animal numbers in this 
section the (S)-DCPG data was compared to the same 6-OHDA lesion alone controls 
utilised in the PHCCC systemic studies. Whilst the PHCCC and DCPG studies were 
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conducted at the same time the 6-OHDA lesion alone controls were treated with the 
drug vehicle for PHCCC, DMSO, whilst the drug vehicle for (S)-DCPG was saline. In 
an ideal situation we would have liked to have run two separate control groups with 
the respective drug vehicles for (S)-DCPG and PHCCC, especially since in chapter 
we had demonstrated some complications with the use of DMSO as a drug vehicle for 
focal injection of PHCCC. For comparison in Fig 5.3 I have included data from a 
separate 6-OHDA lesion alone control group, utilised in studies not included in this 
thesis but treated with an aqueous vehicle administered under the same regimen as 
(S)-DCPG where can see that the presence of DMSO in the vehicle for peripheral 
administration has no effect on the size of the 6-OHDA lesion (TH-DMSO containing 
control: 55.49±3.83% loss, P=0.2762 vs saline containing control: 53.23±4.89% loss; 
NeuN-DMSO containing control: 58.31±2.48% loss, P=0.1827 vs saline containing 
control: 55.63±5.56% loss, Fig 5.3A-B). 
The visual illustration of the nigral dopaminergic neurons in each individual 
group is shown in Fig 5.4. The density of TH-IR neurons in the SNc was preserved by 
(S)-DCPG. Similarly, systemic administration of (S)-DCPG significantly attenuated 
the 6-OHDA induced depletion of striatal DA level (5mg/kg: 62.06±3.73% loss, 
P<0.01, and 15mg/kg: 32.84±3.64% loss, P<0.0001, vs 6-OHDA: 87.06±4.27% loss; 
Table 5.1A), DOPAC (5mg/kg: 32.84±2.41% loss, P<0.001, and 15mg/kg: 
37.24±2.82% loss, P<0.0001, vs 6-OHDA: 51.81±3.51% loss, Table 5.1A) and HVA 
(5mg/kg: 34.78±2.89% loss, P<0.01, and 15mg/kg: 23.30±1.59% loss, P<0.0001, vs 
6-OHDA: 48.86±4.07% loss; Table 5.1A). However, 30mg/kg (S)-DCPG did not 
afford any protection against the 6-OHDA-induced reduction of striatal DA 
(78.98±2.79% loss, P=0.1283, vs 6-OHDA: 87.06±4.27% loss, Table 5.1A), DOPAC 
(47.17±3.09% loss, P=0.3475 vs 6-OHDA: 51.81±3.51% loss, Table 5.1A) and HVA 
(44.54±3.99% loss, P=0.4773 vs 6-OHDA: 48.86±4.07% loss, Table 5.1A). 
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Furthermore, the 6-OHDA induced increase in striatal DA turnover ratio was 
normalized by both 5 and 15mg/kg (S)-DCPG but not 30mg/kg (5mg/kg: 0.15±0.03, 
P<0.001, 15mg/kg: 0.08±0.01, P<0.0001, and 30mg/kg: 0.22±0.03, P=0.4038, vs 
6-OHDA: 0.19±0.02; Table 5.1B). From these observations, it is clear that the 
neuroprotective effects of focally administered (S)-DCPG against 6-OHDA toxicity 
can be replicated following systemic administration of (S)-DCPG but only utilising 
the lower doses of (S)-DCPG (5 and 15mg/kg).  
 
5.3.4 Glial mediated mechanism of neuroprotection by systemic administered 
PHCCC against 6-OHDA-induced toxicity 
The intra-L-MFB infusion of 6-OHDA induced a significant proliferation of 
GFAP-IR cells in the lesioned side of brain (35.35±4.77% increase, P<0.0001 vs 
9.03±1.18% increase, Fig. 5.5A), whereas there was only a negligible amount of 
astrocytic activation in the sham-operated group. Similar to the infusion of 6-OHDA 
directly to the SNc, unactivated GFAP-IR cells were depicted with small cell bodies 
and thin processes whilst activated GFAP-IR cells in the MFB 6-OHDA model were 
depicted as large cell bodies and thickened and longer processes with  a stronger 
intensity of GFAP immunoreactivity (Fig 5.6). However, the underlying mechanism 
of this astrocytic activation in two different 6-OHDA models should be different since 
in SNc 6-OHDA model astrocytes were exposed to 6-OHDA directly whilst those in 
MFB 6-OHDA model did not. The morphological changes of GFAP-IR cells in the 
MFB 6-OHDA model were consistent to the previous reports (Rodrigues et al, 2001 
and 2004). Concomitantly, infusion of 12µg 6-OHDA in 4µl into L-MFB induced a 
proliferation of OX6-IR cells in the SNc on the lesioned side of brain in the 6-OHDA 
treated group compared to the unlesioned side of the brain (6.27±0.45 fold increase, 
P<0.0001 vs Sham: 2.46±0.26; Fig 5.5B). Morphologically, activated microglia were  
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A
B
Fig 5.5: Effect of sham and 6-OHDA lesioning on the number of 
GFAP-IR cells in the SNc
Infusion of 12 µg 6-OHDA in 4 µl into the left MFB results in a 
significant increase of A) GFAP and B) OX6-IR cells at 9 days post-
lesion, whereas in sham-lesioned animals no significant GFAP and 
OX6-IR cell increase observed. Sham group received a single 
injection of ascorbic acid (0.1%) to L-MFB. Data were expressed as 
the percentage increase of GFAP-IR cells ± SEM in lesioned side 
when compared to contralateral side or mean fold increase of OX6-
IR cells ± SEM. Sham and 6-OHDA treatment groups for left MFB 
injection n=7. *** P<0.0001 when compared to 6-OHDA (Student’s 
t test). 
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Fig 5.6: Representative photomicrographs of SNc GFAP and 
OX6-IR cells from 6-OHDA lesioned animals. 
High power (x400, scale bar = 25µm) representative
photomicrographs of GFAP and OX6-IR cells from the sham-
lesioned and 6-OHDA lesioned SNc illustrated that infusion of 
12µg 6-OHDA in 4µl to the left MFB induced the activation of 
GFAP and OX6-IR cells. Sham group received a single injection of 
ascorbic acid (0.1%) to L-MFB. Sham and 6-OHDA treatment 
groups for left MFB injection n=7. A) Sham GFAP, B) 6-OHDA 
GFAP, C) Sham OX6 and D) 6-OHDA OX6. 
C D
A B
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depicted with larger cell bodies and numerous processes after 6-OHDA-induced 
toxicity (Fig. 5.6). 
We also investigated the effect of systemically administered PHCCC on glial 
response following 6-OHDA. However, the systemic administration of PHCCC did 
not prevent the 6-OHDA-induced astrocytic activation as apposed to when PHCCC 
was administered focally in the SNc (F1.919, P=0.1608; 1mg/kg: 41.31±1.37% increase, 
P=0.0531; 3mg/kg: 40.17±2.31% increase, P=0.1249; 10mg/kg: 34.92±1.37% 
increase, P=0.0936; vs 6-OHDA: 35.12±4.77% increase; Fig 5.7A). Contrastingly, 
there was a concentration dependent reduction in microglial activation (F9.813, 
P<0.0001; 1mg/kg: 6.35±0.24 folds increase, P=0.8114; 3mg/kg: 5.08±0.35 folds 
increase, P<0.01; 10mg/kg: 4.19±0.33 folds increase, P<0.001; vs 6-OHDA: 
6.27±0.45 folds increase; Fig 5.7B).  
 
5.3.5 Glial mediated mechanism of neuroprotection by systemic administered 
(S)-DCPG against 6-OHDA-induced toxicity 
Similar to the investigation with focal administration of (S)-DCPG, there was no 
modulation of the 6-OHDA induced astrocytic activation when (S)-DCPG was 
administered systemically when considering the numbers of activated cells (F1.919, 
P=0.1608; 5mg/kg: 42.33±1.91%, P=0.1575; 15mg/kg: 40.31±1.14%, P=0.2714; 
30mg/kg: 40.17±1.13, P=0.2761 vs 6-OHDA: 35.12±4.77%, Fig 5.7A). On the other 
hand, the 6-OHDA induced microglial activation was diminished by the systemic 
administration of (S)-DCPG in a concentration-dependent fashion (F9.813, P<0.0001; 
5mg/kg: 6.25±0.34 fold increase, P=0.0941; 15mg/kg: 4.55±0.49 fold increase, 
P<0.01; 30mg/kg: 3.85±0.27 fold increase, P<0.0001; vs 6-OHDA: 6.27±0.45 fold 
increase, Fig 5.7B).  
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Fig 5.7: Effect of systemic injection of PHCCC and (S)-DCPG on 6-
OHDA induced increasing number of GFAP and OX6-IR cells
A) Subchronic systemic administration of PHCCC (1, 3 and 10mg/kg) and 
(S)-DCPG (5, 15 and 30mg/kg) for 4 consecutive days did not significantly 
reduced the increasing number of GFAP-IR cells. Data shown were mean 
percentage increase of GFAP-IR cells ± SEM in lesioned side when 
compared to contralateral side. B) Subchronic systemic administration of 
PHCCC (1, 3 and 10mg/kg) and (S)-DCPG (5, 15 and 30mg/kg) for 4 
consecutive days significantly reduced the increasing number of OX6-IR 
cells in a concentration-dependent manner. 6-OHDA group received the 
systemic injections of DMSO containing vehicle. Data shown were mean 
fold  increase of OX6-IR cells ± SEM in lesioned side when compared to 
contralateral side.; n values in brackets: 6-OHDA (7), 1mg/kg PHCCC (7), 
3mg/kg PHCCC (7), 10mg/kg PHCCC (7), 5mg/kg (S)-DCPG (7), 15mg/kg 
(S)-DCPG (7) and 30mg/kg (S)-DCPG (7). * P<0.01, ** P<0.001 and *** 
P<0.0001 when compared to 6-OHDA. 
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5.4 Discussion 
Similar to the administration of 6-OHDA directly to the SNc via the implanted 
cannulae, the intra-L-MFB infusion of 6-OHDA also induced a significant loss of the 
dopaminergic neurons in the SNc and a reduction in striatal dopamine content and its 
metabolites. Similarly, a consistent pattern of degeneration of dopaminergic neurons 
characterized by TH and NeuN antibodies under the challenge of 6-OHDA proved 
that there was the dopaminergic neuronal loss rather than just the down regulation of 
the expression of TH. Therefore, by the data demonstrated herein, 6-OHDA infused to 
L-MFB induced a specific and partial lesion of dopaminergic neurons in the SNc 
similar to that focally infused to the SNc.   
We demonstrated the neuroprotective effect of both PHCCC and (S)-DCPG was 
still maintained when administered systemically. Systemically administered PHCCC 
provided the concentration dependent neuroprotection of TH and NeuN-IR cells and 
maintained the nigrostriatal functionality. Systemic administration of PHCCC was 
associated with a modest prevention of 6-OHDA induced activation and proliferation 
of OX6-IR cells in the SNc in a concentration dependent manner. However, there was 
a ‘bell-shape’ profile of neuroprotection observed with the treatment of (S)-DCPG 
systemically. 5 and 15 mg/kg (S)-DCPG significantly attenuated the 
neurodegenerative effects of 6-OHDA but 30mg/kg (S)-DCPG failed to produce any 
neuroprotection. Surprisingly, although 30mg/kg (S)-DCPG failed to provide any 
neuroprotection, it still prevented the 6-OHDA induced microglial activation. 
However, systemically administered PHCCC and (S)-DCPG failed to reverse the 
6-OHDA induced proliferation and activation of GFAP-IR cells. 
 
5.4.1 The neuroprotective mechanism of systemic administration of PHCCC 
The neuroprotective effects of PHCCC following systemic administration further 
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support its potential clinical use. The neuroprotection produced by systemic 
administration of PHCCC was consistent with the neuroprotective effect of focally 
administered PHCCC and may be brought about by the down regulation of the 
glutamate release from the STN-SNc pathways (Valenti et al, 2003). The 
neuroprotective effect of the SNc focal administered PHCCC on the striatal DA level 
was not in a typical concentration dependent manner, rather an all or nothing effect 
(chapter 3). In the current study, systemic administration of PHCCC provided a 
concentration dependent protection of the striatal monoamines level. At low 
concentration, PHCCC could not reverse the loss of DOPAC and HVA. This could be 
putatively explained by Valenti et al (2005) in which PHCCC fails to reverse the 
release of monoamines from the striatal terminals of the dopaminergic neurons until 
PHCCC reach a high concentration. Since PHCCC was administered systemically, 
different pharmacological targets in the BG and even the entire brain could be 
activated by PHCCC. Thus, other protective mechanisms involving dopaminergic 
terminals in striatum or other basal ganglial nuclei could also be activated by systemic 
administration of PHCCC. This hypothesis was supported by the detection of the 
mRNA expression of mGluR4 on other nuclei in the BG previously (Messenger et al, 
2002). Therefore, the mGluR4 activation by PHCCC in the BG may modulate the 
glutamate excitotoxicity to the SNc. For instance, the activation of presynaptic 
mGluR4 on the striatal-GPe synapse would lead to a reduction in GABA release in the 
GPe, the net result of which would be to decrease glutamatergic activity from the 
STN (Marino et al, 2003a). Indeed, the presence of mGluR4 in the presynaptic STN 
glutamatergic neurons would facilitate the inhibition of the excessive release of 
glutamate to the SNc (Valenti et al, 2003). This action would inhibit the indirect 
pathway which is activated in PD. In addition mGluR4 was also found in the nucleus 
accumbens, the activation of which could inhibit the glutamate release (Xi et al, 2003). 
 215 
Additionally there are glutamatergic projections from cerebral cortex to the striatum 
(Cepeda and Levine, 1998 and Watson et al, 2009), which are negatively modulated 
by the activation of group III mGluR. Moreover, the prevalent expression of mGluR1 
in the SNc implied that PHCCC could prevent the glutamate excitotoxicity in the SNc 
(Messenger et al, 2002). The antagonism of group I mGluRs, another property of 
PHCCC, could down-regulate the activity of PKC, suggesting that PHCCC could also 
inhibit the PKC-mediated degeneration especially in the striatum (Paolillo et al, 1998). 
Indeed, the synchronous activation of mGluR1 and 4 in different nuclei in BG could 
provide a synergistic neuroprotection against 6-OHDA neurotoxicity. 
PHCCC neuroprotection may rely on both modulation of glutamate 
neurotransmission and microglial mediated neuroinflammation as discussed in chapter 
3. However, the inhibitory effect on astrocytic activation following SNc focal 
administration was absent when PHCCC was administered systemically. Such 
differences may be due to the different route of 6-OHDA administration and the 
subsequent differences in the degree of activation of astrocytes in two different 
models. In focal SNc 6-OHDA model, glial cells are activated by direct exposure to 
6-OHDA and via traumatised neurons whilst glial cells are indirectly activated only 
by traumatised dopaminergic neurons in the intra-MFB infused 6-OHDA model. 
Possibly PHCCC can only modify the activity of astrocytes that have been directly 
exposed to toxins where the level of activation is much greater. This could possibly 
explain why systemic administered PHCCC failed to prevent the astrocytic activation.  
 Similarly, although there was a strong neuroprotection when PHCCC was 
administered systemically, prevention of microglial activation was not significant 
until concentration reach 10mg/kg which was different from the action of focally 
administered PHCCC (chapter 3). These could be similarly explained again by 
multiple action sites of PHCCC since mGluR4 and mGluR1 are expressed in different 
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brain nuclei.  
 
5.4.2 The neuroprotective mechanism of systemic administration of (S)-DCPG 
Systemic administration of (S)-DCPG produced neuroprotection in the SNc 
against the intra-MFB infusion of 6-OHDA. Unlike the focally administered 
(S)-DCPG, systemic administration of (S)-DCPG could target other mGluR8 
activation in different brain nuclei. For example, stimulation of thalamic mGluR8 
could play an important role in the regulation of glutamate excitation to striatum and 
SNc (Linden et al, 2003). However, the release of GABA in the striatopallidal tract 
could not be inhibited by (S)-DCPG since there is an absence of mGluR8 in the 
striatopallidal pathway (Valenti et al, 2003 and Ossowska et al, 2007). Therefore, the 
anti-excitotoxicity by systemically administered (S)-DCPG may be produced via 
mGluR8 in thalamus and SNc but not by modulation of the indirect pathway in the 
BG.  
However, not all doses of (S)-DCPG were neuroprotective with twice daily 
injections of 30mg/kg (S)-DCPG systemically failed to provide any neuroprotection 
of dopaminergic neurons against the 6-OHDA neurotoxicity. The therapeutic effective 
window is narrow although there was a significant neuroprotection by (S)-DCPG in 
lower concentration (5 and 15mg/kg). One possibility is that utilising the high 
concentration of (S)-DCPG in this study, 30mg/kg, we may lose receptor specificity at 
mGluR8; however, there is no evidence in the literature to support this idea.  
A more likely explanation for the loss of neuroprotection is that the 30mg/kg 
dose of (S)-DCPG produced a significant loss of body weight during the drug 
administration period (Data not shown) whilst the animals began to regain weight 
immediately after the termination of drug administration on day 4. This unwanted 
effect is possibly due to the activation of systemic mGluR8. Antagonism of mGluR8 
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in pancreatic cells leads to obesity and enhanced insulin secretion in rats (Brice et al, 
2002 and Tong et al, 2002), whereas (S)-DCPG may cause animals to lose weight. 
Interestingly, decreases in insulin levels which could be triggered by mGluR8 
activation have been shown to worsen 6-OHDA-induced neurotoxicity (Quesada et al, 
2008 and Wilcox et al, 1989). Moreover, the excessive activation of mGluR8 on 
GABAergic projections from cortex or hippocampus to the BG would prevents the 
release of GABA which may worsen excitotoxicity in the BG after 6-OHDA 
administration (Ferraguti et al, 2005). Although the mGluR8 expression has been 
demonstrated in the globus pallidus and STN, the modulation of neurotransmission in 
these nuclei by activating mGluR8 has not been shown (Messenger et al, 2002 and 
Ossowska et al, 2007). Therefore, systemically administered (S)-DCPG may mainly 
affect the non neuronal cell types in the SNc. 
Systemic administration of (S)-DCPG failed to modulate the 6-OHDA induced 
astrocytic activation which is consistent with that observed with focal administration 
of (S)-DCPG. Such finding indicates that the neuroprotective effect of (S)-DCPG are 
not via the down regulation of astrocytic activation. On the contrary, as reported in 
chapter 4, (S)-DCPG administration alone led to the activation of astrocytes. In this 
chapter, the finding of astrocytic activation in the contralateral hemisphere further 
confirms such hypothesis (Data not shown). However, this could be due an indirect 
effect of 6-OHDA lesioning. If (S)-DCPG could increase astrocytic activation, 
systemically administered (S)-DCPG could enhance produce and release the 
neurotrophic factors which could protect dopaminergic neurons against the 6-OHDA 
neurotoxicity.  
Interestingly, all concentrations of (S)-DCPG injected systemically prevented 
the 6-OHDA-induced activation of microglia in a concentration-dependent fashion. In 
particular 30mg/kg (S)-DCPG still modulated microglial activation although it failed 
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to induce any neuroprotection. As discussed previously in Chapter 4, (S)-DCPG may 
act on the microglia directly. One of the possible explanations is that (S)-DCPG 
maintain the integrity of the neuron-microglia interactions or downgrades microglial 
activation. However, 5mg/kg (S)-DCPG did not significantly affect microglial 
activation, indicating that the neuroprotection effect of (S)-DCPG does not simply 
rely on the modulation of microglial activation.  
 
5.4.3 Conclusion 
The neuroprotective effects of PHCCC and (S)-DCPG following administered 
systemically support the concept that such drugs are the promising candidates for the 
therapeutic treatment of PD.  
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Chapter 6: Neuroprotective effect of PHCCC and (S)-DCPG in the 
rodent lactacystin PD model  
6.1 Introduction 
 
6.1.1 Derivatives of PD models: familial vs sporadic  
One of the pathological hallmarks of PD is protein inclusions (Jenner and 
Olanow, 1998). Such protein inclusions were first described by Lewy F.H. in post 
mortem tissue in 1913 and hence named as Lewy body (LB; Bethlem et al, 1960). 
LB’s form in the PD brains and are believed to prevent the accumulation of oxidized 
proteins in the dopaminergic neurons in the SNc (Halliwell and Jenner, 1998).  
LBs are found in both familial and sporadic PD (Spira et al, 2001; Jenner and 
Olanow, 1998) whilst they are also found in some cases of dementia, such as 
dementia with LB (Korczyn and Reichmann, 2006; Dodel et al, 2008; McKeithl, 
2007). Indeed, LB consists of different protein components such as ubiquitin, α-
synuclein, Tau and etc (Rideout et al, 2001; Geetha and Wooten, 2008). However, the 
proportion of these proteins in LB is not clear (Johnson, 2000). Furthermore, these 
proteins are not functional since they are misfolded or oxidised. Since such misfolded 
and damaged proteins are toxic to cells and it has been proposed that the formation of 
LB prevents the build up of altered protein in the cytosol of neurons (Sherman and 
Goldberg, 2001). However, LB’s are large structures and may have an impact 
themselves on cellular function. Furthermore, the LB is not a bottomless pit with only 
a limited amount of altered proteins being able to be packed into the LB, hence 
ultimately altered proteins will overflow into the cytoplasm.  
 
6.1.2 Ubiquitin-Proteasome system 
Certain familial PD gene mutations, such as Parkin, ubiquitin carboxyl terminal 
hydrolase L1 (UCH-L1), DJ-1 and α-synuclein, are related to the formation of LB 
found in PD brains. Parkin and UCH-L1 participate in the ubiquitin-proteasome 
system (UPS), which is the intracellular machinery for the degradation of the 
unwanted proteins. Mutation of these enzymes leads to the down regulation of UPS 
function and the accumulated of unwanted proteins. In both familial and sporadic PD, 
the activity of proteasome is down regulated since there is a decrease in the number of 
proteasome components in PD (McNaught and Jenner, 2001; McNaught et al, 2003). 
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These findings indicated that the reduction in proteasome-mediated protein 
degradation and subsequently the formation of LB could be one of the major 
mechanisms of nigral dopaminergic degeneration in PD. Indeed, the failure of UPS is 
also found in several other neurodegenerative diseases and hence may be a common 
downstream mechanism from the original disease trigger (Lim, 2007). Consequently, 
since the formation of altered protein is thought to be a key player in PD it would be 
advantageous if animal models of the disease also featured this pathology. 
As with many toxin based models of PD the 6-OHDA model does not trigger 
the formation of LB-like inclusions (Schober et al, 2004; and Inden et al, 2005). This 
may relate to the acute nature of this model. However, the 6-OHDA model does 
mirror several other features of PD such as selective nigrostriatal degeneration, an 
innate inflammatory response, iron accumulation and oxidative stress etc. Indeed, no 
single animal model of PD replicates all of the pathological and biochemical features 
of the disease. Even the newly created transgenic mouse models mimicking familial 
PD do not satisfy these criteria. Hence, potential therapies must be tested in a range of 
animal models before being considered for testing in man. Hence, this study was 
designed to test our mGluR ligands in an animal model of PD principally 
demonstrating neurodegeneration associated with altered protein formation/deposition. 
 
6.1.3 Lactacystin 
Epoxomicin, PSI and lactacystin (Fig 5.1) were developed as proteasome 
specific inhibitors. The ability of epoxomicin and PSI to generate models of PD is 
controversial, with just as many scientists reporting their failure to cause nigrostriatal 
toxicity (Mathur et al, 2007 and Kadoguchi et al, 2008) as those demonstrating 
dopaminergic degeneration (Rideout et al, 2001; McNaught et al, 2004; Schapira et al, 
2006; and Reaney et al, 2006). On the other hand a few studies have reported that the 
focal infusion of lactacystin, which fails to cross the BBB, reliably induces the 
dopaminergic degeneration with significant formation of LB-like structures 
(McNaught et al, 2002; Miwa et al, 2005; and Zhu et al, 2007). Interestingly, the 
retrograde lesion by infusion of lactacystin to the median forebrain bundle (MFB) is 
also demonstrated as PD model (Zhu et al, 2007). However, the dopaminergic 
selectivity of lactacystin was still unclear.  
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Fig 6.1: The chemical structure of lactacystin. 
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6.1.4 Hypothesis and aim 
In this chapter we employed the lactacystin PD model in order to investigate the 
neuroprotective potential of PHCCC and (S)-DCPG. The details of the aims are as 
followed: 
1. The lactacystin model was not an established model in this laboratory, hence the 
first aim was to establish the optimal conditions for the lactacystin induced 
degeneration of dopaminergic neurons in the SNc.  
2. To examine the neuroprotective potential of focally administration of (S)-DCPG 
and PHCCC against the lactacystin-induced neurotoxicity.  
3. To examine the effect of PHCCC and (S)-DCPG could modulate the astrocytic 
(GFAP-IR) and microglial (OX6-IR) activation induced by lactacystin.  
4. To examine whether PHCCC and (S)-DCPG could modulate the lactacystin 
induced formation of LB-liked inclusion.  
 
6.2 Experimental Design  
6.2.1 Establishment of lactacystin lesion model 
The most extensive studies on the lactacystin have been carried out in the mouse 
(Zhu et al, 2007) with very few studies carried out in the rat. Hence, the first step in 
the optimisation of the model was to carry out a small time course to see whether the 
degree of neuronal loss observed with time was similar to that observed in the mouse 
(Zhu et al, 2007) and secondly to determine the optimal dose of lactacystin to 
generate a suitable partial lesion. To estimate the time-course effect, 5µg lactacystin 
in a total injection volume of 4µl 10% DMSO was infused into the SNc through the 
indwelling cannulae with the animals being assessed at 1 and 3 weeks post lesion. 
Subsequently, the concentration-dependent effect of the lactacystin was investigated 
by administering 5 and 7 µg lactacystin in a total volume of 4µl 10% DMSO to the 
SNc through the indwelling cannulae. Furthermore, to compare the extent of the 
lesion induced by direct lactacystin infusion into the SNc with that of an MFB lesion 
7µg lactacystin was infused to the L-MFB with the animal being examined 3 weeks 
post lesioning. To assess the integrity of the nigrostriatal tract rats were sacrificed as 
described previously with subsequent immunohistochemical detection of NeuN-IR 
and TH-IR cells (see section 2.2.6-7) whilst striatal monoamines content was assessed 
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by HPLC (see section 2.2.8). The treatment regime is schematically illustrated in Fig 
6.2-3.  
 
6.2.2 Neuroprotective Study of (S)-DCPG and PHCCC  
To investigate the neuroprotective effect of PHCCC and (S)-DCPG in 
lactacystin model, effective concentrations of 50nmol (S)-DCPG and 75nmol PHCCC 
derived from the previous chapters utilising the 6-OHDA model was infused to the 
SNc starting 7 days after the infusion of 7µg lactacystin to the SNc via the indwelling 
cannulae in a total injection volume of 4µl (see section 2.4.1). (S)-DCPG or PHCCC 
was then administered daily in an injection volume of 4µl for a further 14 consecutive 
days. At the end of the study period rats were sacrificed and tissues were removed for 
further analysis. The lactacystin-induced lesions were analysed by the 
immunohistochemical detection of NeuN-IR and TH-IR cells (see section 2.4.2). The 
monoamine contents in the striata were measured by HPLC (see section 2.2.8). The 
treatment regimen is illustrated in Fig 6.3.  
 
6.2.3 Involvement of glial cells and Lewy body-like inclusions in the animal 
model and effects of (S)-DCPG or PHCCC treatment 
To investigate potential glial factors in the lactacystin PD model, cryostat 
sections were analyzed by immunohistochemistry with specific markers for astrocytes 
(GFAP-IR) and activated microglia (OX6-IR) (see section 2.2.7). The morphological 
changes were illustrated by the photomicrographs at x400 magnification. The 
lactacystin-induced formation of LB-like structure was characterized with dual 
staining for α-synuclein and TH. The photomicrographs of α-synuclein containing 
aggregates are illustrated at x400 magnification (see section 2.4.3).  
 
6.2.4 Statistical analysis 
NeuN, TH, OX6 and GFAP-IR cells in the lesioned hemisphere of all treatment 
groups were expressed as the percentage loss ± S.E.M relative to the unlesioned side. 
For the striatal monoamines concentration, the data was presented as the mean 
percentage loss of monoamine concentration ± S.E.M in the lesioned side when 
compared to contralateral side. For the turnover ratio of striatal DA (T/O), the data  
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was expressed as the turnover ratio ± S.E.M. The calculation of turnover was shown 
below:  
{[DOPAC (nmol/mg) + [HVA (nmol/mg)]} 
[DA (nmol/mg)] 
 
In all figures, n values (number of animals in each treatment group) are shown in the 
caption of each figure. Data was analyzed by a series of statistical analysis. By the 
one-way analysis of variants (ANOVA) among different treatment groups, the 
statistic significance among different treatment groups was analyzed under the 
assumption of random sampling and normal distribution. Subsequently, post hoc 
analysis in the form of an unpaired two-tailed Student's t test made between the 
lesioned sides of the drug treatment groups to the control group. The significant 
differences were shown by expressing the P value as P<0.01, 0.001 and 0.0001, 
which was also annotated in the figures. All statistical analysis was performed using 
Software package of GraphPad Prism version 4.00 (GraphPad Software, USA). 
 
6.3 Result 
6.3.1 Lesion of lactacystin 
6.3.1.1 Effect of lactacystin on the integrity of dopaminergic neurons and the 
functionality of nigrostriatal tract 
To study the toxic effect of lactacystin on the dopaminergic neurons in the SNc, 
5µg lactacystin was infused to the SNc via the indwelling cannulae and examined 1 or 
3 weeks post lesioning. There was no significant toxicity induced by 5µg lactacystin 
in animals assessed 1 week post lesioning (TH: 12.62±1.11% loss, P=0.7655 vs Sham: 
11.68±3.09% loss; NeuN: 10.72±1.75% loss, P=0.7852 vs Sham: 10.02±1.51% loss, 
Fig 6.4A and B). In addition, 5µg lactacystin failed to have any effect on striatal DA 
concentration or its metabolites except DOPAC or turnover 1 week after lesion 
induction (DA: 10.09 ±1.29% loss, P=0.0715 vs Sham: 6.49±0.82% loss; DOPAC: 
11.22±0.82% loss, P<0.001 vs Sham: 5.14±0.71% loss; HVA: 8.33±0.51% loss, 
P=0.1023 vs Sham: 10.34 ± 1.12% loss and TO: 0.21±0.01, P=0.0712 vs Sham: 
0.28±0.02; Table 6.1-2). Taking these results together, 5µg lactacystin did not induce 
a significant lesion of the nigrostriatal tract. In contrast, administration of 5 and 7µg  
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Fig 6.4: Effects of intranigral and intra-L-MFB administration of 
lactacystin on the number of TH and NeuN-IR cells
Administration of lactacystin in 5 or 7µg dissolved in 4µl 10% DMSO saline 
into the left SNc exposed for 1 or 3 weeks, or 7µg to L-MFB results in a time-
and concentration-dependent reduction of both A) TH and B) NeuN-IR cells, 
whereas in sham-lesioned animals no significant cell loss observed. C) The 
infusion of 7µg lactacystin to SNc, but not L-MFB, induced an even lesion 
among the five stereotaxic levels. Sham (L-MFB) received a single injection of 
10% DMSO saline vehicle to L-MFB whilst Sham (SNc) received a single 
injection of 10% DMSO saline vehicle to SNc. Data were expressed as 
percentage loss of TH and NeuN-IR cells ± SEM. n values in brackets: Sham 
(L-MFB) (4), 7µg lactacystin for 3 weeks (L-MFB) (6), Sham (SNc) (4), 5µg 
lactacystin for 1 week (6), 5µg lactacystin for 3 week (SNc) (6) and 7µg 
lactacystin for 3 weeks (SNc) (6). *** P<0.0001 lactacystin vs. sham-lesioned 
animals, analysed by Student’s t test. 
A                                                            B
C
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DOPAC (% loss) 
19.17±1.04 ###   6.52±0.77 ###   8.57±1.21 ### DCPG 50 
50.04±3.51 # 30.60±1.74 ### 74.63±2.50 PHCCC 75 
39.29±0.64 *** 46.67±1.62 *** 74.79±2.43 *** Lact 7 (3w) 
32.14±1.27 *** 22.84±1.35 *** 31.11±1.43 *** Lact 5 (3w) 
  8.33±0.51 11.22±0.82 ** 10.09±1.29 Lact 5 (1w) 
10.34±1.12   5.14±0.71   6.49±0.82 Sham (SNc) 
  3.70±0.39 *** 13.39±1.25 ** 40.93±3.45 *** LMFB 
10.53±0.89   5.17±0.47   6.40±0.86 Sham (LMFB) 
HVA (% loss) DA (% loss)   Group 
Table 6.1: The exposure of lactacystin (5 or 7µg) for 1 or 3 weeks 
infused to the left SNc or MFB induced the loss of monoamines (DA, 
DOPAC and HVA) level. Subchronic intranigral administration of 
50nmol (S)-DCPG 7 days after lesion for 14 consecutive days reversed 
the lactacystin-induced depletion of monoamines level in the striata, 
whilst 75nmol PHCCC failed to reversed this depletion of striatal 
monoamines. Sham (L-MFB) received a single injection of 10% DMSO 
saline vehicle to L-MFB whilst Sham (SNc) received a single injection 
of 10% DMSO saline vehicle to SNc. Lact 7 (3w) group received 
intranigral injection of saline vehicle for 14 days. Data were shown as 
percentage loss of monoamines level±SEM. n value in brackets: Sham 
(LMFB) (4), LMFB: 7µg lactacystin for 3 weeks to LMFB (6), Sham 
(SNc) (4), Lact 5 (1w): 5µg lactacystin for 1 week (6), Lact 5 (3w): 5µg 
lactacystin for 3 weeks (6); Lact 7 (3w): 7µg lactacystin for 3 weeks (6); 
PHCCC 75: 75nmol PHCCC (6); and, DCPG 50: 50nmol (S)-DCPG 
(6); ** P<0.001 and *** P<0.0001, when compared to Sham. # P<0.01 
and ### P<0.0001, when compared to Lact 7 (3w). 
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0.24±0.01 ## 0.23±0.01 DCPG 50 
0.45±0.02 0.13±0.01 PHCCC 75 
0.43±0.03 * 0.32±0.02 Lact 7 (3w) 
0.31±0.01 0.25±0.01 Lact 5 (3w) 
0.21±0.01 0.17±0.01 Lact 5 (1w) 
0.28±0.02 0.26±0.01 Sham (SNc) 
0.33±0.03 * 0.21±0.02 LMFB 
0.28±0.01 0.29±0.01 Sham (LMFB) 
Ipsilateral Contralateral Group 
TO   
Table 6.2: The exposure of lactacystin (5 or 7µg) for 1 or 3 weeks 
infused to the left SNc or MFB induced the increase of dopamine 
turnover (TO). Subchronic intranigral administration of 50nmol (S)-
DCPG 7 days after lesion for 14 consecutive days reversed the 
lactacystin-induced increase of TO, whilst 75nmol PHCCC failed to 
reversed this increase of TO. Sham (L-MFB) received a single injection 
of 10% DMSO saline vehicle to L-MFB whilst Sham (SNc) received a 
single injection of 10% DMSO saline vehicle to SNc. Lact 7 (3w) group 
received intranigral injection of saline vehicle for 14 days. Data were 
shown as mean turnover ratio ±  SEM. n values in brackets: Sham 
(LMFB) (4), LMFB: 7µg lactacystin for 3 weeks to left MFB (6), Sham 
(SNc) (4), Lact 5 (1w): 5µg lactacystin for 1 week to SNc (6), Lact 5 
(3w): 5µg lactacystin for 3 weeks to SNc (6), Lact 7 (3w): 7µg 
lactacystin for 3 weeks to SNc (6); PHCCC 75: 75nmol PHCCC (6); 
and, DCPG 50: 50nmol (S)-DCPG (6). * P<0.01, when compared to 
Sham. ## P<0.001, when compared to Lact 7 (3w). 
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lactacystin induced a significant loss of TH-IR neurons when assessed 3 weeks after 
lesioning (5µg: 41.87±1.48% loss, P<0.0001; and 7µg: 52.97±1.97% loss, P<0.0001; 
vs Sham: 11.68±3.09% loss; Fig 6.4A), which was mirrored by a similar loss of 
NeuN-IR cells (5µg: 35.67±1.51% loss, P<0.0001; and 7µg: 57.23±2.41% loss, 
P<0.0001 vs Sham: 10.02±1.51% loss; Fig 6.4B). The extent of the SNc lesion is 
illustrated in Fig 6.5 in which the different concentration of lactacystin exposed for 
different time point decreased the density of TH-IR cells in the SNc. Furthermore, the 
lesion induced by lactacystin injected to the SNc focally was consistent across all the 
five different stereotaxic levels of the SNc (from A to E; F72.11, P=0.7216), indicating 
that lactacystin affected the entire structure of the SNc evenly. Additionally, 
administration of 5 and 7 µg lactacystin induced a significant loss of striatal level of 
DA when assessed 3 weeks post lesioning (5µg for 3 weeks: 31.11±1.43% loss, 
P<0.0001; 7µg for 3 weeks:  74.79±2.43% loss, P<0.0001; vs Sham: 6.49±0.82% loss; 
Table 6.1), DOPAC (5µg for 3 weeks: 22.84±1.35% loss, P<0.0001; 7µg for 3 weeks: 
46.67 ± 1.62% loss, P<0.0001; vs Sham: 5.14±0.71% loss; Table 6.1) and HVA 
concentrations (5µg for 3 weeks: 32.14±1.27% loss, P<0.0001; 7µg for 3 weeks: 
39.29±0.64% loss, P<0.0001; vs Sham: 10.34±1.12% loss; Table 6.1). The exposure 
to 5 and 7µg lactacystin for 3 weeks induced a significant increase of striatal DA T/O 
(5µg for 3 weeks: 0.31±0.01, P=0.0982; 7µg for 3 weeks: 0.43±0.03, P<0.01; vs 
Sham: 0.28±0.02; Table 6.2).  
Similarly a significant cellular degeneration (TH and NeuN-IR) was found 
following the administration of lactacystin to the L-MFB when assessed 3 weeks after 
lesioning (TH: 31.23±1.91% loss, P<0.0001 vs Sham: 8.79±1.30% loss; and NeuN: 
36.02±2.52% loss, P<0.0001 vs Sham: 8.24±1.23% loss; Fig 6.4A-B). Intra-L-MFB 
administration of 7µg lactacystin also induced the depletion of striatal DA 
(40.93±3.45% loss, P<0.0001 vs Sham: 6.40±0.86% loss; Table 6.1) and DOPAC 
(13.39±1.25% loss, P<0.001 vs Sham: 5.17±0.47% loss; Table 6.1), but not HVA 
content (3.7±0.39% loss, P<0.0001 vs Sham: 10.53±0.89% loss; Table 6.1) when 
assessed 3 weeks post lesioning. Furthermore, lactacystin administration induced an 
increase in DA T/O (0.33±0.03, P<0.01 vs Sham: 0.28±0.01; Table 6.2). Unlike the 
lesion pattern in focal administration to the SNc, the intra-L-MFB infusion of 
lactacystin induced a more uneven pattern of cell loss in the SNc among the five  
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SNc
SNc
SNc
SNc SNc
Fig 6.5: Representative photomicrographs of TH and NeuN-IR cells from the 
sham-lesioned and intranigral infused lactacystin lesioned SNc. 
Panels A-E, low power (x40; scale bar=250µm) representative photomicrographs of 
contralateral (Cont) and ipsilateral (Ipsil) to illustrate that single intranigral 
administration of lactacystin in 10% DMSO induced degeneration of the SNc with a 
decreasing density of TH-IR cells. Sham group received a single 10% DMSO 
containing vehicle to SNc. A) Sham (intranigral, n=4), B) 5µg lactacystin for 1 week 
(n=6), C) 5µg lactacystin for 3 week (n=6), D) 7µg lactacystin for 3 weeks (n=6), 
and E) 7µg lactacystin for 3 weeks (NeuN). 
B (Cont)
A (Cont)
B (Ipsil)
A (Ipsil)
C (Cont) C (Ipsil)
D (Cont) D (Ipsil)
SNc
SNc
SNc
SNc
E (Ipsil)
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different stereotaxic levels (F132.13, P<0.001). The reduction of TH-IR neurons in level 
D (24.86±0.41%, P<0.001; Fig 6.4C) and E (19.77±1.04%, P<0.0001; Fig 6.4C) was 
significantly lower than other level in the same treatment group. For the 
morphological changes of dopaminergic neurons in the SNc, photomicrographs were 
illustrated in Fig 6.6. In the current study, we demonstrated that 7µg lactacystin 
exposed for 3 weeks induced a significant cellular lesion and the depletion of striatal 
DA, which was utilized as the PD model for the further study of neuroprotective 
action of PHCCC and (S)-DCPG.   
 
6.3.1.2 Activating Effect of lactacystin on glial cells 
Administration of 5µg lactacystin induced an increase in the number of GFAP-
IR cells when assessed 1 or 3 weeks post lesion (1 week: 12.02±2.02% increase, 
P=0.1808; and 3 weeks: 18.02±2.47% increase, P<0.01 vs Sham: 7.28±2.56% 
increase; Fig 6.7A). Similarly, administration of 7µg lactacystin significantly induced 
a proliferation of GFAP-IR cells when assessed 3 weeks post lesion (19.23±1.10% 
increase, P<0.001 vs Sham: 7.28±2.56% increase, Fig 6.7A), indicating that the 
lactacystin-induced dopaminergic lesion was associated with astrogliosis. However L-
MFB infusion of 7µg lactacystin did not increase the number of astrocytes 
significantly when assessed three weeks after lesioning (14.27±2.80% increase, 
P=0.0988 vs Sham: 7.54±1.08% increase, Fig 6.7A). However, the degree of 
astrocytic activation in the lactacystin model was only half that observed in the 6-
OHDA model. Morphologically, cell bodies of GFAP-IR cells were enlarged and the 
processes were elongated and thickened after exposure to lactacystin (Fig 6.7B with 
only treatment of 7µg lactacystin exposed for 3 weeks).  
Lactacystin also induced a concentration and time dependent activation of 
microglia. Administration of 5µg lactacystin induced an increase in the number of 
OX6-IR cells in the SNc when assessed 1 or 3 weeks post lesioning (5µg for 1 week: 
3.01±0.33 fold increase, P<0.01; 5 µg for 3 weeks: 3.78±0.38 fold increase, P<0.01, 
vs Sham: 1.34±0.31 fold increase; Fig 6.8A). Administration of 7µg lactacystin 
induced a greater proliferation of microglia when assessed 3 weeks post lesioning 
(5.39±0.60 fold increase, P<0.001 vs Sham: 1.34±0.31 fold increase, Fig 6.8A). 
Morphologically, administration of 7µg lactacystin induced a greater increase in 
microglial activation as demonstrated by thickened processes and an increase in size  
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SNc
SNc
SNc
B (Ipsil; TH)B (Cont; TH)
C (NeuN)
A (Ipsil; TH)A (Cont; TH)
SNc
SNc
Fig 6.6: Representative photomicrographs of TH and NeuN-
IR cells from the sham-lesioned and intra-L-MFB infused 
lactacystin lesioned SNc. 
Panels A-C, low power (x40; scale bar=250µm) representative 
photomicrographs of contralateral (Cont) and ipsilateral (Ipsil) to 
illustrate that single intra-L-MFB administration of lactacystin in 
10% DMSO induced degeneration of the SNc with a decreasing 
density of TH-IR cells. Sham group received a single injection of 
10% DMSO vehicle to L-MFB. A) Sham (L-MFB) (n=4), B) 7µg 
lactacystin for 3 weeks (L-MFB) (n=6) and (C) 7µg lactacystin 
for 3 weeks (L-MFB; NeuN). 
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Sham Lact 7µg for 3 weeks
Fig 6.7: Effect of lactacystin on GFAP-IR cells activation 
A) Administration of 5 or 7µg lactacystin dissolved in 4µl 10% DMSO 
saline into the left SNc exposed for 1 or 3 weeks, or 7µg to the left L-
MFB results in a time- and concentration-dependent increase of GFAP-
IR cells, whereas in sham-lesioned animals no significant increase of 
GFAP-IR cells observed. Sham (L-MFB) received a single injection of 
10% DMSO saline vehicle to L-MFB whilst Sham (SNc) received a 
single injection of 10% DMSO saline vehicle to SNc. Data were 
expressed as the percentage increase of GFAP-IR cells ± SEM in 
lesioned side when compared to contralateral side. n values in blanket: 
Sham (L-MFB) (4), 7µg lactacystin for 3 weeks (L-MFB) (6), Sham 
(SNc) (4), 5µg lactacystin for 1 week (6), 5µg lactacystin for 3 week 
(SNc) (6) and 7µg lactacystin for 3 weeks (SNc) (6). * P<0.01 and ** 
P<0.001 lactacystin vs. sham-lesioned animals; analysed by Student’s t-
test. B) High power (x400; scale bar=50µm) representative 
photomicrographs of GFAP-IR cells from the sham-lesioned and 
lactacystin (7µg for 3 weeks) lesioned SNc. The administration of 7µg 
lactacystin into the SNc for 3 weeks increases the number of astrocytic 
process and intensity of GFAP staining. 
A
B
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Sham Lact 7µg for 3 weeks
Fig 6.8: Effect of lactacystin on the number of OX6-IR cells
A) Administration of 5 or 7µg lactacystin dissolved in 4µl 10% 
DMSO saline into the left SNc exposed for 1 or 3 weeks, or 7µg to the 
left L-MFB results in a time- and concentration-dependent increase of 
OX6-IR cells, whereas in sham-lesioned animals no significant 
increase of OX6-IR cells observed. Sham (L-MFB) received a single 
injection of 10% DMSO saline vehicle to L-MFB whilst Sham (SNc) 
received a single injection of 10% DMSO saline vehicle to SNc. Data 
was expressed as the increase folds of OX6-IR cells ± SEM in the 
lesioned side when compared to the contralateral side. n values in 
brackets: Sham (L-MFB) (4), 7µg lactacystin for 3 weeks (L-MFB) (6), 
Sham (SNc) (4), 5µg lactacystin for 1 week (6), 5µg lactacystin for 3 
week (SNc) (6) and 7µg lactacystin for 3 weeks (SNc) (6). * P<0.01 
and ** P<0.001 lactacystin vs. sham-lesioned; analysed by Student’s t-
test. B) High power (x400; scale bar=50µm) representative 
photomicrographs of OX6-IR cells from the sham and lactacystin 
lesioned SNc. The administration of 7µg lactacystin into the SNc for 3 
weeks increase the number of microglial process and cell size. 
A
B
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of cell bodies, with the cells having a spider-like cell shape (Fig 6.8B). Interestingly, 
the degree of microglial activation associated with lactacystin toxicity was similar to 
that observed with 6-OHDA. 
 
6.3.1.3 Lactacystin-induced α-synuclein aggregates 
An objective of the utilization of the lactacystin PD model was to mimic the 
formation of LB-like inclusions. In this study, we successfully illustrated α-synuclein 
containing aggregates in the remaining dopaminergic neurons in the lesioned SNc. By 
the double-labelled immunohistochemistry, α-synuclein aggregates were located in 
the TH-IR neurons in those animals treated with 5 and 7µg lactacystin when assessed 
three weeks post lesioning. α-synuclein containing aggregates were absent in the 
Sham operated group (Fig 6.9). Interestingly, the injection of lactacystin to the L-
MFB did not induce any aggregates to form (Fig 6.9).  
Therefore, these findings demonstrate that lactacystin induces a concentration 
and time-dependent degeneration of nigrostriatal tact accompanied with the activation 
of astrocytes and microglia which are consistent with the previous studies (Zhang et al, 
2005a). Furthermore, SNc administered lactacystin also induced the formation of α-
synuclein aggregates.  
 
6.3.2 Neuroprotective effect of PHCCC and (S)-DCPG against the lactacystin-
induced toxicity  
Utilizing the 7µg lactacystin lesion model with a 3 week exposure, we then 
investigated the neuroprotective effect of PHCCC and (S)-DCPG by the daily 
infusion of either 75nmol PHCCC or 50nmol (S)-DCPG for 14 consecutive days into 
the SNc via the indwelling cannulae commencing 7 days after  lactacystin lesioning. 
Administration of 7µg lactacystin to the SNc induced a significant loss of TH-IR in 
the SNc (52.97±1.97% loss, P<0.0001 vs TH in Sham: 11.68±3.09% loss; Fig 6.10A) 
and NeuN-IR cells (57.23±2.41% loss, P<0.0001 vs NeuN in Sham: 10.02±1.51% 
loss; Fig 6.10B) when assessed 3 weeks post lesioning. Dopaminergic neuronal 
degeneration was mirrored by a lactacystin induced depletion of striatal DA content 
and its metabolites (DA: 74.79±2.43% loss, P<0.0001 vs DA in Sham: 6.49±0.82% 
loss; DOPAC: 46.67±1.62% loss, P<0.0001 vs DOPAC in Sham: 5.14±0.71% loss;  
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Fig 6.9: Representative photomicrographs of lactacystin-induced 
Lewy body-like inclusion in TH-IR cells from the sham-lesioned 
and lactacystin lesioned SNc. 
High power (x400; scale bar=50µm) representative photomicrographs 
to illustrated that only lactacystin (5 or 7µg) administered to the SNc 
for 3 weeks induces the α-synuclein–aggregates in TH-IR cells, 
which is absent in intra-L-MFB infusion treatment. Sham (L-MFB) 
received a single injection of 10% DMSO containing vehicle to L-
MFB, whilst Sham (SNc) received a single injection of 10% DMSO 
containing vehicle to SNc. A) Sham (n=4), B) 7µg lactacystin for 3 
weeks (L-MFB; n=6), C) 5µg lactacystin for 3 weeks (SNc; n=6), and 
D) 7µg lactacystin for 3 weeks (SNc; n=6). The highlighted area (□) 
of the α-synuclein aggregates was shown in the corner of each panel. 
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Fig 6.10: Neuroprotective Effect of PHCCC and (S)-DCPG on the 
number of TH and NeuN-IR cells in the SNc. 
Subchronic intranigral administration of 50nmol (S)-DCPG 7 days after 
the lactacystin lesion (7µg for 3 weeks) for 14 days significantly 
attenuated the lactacystin induced loss of A) TH and B) NeuN -IR cells. 
C) There were the even effect of PHCCC and (S)-DCPG on 5 different 
stereotxic levels (A-E) of the SNc. Lact 7 (3w) group received intranigral 
injection of saline vehicle for 14 days. Data shown were mean percentage 
loss NeuN and TH-IR cells ± SEM in the lesioned side when compared to 
the contralateral side; n values in brackets: lactacystin 7µg for 3 weeks (6; 
same group as in Fig 6.4), 75nmol PHCCC (6), and 50nmol (S)-DCPG 
(6). *** P<0.0001 when compared to lactacystin; analysed by Student’s t-
test. 
A                                                  B
C
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HVA: 39.29 ± 0.65% loss, P<0.0001 vs HVA in Sham: 10.34±1.12% loss; TO: 
0.43±0.03, P<0.01 vs TO in Sham: 0.43±0.03; Table 6.1-2).  
Intranigral PHCCC administration did not attenuate the lactacystin induced loss 
of dopaminergic neurons (TH: 48.26±2.13% loss, P=0.1356 vs 7µg lactacystin: 
52.97±1.97% loss; NeuN: 50.13±2.49% loss, P=0.0676 vs 7µg lactacystin: 
57.23±2.41% loss; Fig 6.10A-B). Similarly, intranigral PHCCC failed to protect 
against the lactacystin induced depletion of striatal DA (74.63±2.50% loss, P=0.9640, 
vs 7µg lactacystin: 74.79±2.43% loss; Table 6.1) and the enhanced turnover ratio of 
striatal DA (0.45±0.02, P=0.4644, vs 7µg lactacystin: 0.43±0.03; Table 6.2). However, 
PHCCC administration did reduce the lactacystin induced loss of DOPAC (30.60±
1.74% loss, P<0.0001, vs 7µg lactacystin: 46.67±1.62% loss; Table 6.1) and HVA 
content (50.04±3.51% loss, P<0.01, vs 7µg lactacystin: 39.29±0.65% loss; Table 6.1).  
In contrast, (S)-DCPG protected against lactacystin induced dopaminergic 
neurons loss (TH: 19.87±1.97% loss, P<0.0001 vs 7µg lactacystin: 52.97±1.97% loss; 
NeuN: 23.19±1.86% loss, P<0.0001 vs 7µg lactacystin: 57.23±2.41% loss; Fig 6.10A-
B) when assessed 3 weeks post lesion. Similarly the neuroprotection at the cellular 
level observed with (S)-DCPG treatment was mirrored by preservation of striatal DA 
and its metabolites against lactacystin toxicity when assessed at 3 weeks post lesoning 
(DA: 8.57±1.21%, P<0.0001 vs 7µg lactacystin: 74.79±2.43% loss; DOPAC: 6.52±
0.77% loss, P<0.0001 vs 7µg lactacystin: 46.67±1.62% loss; HVA: 19.17±1.03% loss, 
P<0.0001 vs 7µg lactacystin: 39.29±0.65% loss; TO: 0.24±0.01, P<0.001 vs 7µg 
lactacystin: 0.43±0.03; Table 6.1-2). Typical photomicrographs of TH-IR staining in 
the lactacystin treated animals, where the failure of PHCCC to protect such cells 
whilst the ability of DCPG to afford protection can be seen in Fig 6.11.  
 
6.3.3 Ability of PHCCC or (S)-DCPG to modulate glial activity in the lactacystin 
model 
After investigating the neuroprotective potential of PHCCC and (S)-DCPG, we 
then investigated whether the underlying mechanisms involved modification of glial 
cell activation by analyzing astrocytes and microglia responses with 
immunohistochemistry in the lactacystin model. Intranigral administration of both 
PHCCC and (S)-DCPG failed to eliminate astrocytic activation associated with  
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Fig 6.11: Representative photomicrographs of TH-IR neurons from 
lactacystin lesioned SNc. 
Panels A-C, low power (x40; scale bar=250µm) representative 
photomicrographs of contralateral (Cont) and ipsilateral (Ipsil) to 
illustrate that subchronic intranigral administration of 50nmol (S)-
DCPG, but not 75nmol PHCCC, reversed the loss of the integrity of the 
SNc induced by lactacystin. Lact 7 (3w) group received intranigral 
injection of saline vehicle for 14 days. A) Lactacystin (7µg for 3 weeks; 
n=6; same group as in Fig 6.5), B) 75nmol PHCCC (n=6), and (C) 
50nmol (S)-DCPG (n=6) in this lactacystin model. 
A (Ipsil)
B (Ipsil)
C (Ipsil)
SNc
SNc
SNc
SNc
SNc
SNc
A (Cont)
B (Cont)
C (Cont)
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lactacystin toxicity (PHCCC: 17.14±0.93% increase, P=0.1783; (S)-DCPG: 
20.14±0.92% increase, P=0.5391; vs 7µg lactacystin: 19.23±1.10% increase; Fig 
6.12A). Morphologically, PHCCC and (S)-DCPG administration clearly failed to 
decrease the density of GFAP-IR cells in the SNc of lesion hemisphere which was a 
similar level in the vehicle treated lactacystin lesion group. Furthermore, activated 
GFAP-IR cells in the lesion side still had a phenotype of highly activated astrocytes 
possessing large cell bodies and thickened and elongated processes (Fig 6.12B). 
Therefore, the neuroprotective effect of (S)-DCPG was not associated with a decrease 
in astrocytic activation. In addition, the finding with PHCCC in the lactacystin model 
are also contradictory to the findings in the 6-OHDA where intranigral administration 
was associated with a decrease in astrocytic activation. 
Similarly, intranigral PHCCC administration failed to modulate the activation of 
the microglia when assessed 3 weeks after lactacystin lesioning (OX6; PHCCC 
6.93±0.59 fold increase, P=0.1031 vs 7µg lactacystin: 5.39±0.60 fold increase; Fig 
6.13A) whereas in the 6-OHDA lesion model intranigral administration of PHCCC 
was associated a small decrease in OX6-IR cell numbers. In contrast, neuroprotection 
with (S)-DCPG against lactacystin toxicity was associated with a reduction in the 
proliferation of activated microglia when assessed 3 weeks after lesioning ((S)-DCPG 
of UPS by lactacystin induces protein aggregation in TH-IR cells. Intranigral 
administration of 50nmol (S)-DCPG 7 days after lesion for 14 consecutive days 
prevented the deposition of α-synuclein in the surviving TH-IR neurons. 
Morphologically, in the (S)-DCPG treatment group, there were no deposits located in 
the cytosol of the remaining dopaminergic neurons (Fig 6.14C). Consistent with the 
failure to provide neuroprotection for the nigral dopaminergic neurons, PHCCC 
administration also failed to eliminate α-synuclein deposition induced by lactacystin 
(Fig 6.14B). Therefore, from these findings, the inhibited proteasome and the 
subsequent formation of α-synuclein aggregates may be reversed by (S)-DCPG but 
not PHCCC.  
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7µg Lact for 3 weeks
PHCCC DCPG
Fig 6.12: Effect of PHCCC and (S)-DCPG on the number of GFAP-
IR cells in lactacystin lesioned rats. 
A) Subchronic intranigral administration of both 50nmol (S)-DCPG and 
75nmol PHCCC 7 days after lesion for 14 consecutive days did not
inhibit the lactacystin-induced GFAP-IR activation. Lact 7 (3w) group 
received intranigral injection of saline vehicle for 14 days. Data shown 
were mean percentage increase of GFAP-IR cells ± SEM in the 
lesioned side when compared to contralateral side. n values in brackets: 
7µg lactacystin for 3 weeks (6; same group as in Fig 6.7), 75nmol 
PHCCC (6) and 50nmol (S)-DCPG (6). Data were analysed by 
Student’s t test. B) High power (x400; scale bar=50µm), representative 
photomicrographs illustrated that (S)-DCPG and PHCCC did not 
eliminated the GFAP-IR cells activation in the SNc.
A
B
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7µg Lact for 3 weeks
PHCCC DCPG
Fig 6.13: Effect of PHCCC and (S)-DCPG on the number of OX6-
IR cells in lactacystin lesioned rats. 
A) Subchronic intranigral administration of 50nmol (S)-DCPG, but not 
75nmol PHCCC, 7 days after lesion for 14 days significantly attenuates 
the lactacystin-induced increase of OX6-IR cells. Lact 7 (3w) group 
received intranigral injection of saline vehicle for 14 days. Data shown 
were mean increase folds of OX6-IR cells ± SEM in the lesioned side 
when compared to contralateral side. * P<0.01 when compared to 
lactacystin (Student’s t-test). n values in brackets: 7µg lactacystin for 3 
weeks (6; same group as in Fig 6.8), 75nmol PHCCC (6), and 50nmol 
(S)-DCPG (6). B) High power (x400; scale bar=50µm) representative 
photomicrographs to illustrate the administration of lactacystin induces 
the activation of OX6-IR neurons. (S)-DCPG successfully reverses the 
increase of the number of microglial processes and cell body size.
A
B
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Fig 6.14: Effect of PHCCC and (S)-DCPG on lactacystin induced 
formation of Lewy body-like inclusion. 
Panel A-C, high power Subchronic intranigral administration of 50nmol 
(S)-DCPG, but not 75nmol PHCCC, 7 days after lesion for 14 days 
significantly prevented the lactacystin induced formation of α-synuclein 
aggregates. High power (x400; scale bar=50µm) representative 
photomicrographs illustrated the prevention of a-synuclein aggregates in 
the remaining TH-IR cells by 50nmol (S)-DCPG. Lact 7 (3w) group 
received intranigral injection of saline vehicle for 14 days. A) 
Lactacystin (7µg for 3 weeks; n=6; same group as in Fig 6.9), B) 75nmol 
PHCCC (n=6), and C) 50nmol (S)-DCPG (n=6). The highlighted area 
(□) of the α-synuclein aggregates were shown in the corner of each 
panel. 
A                                                B
C
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6.4 Discussion and conclusion 
6.4.1 Mechanism of action of lactacystin 
6.4.1.1 Neurodegeneration of dopaminergic neurons in the SNc 
 Lactacystin selectively inhibits the proteasome and induces cytotoxicity in a 
variety of cell types (Fenteany et al, 1995; Tanaka, 1995; and Coux et al, 1996). In the 
current study, lactacystin administered to the SNc induced a significant loss of TH-IR 
neurons in the SNc and from this limited study it appeared to be time and 
concentration dependent. Furthermore, MFB administration of lactacystin also 
induced dopaminergic neuronal loss (see section 5.3.1). Indeed, the retrograde 
degeneration of nigrostriatal system by intrastriatal injection of lactacystin was 
established previously, in which a high concentration of lactacystin infused to 
striatum induced a large lesion size after one week (Miwa et al, 2005).  However, 
MFB lesioning by lactacystin produced a smaller amount of cell loss than intranigral 
lesioning (see section 6.3.1).  
 
6.4.1.2 Oxidative stress in lactacystin induced neurotoxicity 
The neuroprotective effect observed with iron chelators in the lactacystin model 
would suggest that the iron-mediated oxidative stress is one of the underlying 
mechanisms of the lactacystin-induced dopaminergic degeneration along with the 
direct effects of the build up of altered proteins (Zhang et al, 2005b; Zhu et al, 2007). 
In addition, lactacystin increases the intracellular level of reactive oxygen species 
(ROS) such as superoxide in both primary and cell line culture of dopaminergic 
neurons, whilst lactacystin decreases the glutathione level (Lee et al, 2001; 
Mytilineou et al, 2004; and Lev et al, 2006). Recent studies have suggested that the 
oxidative stress observed in PD could possibly be the primary factor of dysfunction of 
proteasome mediated protein degradation (Zhu et al, 2007; Domingues et al, 2008; 
and Gurusamy et al, 2008). From these studies lactacystin-inhibited proteasome 
activity also induced oxidative damage to the dopaminergic neurons by increasing 
ROS and suppressing the antioxidant systems. 
 
6.4.1.3 Glial-dependent mechanism  
As with the 6-OHDA-induced neurotoxicity, lactacystin induced 
neurodegeneration was also associated with the activation of astrocytes in the SNc, 
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however the degree of activation was smaller than that with 6-OHDA. 
Morphologically, the activated astrocytes had larger cell bodies and elongated 
astrocytic processes. Consistent with this observation, Zhu and colleagues (2007) also 
observed activated astrocytes in the SNc in mice receiving an intra-L-MFB infusion 
of lactacystin when assessed 28 days after lesioning. However, McNaught and 
colleagues (2002) failed to observe any astrocytic activation in the lactacystin rat 
model; indeed there was a small degree of astrocytic loss (McNaught et al, 2002). 
Such controversial phenomenon could be explained by the different concentration of 
lactacystin utilized in these two studies. In the study by McNaught and colleagues 
(2002), 20µg was directly injected to the SNc. Since lactacystin is not cell specific, 
such a high concentration could induce non-specific loss of all cell types, including 
astrocytes. Interestingly, administration of 5µg or 7ug lactacystin also induced a 
similar degree of astrocytic activation when assessed 3 weeks post lesioning. 
Although the astrocytic activation is observed in many different PD model, including 
lactacystin, the exact role of the astrocytic activation remain unclear. In some studies, 
astrocytic activation was reported to mediate neuroinflammation by the release of pro-
inflammatory factors (Wu et al, 1998). Contrastingly, a few studies report a 
neuroprotective role of astrocytic activation with the synthesis of neurotrophic factors 
(Kordower, 2003; Aoi et al, 2000; Onyango et al, 2005). Such difference may be due 
to the degree of astrocytic activation and the mechanism by which the astrocytes are 
activated. 
Furthermore, the activation of microglia by lactacystin, in term of the 
proliferation of OX6-IR microglia and morphological changes, was also observed in 
the current study. Such an effects was not only  time dependent after lactacystin 
administration but also dose dependent with the 7µg dose producing the greatest 
degree of activation, similar to that observed with 6-OHDA. A similar finding was 
observed in vitro with the microglial cell line, BV 2, which was activated by 
lactacystin and the conditioned medium from such cultures induced apoptosis of 
dopaminergic neurons (Kwon et al, 2008). Similar effects have also been observed 
with lactacystin in activating primary microglial cultures (Ahn and Jeon, 2006). In our 
current studies, microglial activation could result directly from changes in neuronal-
glial interactions, the release of distress signal factors by neurons e.g. MMP-3 or from 
cell debris from degenerating neurons. Furthermore, aggregates of α-synuclein in 
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extracellular space have also been shown to stimulate microglial activation (Zhang et 
al, 2005a; and Ahn and Jeon, 2006). Therefore, lactacystin may activate the microglia 
via the increase level of extracellular α-synuclein. However, microglial activation was 
observed 1 week after lactacystin administration before any significant cell loss, 
suggesting that in the early phases microglial activation may be due to changes in 
neuronal-glial communications. 
 
6.4.1.4 The formation of Lewy body-like inclusion  
In sporadic PD, the enzymatic activity of proteasome in the SNc is decreased 
(McNaught and Jenner, 2001). Therefore, unwanted proteins accumulate, some of 
which may be packaged into LBs. However, the cause of the defects of proteasomes 
in sporadic PD remains unclear. In familial PD, the accumulation of mutant forms of 
α-synuclein, the main component of LB, resists the proteasome-mediated degradation 
and subsequently inhibits the proteasome activity (Conway et al, 1998; Bennett et al, 
1999; and McNaught et al, 2001). Normally, unwanted proteins are transported to the 
centrosome for further proteolytic degradation. In the centrosome, the oxidized 
proteins usually with the exposure of hydrophobic domains on the outermost surface 
aggregate to form an inclusion structure. The aggregation, known as the aggresome, 
prevents the cytosolic accumulation of unwanted protein from damaging other 
organelles and nucleus (Johnston et al, 1998; and Kopito, 2000).  
Lactacystin inhibits the activity of proteasome without down regulating the 
expression of the 26S proteasomes (McNaught et al, 2002). Furthermore, in 
lactacystin PD models, the level of altered proteins are higher than normal (Halliwell 
and Jenner, 1998; and Yoritaka et al, 1996). Therefore, our observation of LB-like 
inclusions in the lactacystin leioned SNc are consistent with previous reports 
(McNaught et al, 2002; Conn et al, 2004; Rideout et al, 2005 and Zhu et al, 2007). 
The LB-like inclusions present as α-synuclein aggregates, with a dark robust structure 
adjacent to the nuclei of the dopaminergic neurons. Therefore, the dysfunction of the 
proteasome system induced by lactacystin could trigger the accumulation and 
aggregation of α-synuclein in dopaminergic neurons. However, the α-synuclein 
aggregates observed in this study are not characteristic of LBs observed in PD and no 
additional staining was carried out in this study to indicate whether the α-synuclein 
aggregates observed also contain other altered proteins e.g. ubiquitin, as found in LBs 
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in PD. Furthermore, the LB-like inclusions were only observed in animals examined 3 
weeks after lesioning with lactacystin, indicating that time is required for the 
aggregates to form. Intra-L-MFB administration of lactacystin was not associated 
with α-synuclein aggregates in remaining TH-IR neurons, however the degree of 
neuronal loss was not as severe as that observed after intranigral administration.  
Overall lactacystin proved to be a reliable toxin mimicking dopaminergic 
degeneration with the formation of LB-like inclusions which was time dependent. 
 
6.4.2 Mechanisms of (S)-DCPG neuroprotection: prevention of microglial 
activation and prevention of α-synuclein aggregate formation. 
6.4.2.1 (S)-DCPG produce neuroprotective effect on the dopaminergic neuron but not 
PHCCC 
As opposed to the mGluR drug administration regime in the 6-OHDA study, the 
mGluRs ligands were administered intranigrally starting 7 days after lactacystin lesion 
rather than at the time of lesioning in the 6-OHDA model. This time schedule was 
adopted since the onset of neurodegeneration in this model slower, coupled with the 
fact that we wanted to limit the number of times we intranigrally administer the 
mGluR ligands to minimise mechanical damage. In addition we were keen to 
investigate whether mGluR ligands administered into an already degenerating 
nigrostriatal system could rescue dying neurons. Due to time constraints in the final 
phases of this thesis we adopted to choose effective neuroprotective doses from our 6-
OHDA studies rather than conduct separate dose response curves. Although the 
concentrations of both ligands were neuroprotective against 6-OHDA toxicity, only 
the post lesion treatment of (S)-DCPG but not PHCCC prevented the lactacystin-
induced dopaminergic lesion and the depletion of striatal DA. This could suggest that 
(S)-DCPG has neuroprotective/neurorescue properties no matter whether it is 
administered at the same time as lesion induction or several days after. Likewise, the 
lack of effectiveness of PHCCC could possibly be explained by differences in the 
animal models and/or it may only be effective in the early phase of the 
neurodegenerative process. However, the hypothesis could not be tested since we did 
not perform any neuroprotective studies where PHCCC was administered post lesion 
in the 6-OHDA model. If PHCCC is only effective in the early phase of the treatment, 
there should have been no neuroprotective effect in 6-OHDA rat model when PHCCC 
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was administered post-lesioned. Biggs and colleagues (1997) have shown that 6-
OHDA induces a transient increase of glutamate release from STN in the early phases 
of the lesion, which returns to normal levels with time, as indicated by microdialysis 
studies. This could support the concept that PHCCC may only be effective the early 
phases of neurodegeneration where PHCCC could modulate glutamate transmission 
(see Chapter 3). Whereas the lactacystin model may not produce increased glutamate 
levels, however such a hypothesis could have been tested with PHCCC administration 
immediately after the induction of the lactacystin lesion. An alternate explanation of 
the lack of PHCCC neuroprotection is that the utilized concentration of PHCCC was 
not an optimal dose for providing neuroprotection against lactacystin induced lesion. 
This hypothesis could be proved by a concentration dependent study of PHCCC 
neuroprotection in this model. Clearly further studies are required to elucidate the 
mechanisms of (S)-DCPG neuroprotection and the lack of PHCCC neuroprotection in 
this model. 
 
6.4.2.2 (S)-DCPG prevents the microglial activation but not PHCCC  
As well as the absence of a neuroprotective effect of PHCCC on the 
dopaminergic neurons against lactacystin toxicity, there was also an absence of a 
modulatory effect by PHCCC on microglial activation. The ability of PHCCC to 
prevent the microglial activation in 6-OHDA model could be due to the differences in 
the mechanisms of action of the toxins. 6-OHDA, through oxidative stress may 
activate microglia via mechanisms which can be modulated by PHCCC. Alternately, 
this may simply reflect the distinct possibility that since PHCCC failed to have any 
neuroprotective effect the stimulus for microglial activation remains in place. 
In contrast, neuroprotection observed with (S)-DCPG against lactacystin-
induced neurotoxicity was associated with a reduction in microglial activation. 
Although this could simply reflect the preservation of dopaminergic neurons, the 
presence of mGluR8 receptors on the microglia would suggest that (S)-DCPG may 
have a direct effect on microglial activation since 30mg/kg (S)-DCPG administered 
systemically could prevent microglial activation without providing any 
neuroprotection. Inhibition of the microglial activation may prevent dopaminergic cell 
loss via the decrease in release of microglial NO and superoxide (Zhu et al, 2007, Gao 
et al, 2008). As the activation of group III mGluRs reduces the NO synthesized in 
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microglia, the activation of mGluR8 by (S)-DCPG may prevent the microglial release 
of NO for inducing dopaminergic neuronal death and further microglial activation.  
 
6.4.2.3 Preventive effects of (S)-DCPG on the formation of α-synuclein aggregation 
The irreversibly covalent reaction between lactacystin and the proteasomal 
catalytic site would rule out any possible reversal of the proteasomal inhibition by 
(S)-DCPG (Fenteany et al, 1995, Tanaka, 1995; and Coux et al, 1996). Without 
further investigations it is a little difficult to say exactly how (S)-DCPG could 
produce this effect. However, it is possible to postulate some alternative mechanisms. 
Microglial activation was observed before α-synuclein deposition/aggregation in the 
lactacystin model. Hence, the modulation of microglial or even astrocytic function by 
(S)-DCPG may be a possible mechanism. Furthermore, microglial activation induced 
by lactacystin is associated with the secretion of cytokines and elimination of the 
extracellular neurotrophic factors from astrocytes (Imamura et al, 2005). Certain 
neurotrophic factors, such as ciliary neurotrophic factor (CNTF), increase proteasome 
activity by activating the expression of the 20S proteasome (Jho et al, 2004). Indeed, 
nerve growth factor (NGF) promotes the proteasome-mediated protein degradation by 
increasing the expression of the catalytic subunits of proteasome in dopaminergic cell 
line models (Laser et al, 2003; Klimaschewski et al, 2006; Bai et al, 2007; and Geetha 
and Wooten, 2008). Therefore, the increase of neurotrophic factors level, such as 
CNTF, GDNF, BDNF and NGF as mentioned, by inhibiting microglial activation 
reverses the down-regulated activity of proteasome in the lactacystin model. 
Therefore, (S)-DCPG may reverse the depletion of neurotrophic factors and hence 
prevent the formation of LB-like inclusion. Alternatively, mGluR8 activation on 
dopaminergic neurons may have a direct effect on protein metabolism, although there 
is no supporting evidence for such a theory to date. 
 
6.4.2.4 Possible molecular mechanism of the neuroprotective effect of (S)-DCPG 
against lactacystin neurotoxicity 
Lactacystin also activates certain apoptotic pathways, such as p38 and JNK 
which are also influenced by the neurotrophic factors, such as CNTF and GDNF 
(Sango et al, 2008; and Dai et al, 2003). Some of the neurotrophic factors, such as 
GDNF and BDNF, produce the neuroprotection against lactacystin via the activation 
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of ERK1/2 (Du et al, 2008) and PI3K/AKT pathways (Du et al, 2008; Hausott et al, 
2008). Furthermore, the inhibition of the formation of cGMP and cAMP by group III 
mGluRs activation promote the activity of AKT pathway (Liu et al, 2005; and Fryer 
et al, 2006). Therefore, the activation of mGluR8 by (S)-DCPG may provide 
neuroprotection for the dopaminergic neurons against the lactacystin toxicity via the 
modulation of AKT and possibly other signalling pathways.  
 
6.4.4 Conclusion 
In the current study, we utilized lactacystin PD model for the investigation of 
neuroprotective potential of (S)-DCPG and PHCCC. Surprisingly, only (S)-DCPG 
provides neuroprotection for the dopaminergic neurons against the neurotoxicity of 
lactacystin, possibly via the prevention of the microglial activation. Furthermore (S)-
DCPG prevented the formation of α-synuclein deposits/aggregates. Therefore, we 
proposed that (S)-DCPG is a promising neuroprotective reagent for slowing down the 
neurodegeneration in PD. PHCCC may rely on the down regulation of glutamate 
transmission for its neuroprotective effects, which may not be a feature in the 
lactacystin model.  
 252 
Chapter 7: Discussion 
7.1 Possible limitations of the study  
7.1.1 Limitations of the 6-OHDA and lactacystin PD models  
Although 6-OHDA is commonly employed as an experimental PD model in a 
wide variety of studies including some studies detailed in this thesis, there are some 
drawbacks with this model. Firstly, due to the inability of 6-OHDA to cross the BBB, 
the toxin is administrated focally to the nigrostriatal system (Ungerstedt, 1968; 
Lehmensiek et al, 2006). However, such drawbacks have not prevent the unilateral 6-
OHDA lesion from being one of the most commonly used dopaminergic toxins for PD 
animal models since 6-OHDA induces several pathological changes similar to PD 
such as oxidative stress, mitochondrial dysfunction, iron accumulation, mixed cell 
death mechanisms - apoptosis and necrosis, an innate inflammatory response and in 
some situations a progressive degeneration of dopaminergic neurons (Carman et al, 
1991). Furthermore, the asymmetric Parkinsonian symptoms are used as parameters to 
measure the lesion progress, such as the asymmetric circulation behavioural model 
(Carman et al, 1991; Cousins et al, 1993).  
Additionally, focally administered 6-OHDA to the SNc in the current study 
provides a rapid and partial lesion of the nigrostriatal tract suitable for neuroprotective 
studies (see section 3.3). Although we did not perform a time-course study of the 6-
OHDA induced lesion in the SNc, other studies have demonstrated that there is a 
rapid time dependent loss of dopaminergic neurons and striatal DA content (Faull and 
Laverty, 1969). However, in clinical PD, dopaminergic neurons and striatal DA loss 
are lost in slower manner (Faull and Laverty, 1969). Therefore, 6-OHDA infused 
directly into the SNc induces an appropriate lesion on the SNc but which may be too 
rapid to mimic a chronic and progressive lesion model for PD. In order to overcome 
this weakness, other studies have administered 6-OHDA into MFB, which was also 
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employed in the current study, and the striatum. The 6-OHDA is transported into 
dopaminergic fibres via the dopamine transporters (DAT) and subsequently diffuses 
towards the cell bodies of the neurons. The retrograde lesion induced by intra-striatal 
and MFB infusion of 6-OHDA is slower, producing a more progressive model. 
However, in some of the studies detailed in this thesis we wanted to examine the 
effects of mGluR ligands on the SNc alone, hence we implanted indwelling cannulae 
for the focal administration of PHCCC and (S)-DCPG into the SNc. Due to the 
physical location, size of the cannulae and the simple fact that it had to anchored in 
place with dental cement, lesions with 6-OHDA to the MFB or striatum could not be 
carried out as well as administering the drugs via the cannulae to the SNc. Therefore, 
both 6-OHDA and mGluR ligands were administered to the SNc via the indwelling 
cannulae. However, where we have examined the systemic effects of the mGluR 
ligands we did utilise an intra-L-MFB 6-OHDA lesion.  
Finally, there are a few other limitations to the 6-OHDA PD model due to its 
mode of toxicity. There is an unexpected increase in proteasomes activity in 6-OHDA 
PD model unlike clinical PD but this may not be unexpected due the increased 
amount of oxidised proteins being formed as part of 6-OHDA toxicity (Höglinger et al, 
2003). However, Lewy body (LB)-like inclusions are not a feature of this model. 
Since there is no single experimental model to fully mimic the PD pathology we did 
however utilized another PD model which works via a different mechanism, namely 
inhibition of the proteasome by lactacystin, which does feature LB like inclusions.  
Lactacystin specifically and irreversibly inhibits the proteasome. However, the 
dopaminergic specificity of lactacystin is still unclear, since proteasome inhibition by 
lactacystin may also induce cell death in other cell types e.g. astrocytes and other 
neurons (Ren et al, 2008; Dai et al, 2003). Considering its mechanism of action the 
lactacystin model is still a relatively poorly explored model but what studies have 
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been carried out have utilised a wide range of concentrations of lactacystin, from 5-
20µg/µl, inducing lesions up to ~75% loss of dopaminergic neurons (McNaught et al, 
2002; and Miwa et al, 2005). Therefore, a small concentration and time course studies 
was conducted in this thesis in order to obtain an optimal lesion condition for further 
study of the neuroprotective potential of the mGluRs ligands.  
When compared to other proteasome inhibitors, including PSI and MG132, 
lactacystin induces a relatively reproducible lesion to the SNc (Lee et al, 2001; 
McNaught and Olanow, 2006). The unreliability of PSI and MG132 is thought to be 
due to the poor brain bioavailability and stability problems (McNaught and Olanow, 
2006). Instead, lactacystin, which does not cross the BBB, has to be infused focally to 
the SNc or MFB as utilized in the current study; again leading to a selective exposure 
to the dopaminergic neurons in the nigrostriatal system. Furthermore, the focal 
administration of lactacystin will not induce any unwanted systemic effects 
(McNaught et al, 2004; McNaught and Olanow, 2006). In addition, the concentration 
and time-dependent lesion observed in the current study suggested that lactacystin-
induced dopaminergic degeneration is progressive in nature. Therefore, lactacystin is 
suitable for the induction of the slow and progressive dopaminergic degeneration 
which is more akin to clinical PD.  
One other limitation of both models utilised is that both toxins, due to the nature 
of their administration and mechanisms, just target the nigrostriatal system. PD affects 
multiple neuronal pathways, hence it would have been advantageous to investigate 
whether PHCCC and (S)-DCPG were also protective to other neuronal populations 
involved in PD e.g. noradrenergic neurons in LC, but unfortunately no animal models 
exist that model cell loss in all the neuronal populations that are seen to be affected in 
PD. 
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7.1.2 Limitations on the experiment design 
There is no information on the pharmacokinetics of PHCCC and (S)-DCPG in 
the literature. Therefore, the ligands were infused subchronically for 7 consecutive 
days via indwelling cannuale (4 days in the case of systemic administration), 
including the day of 6-OHDA lesioning, until the end point of experiment. This 
regime was consistent with the previous reports about the neuroprotective effects of 
L-AP4 from which were trying to determine which receptor subtype may be 
responsible for L-AP4 neuroprotection (Vernon et al, 2007a and b). Hence, in the 6-
OHDA studies the mGluR ligands were present at the start of the neurodegenerative 
process. If time had been available it would have also been advantageous to 
investigate whether delayed administration of PHCCC and (S)-DCPG, say after 48 
hours post 6-OHDA when the neurons are starting to degenerate, was also 
neuroprotective. This would have mimicked more the clinical situation and hence 
would be an important feature of any future studies. 
However, to some extent this was examined in the lactacystin model where 
drugs were administered 7 days after lesion induction. Additionally, due to time 
limitations we were not able to test whether administration of PHCCC and (S)-DCPG 
at the time of lesioning, as in the 6-OHDA model, also produced neuroprotective 
effects in the lactacystin model. In addition, there were also some technical 
considerations that contributed to differences in the dosing schedules in the two 
animal models. Firstly, the lactacystin lesion models develops much slower than 6-
OHDA and we are limited by the number of times we were able to focally administer 
drugs before major mechanical damage occurs from the repeated insertion of the 
injection needle. Secondly, very little is known about the potential of receptor 
desensitisation or internalisation following repeated administration of PHCCC or (S)-
DCPG hence we decided to delay administration for 7 days after lesioning and treat 
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for 14 days. Obviously there are gaps in our studies with the lactacystin models, 
particularly the need to carry out systemic administration of the drugs but the 
promising results in the lactacystin model will give encouragement for further studies.  
 
7.1.3 Technical considerations 
There were some technical considerations to be taken into account when 
analysing the results. Firstly, the methodology of manual cell counting may over-
estimate the TH-IR cell numbers. An alternative approach would have been to utilise 
stereological cell counts in serial sections thus allowing an estimate of the total 
number of cells in the entire SNc. Such techniques could help avoid counting the 
same cell twice in two adjacent sections which can lead to an over-estimated of cell 
numbers. However, the cell counting method utilised in this thesis has previously 
been shown to be a robust and accurate method of quantification of nigral TH-IR cells 
within the entire SNc (Vernon et al, 2005, 2007a, 2007b and 2008) and takes a third of 
the time taken when counting cells stereologically. Importantly, a blinded approach to 
counting cells in the different treatment group was performed to prevent a bias which 
has been described in section 2.2.7. Furthermore, recent studies comparing cell counts 
utilising manual tagging and stereological methods have demonstrated that 
comparable cell number are obtained by both methods (Hedreen, 1999; Iravani et al, 
2002; Vernon et al, 2005. 2007a and b).  
A further problem of cell counting was encountered when quantifying the 
number of GFAP- and NeuN-IR cells. Due to the small cell bodies and thickness of 
the tissue sections it was sometime difficult to distinguish between overlaying cells. 
This was particularly difficult with the GFAP-IR astrocytes and NeuN-IR cells. This 
may explain the small differences in the loss in NeuN and TH-IR cells in the same 
treatment group in certain studies. However, the same trends in results were obtained 
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for both NeuN and TH-IR cell counts in all treatment groups. The use of thinner 
sections in the future may help overcome this. In addition, it was impossible to judge 
the activation states of astrocytes only by the subjective morphological changes. 
Unfortunately, there are no other antibody markers specific for activated astrocytes. 
Furthermore, quantification of astrocytic number may not indicate their role in the 
degenerative process i.e. degree of activation. An alternative approach would be to 
quantify the astrocytic cell density, process thickness and length and the astrocytic 
terminal masses according to the studies of Colombo et al, (2006) and O'Callaghan 
and Miller (1993) where the cell body numbers and size are analyzed stereologically 
thus giving an assessment of the degree of activation.  
Additionally, in the analysis of the LB-like protein inclusion, in order to 
distinguish the protein inclusion in the TH-IR cells, which were illustrated as brown 
DAB staining, nickel ions were utilised to enhance the DAB substrate reaction for 
synuclein yielding a black signal (see section 2.4.3). However, a further development 
of black signal appeared also in the TH-IR cells, resulting in black staining in both TH 
and α-synuclein. This could be due to the residue functioning horseradish peroxidases 
on the secondary antibody in the TH-IR cells. This technical problem could be solved 
by a further inhibition of endogenous and residue horseradish peroxidases by 
hydrogen peroxide before the second immunostaining of α-synuclein. However, most 
importantly, the inclusions illustrated in this thesis are similar to those reported 
literature (Conn et al, 2003).  
For the co-localization of mGluR4 and 8 in different nigral cell types, cell 
type-specific markers were investigated by fluorescent immunostaining. However, a 
relatively strong background was observed in both mGluR4 and 8 fluorescent staining. 
Such interference is due to the impurity of the antibodies utilized in the current study. 
The mGluR8 antibody was in form of anti-sera; thus some other immunoglobulins 
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possibly exist. The possibility of such non-specific background signals was also 
reported by the manufacture. Therefore, when available other further purified 
antibodies for mGluR4 and 8 should be employed in future study. Furthermore, such 
background signals could also be due to the fixation technique used. The protocol 
used in this thesis involves harvesting the striata in the forebrain for HPLC analysis 
which precludes systemic perfusion of fixatives. The perfusion of fixatives with 
paraformaldehyde in PBS provides a more rapid and thorough fixation which should 
reduce background staining but this would have doubled the numbers of animals used 
in the studies. In addition, the use of confocal microscopy techniques would have 
given us a more robust technique for the co-localisation of the mGluRs in the different 
cell types, however this technique was not available to us at the time of analysis but 
will be a feature of future studies. 
Finally, another drawback of the experimental design is that no striatal 
sections were available for the analysis of the integrity of the striatal structure and the 
morphology of other cell types, such as astrocytes and microglia. Hence, it would 
have been more appropriate if time were available to have two animal groups, one for 
immunostaining with systemic perfusion and another for neurotransmitter analysis but 
this would have doubled the animal workload and hence would have reduced the 
number of studies that could have been conducted in this thesis.  
 
7.2 Proposed mechanisms of neuroprotective potential of PHCCC 
and (S)-DCPG 
7.2.1 PHCCC induced the neuroprotection against 6-OHDA  and lactacystein 
toxicity 
From the data presented in this study, we demonstrated that subchronic 
intranigral administration of the positive allosteric modulator (or allosteric potentiator) 
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of mGluR4, PHCCC, provided neuroprotection against 6-OHDA-induced 
neurotoxicity. Certain studies suggest that excessive glutamate found in the SNc may 
be due to the excessive release of glutamate from other brain regions, such as PPN 
and cortex (Obeso et al, 2002; Luquin et al, 2006). As reported in some previous 
literature (Valenti et al, 2003 and 2005) and from the detection of mGluR4 on 
dopaminergic neurons in the current study, the neuroprotective action of PHCCC 
against the 6-OHDA-induced neurotoxicity partly relies on inhibition of glutamate 
excitation of dopaminergic neurons. The modulation/activation of group III mGluRs 
modulates the excitation in postsynaptic neurons by inhibiting Ca2+ release from 
endoplasmic reticulum (Szabadkai et al, 2003). The down regulation of Ca2+ level 
also prevents the activation of Ca2+-dependent apoptotic signal transduction, such as 
calpain, JNK and GSK3β (Ray et al, 2000; Tan et al, 2002; Brewster et al, 2006; 
Takadera et al, 2006; Li et al, 2007a).  
However, the use of the broad spectrum group III mGluR antagonist MSOP 
revealed that the neuroprotection of PHCCC only partially relies on mGluR4. In fact, 
there is another target involved in the neuroprotection by PHCCC, namely weak 
antagonism at mGluR1b (Annoura et al, 1996). Therefore, it was hypothesised that 
the neuroprotective action of PHCCC may rely on both the modulation of mGluR4 
and the blockade of mGluR1b. Such dual receptor targets may go some way to 
explain the additive neuroprotective effect when PHCCC was co-administered with L-
AP4 (Maj et al, 2003; Marino et al, 2003). Furthermore, we demonstrated that 
neuroprotective properties of PHCCC were maintained when PHCCC was 
systemically administrated. In this case systemically administrated PHCCC could not 
only modulate mGluR4 and antagonise mGluR1b expressed in the SNc but also in the 
whole brain. According to previous studies, the activation of mGluR4 in the 
striatopallidal tract alleviates the overactive indirect pathway BG in PD rat models 
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(Battaglia et al, 2006). Therefore, the modulation of mGluR4 at multiple sites in the 
brain may produce an additive neuroprotective effect on the dopaminergic neurons in 
the SNc. The use of more selective mGluR4 allosteric modulators in future studies 
will also allow us to investigate what role antagonism at mGluR1b by PHCCC has 
following systemic administration. 
However, the modulation of glutamate transmission may not be the only 
mechanism involved in the neuroprotective properties of PHCCC. It has also been 
hypothesised that neuroprotection by PHCCC may occur via the modulation of glial 
cells (Yao et al, 2005, Zhou et al, 2006). This hypothesis is also supported by the 
detection of mGluR4 on astrocytes and microglia in the current study. Furthermore, 
focally administered PHCCC was seen to inhibit the 6-OHDA-induced astrocytic 
activation. However, systemic administration of PHCCC failed to provide a similar 
effect. This could partly be explained by the fact that the 6-OHDA lesion was induced 
by administering the toxin via different sites, MFB (systemic PHCCC) versus SNc 
(focal PHCCC). Focally administered 6-OHDA could directly activate astrocytes in 
the SNc. However, in the MFB 6-OHDA model, the toxin is administered distal to the 
SNc. Therefore, in the MFB lesion model the astrocytic activation would be purely 
due to the distress signals emitted from traumatised dopaminergic neurons and from 
their ultimate degeneration (Kondziella et al, 2006).  
Although it has been claimed that allosteric modulator at mGluR’s would not 
induce receptor internalisation (Marino and Conn, 2006), the prolonged 
administration of PHCCC in the lactacystin lesioned rats may still result in functional 
change of the receptors which could abolish the neuroprotection observed in the 6-
OHDA model. Additionally, focal administration of PHCCC failed to modulate the 
activation of astrocytes in the lactacystin model unlike in the 6-OHDA model. On the 
surface this could be taken to imply that the mechanism of astrocytic activation in 
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lactacystin PD model is different from that in SNc 6-OHDA model. Similarly, 
PHCCC prevented microglial activation in 6-OHDA model but not in the lactacystin 
model. However, the most likely explanation lies in the fact the PHCCC was 
administered at the same time as the toxin in the 6-OHDA model but 7 days after 
lesion induction in the lactacystin model, thus suggesting that PHCCC may only be 
effective in the early phases of the lesion. Alternatively, the concentration of PHCCC 
utilised in the lactacystein models may have not been sufficient to yield 
neuroprotection, however the dose chosen was highly effective in the 6-OHDA model. 
Various reports have demonstrated that astrocytes have anti-inflammatory 
effects through the release of growth factors etc but they can also exhibit pro-
inflammatory actions by the release of inflammatory mediators; hence without 
performing functional studies on astrocytes it is very difficult to tease out whether the 
effects of focally administered PHCCC on astrocytes are neuroprotective or damaging. 
 
7.2.2 (S)-DCPG induced neuroprotective effects against 6-OHDA and lactacystin 
neurotoxicity  
As reported previously, (S)-DCPG has been shown not to inhibit the presynaptic 
and postsynaptic EPSP in the STN-SNc pathway (Valenti et al, 2003 and 2005). 
Therefore, it has been proposed that the activation of mGluR8 will not down-regulate 
the glutamate transmission and excitotoxicity unlike PHCCC. However, we illustrated 
the expression of mGluR8 on dopaminergic neurons in the SNc (see section 4.3.4). A 
functional explanation for this may be that mGluR8 activation on SNc dopaminergic 
neurons does not classically modulate glutamate excitation; however via receptor 
activation coupled to Gi proteins (S)-DCPG may be neuroprotective via novel 
mechanisms. It has been shown that Group II mGluRs on different cell types are 
coupled to different types of Gi proteins (Wroblewska et al, 2006). Therefore, it is 
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also possible that Group III mGluRs are also associated with different Gi proteins in 
different cell types. Furthermore, the activation of group III mGluRs through Gi 
proteins has been shown to maintain cell survival via the activation of the PI3K/AKT 
and p42/44 MAPK pathway and inhibition of the nitric oxide synthase (NOSs) 
activity (Iacovelli et al, 2002; Foreman et al, 2005; Lee et al, 2008). Taking the above 
cellular signalling into accounts, the activation of mGluR8 by (S)-DCPG may provide 
dopaminergic neuroprotection by activating cell survival signal transduction which is 
independent to the Ca2+ and glutamate neurotransmission. 
The dopaminergic neuroprotective action of (S)-DCPG may also occur via the 
modulation of astrocytic and microglial activation, which was supported by the 
detection of mGluR8 on these two glial types in the current study (see section 4.3.5). 
However, (S)-DCPG did not prevent the 6-OHDA and lactacystin-induced astrocytic 
activation (see section 4.3.6-7 and 5.3.3). In the current study, we did not examine any 
potential functional changes in the astrocytes. Therefore, the effect of (S)-DCPG on 
astrocytic activation may result in the functional but not morphological changes. As 
reported previously, the activated astrocytes provide a potent anti-apoptotic effect on 
neuronal cells in culture and in vivo models (Nakajima et al, 2001; Nishino, 2001; 
Cunningham and Su, 2002; Wood et al, 2005; Chen et al, 2006; Katoh-Semba et al, 
2007; Patel and Gill, 2007; and Yang et al, 2008). Notably, genetic transfection of 
astrocytes to stimulate the over production of GDNF in the rat and primate midbrain 
successfully maintains the integrity of the SNc in the PD 6-OHDA and MPTP models 
(Ericson et al, 2005; and Oiwa et al, 2006). Furthermore, the activation of astrocytic 
group III mGluRs promoted glutamate reuptake to prevent excitotoxicity in cell 
culture models (Yao et al, 2005; Zhou et al, 2006; Beschorner et al, 2007; and Liang 
et al, 2008). Therefore, although the neuroprotection afforded by (S)-DCPG did not 
prevent the astrocytic deactivation, the modulation of the astrocytic functions, 
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including the release of neurotrophic factors and removal of excessive amount of 
glutamate, may still be an underlying neuroprotective mechanism.  
In both 6-OHDA and lactacystin PD models, (S)-DCPG prevented microglial 
activation (see section 4.3.6 and 5.3.4). This could possibly be due to (S)-DCPG 
preserving neuron-microglia interaction or the microglia not being activated by cell 
debris. Since systemic administration of 30mg/kg (S)-DCPG, which failed to prevent 
dopaminergic neuronal loss, still inhibited microglial activation, it could be suggested 
that (S)-DCPG may directly inhibit microglial activation. However, the underlying 
mechanisms of activation of microglia in 6-OHDA and lactacystin PD models may be 
very different. From studies within our group, microglia were seen to activate and 
proliferate three days after 6-OHDA lesion whilst significant cell loss wasn’t observed 
until day 7 after lesioning (Marinova-Mutafchieva et al, 2009). Furthermore, it was 
reported that the oxidative stress induced by 6-OHDA is the primary factor to activate 
the microglia (Rodrigues et al, 2004). Similarly, from the time-course study of 
lactacystin-induced neurotoxicity, exposure to 5µg lactacystein for 7 days did not 
induce significant dopaminergic degeneration but did induce strong microglial 
activation. This suggests that in both models microglial activation occurs well before 
any dopaminergic cell loss. Lactacystin-induced secretion of damaged and 
undamaged α-synuclein may activate microglia without inducing the dopaminergic 
neuronal death (Zhang et al, 2005a; and Reynolds et al, 2008a and b). It is believed 
that the secretion of α-synuclein is one of the removal mechanisms when excessive 
intracellular α-synuclein builds up, which is subsequently degraded by matrix 
metalloproteases (MMPs; similar function to the proteasomes). Interestingly, as 
reported in other studies, only the monomeric α-synucleins but not the aggregates of 
α-synuclein induce the microglial endocytosis (Park et al, 2008). Although there are 
different activation mechanisms of microglia by 6-OHDA and lactacystin, (S)-DCPG 
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still successfully inhibited microglial activation. Therefore, we conclude that the 
neuroprotective effects of (S)-DCPG relied in part on the inhibition of microglial 
activation, possibly via the activation of microglial mGluR8, in both 6-OHDA and 
lactacystin PD models. Thus, (S)-DCPG and activation of mGluR8 is promising in 
preventing PD-related neuroinflammation.  
 
7.2.3 Are neurotrophic factors playing a neuroprotective role against the 6-
OHDA and lactacystin induced neurodegeneration?  
Although the neuroprotective role of astrocytes remains unclear, the 
neurotrophic factors released from astrocytes are still potential mechanisms of 
neuroprotection. Indeed, neurotrophic factors, such as GDNF and BDNF, are under 
intensively study in certain neurological disease models, such as Alzheimer’s disease 
(AD) and PD (Chen et al, 2004). Furthermore, GDNF not only prevents the cell death 
of the dopaminergic neurons in the SNc, but it also maintains normal striatal 
functionality in primate MPTP model of PD (Nakajima et al, 2001 and 2006). 
Although the clinical significance of GDNF has been extensively illustrated 
previously, neuroprotection by GDNF largely relies on its mode of delivery (Bespalov 
and Saarma, 2007; Yasuhara et al, 2007; and Hong et al, 2008). In addition, BDNF, 
mainly generated from astrocytes, provides neuroprotection similar to that by GDNF 
(Chun et al, 2000; Chen et al, 2004; Evans and Barker, 2008; and Wu et al, 2008b). 
Furthermore, such neurotrophic factors are neuroprotective in both the 6-OHDA and 
lactacystin rodent model (Furuno and Nakanishi, 2006; Smith et al, 2006; Gonzalez-
Barrios et al, 2006; Li et al, 2007b; Lindholm et al, 2007; Yang et al, 2006; Imamura 
et al, 2008 and Weng et al, 2007). Therefore, if PHCCC and (S)-DCPG could 
modulate the astrocytic functions, they may activate the release of neurotrophic 
factors to produce the neuroprotective effect in both 6-OHDA and lactacystin models.  
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In addition, neurotrophic factor receptors have been shown to be expressed on 
the dopaminergic neurons. Taking GDNF as the example, the corresponding receptors 
for GDNF, including GDNF receptor α (GFRα) and RET, are detected on the 
dopaminergic neurons (Cho et al, 2004; Kozlowski et al, 2004; Hirata and Kiuchi, 
2007; and Wang et al, 2008a). Neurotrophic factors also associate with different types 
of G-proteins (Rajagopal and Chao, 2006; Skaper, 2008), implying the possibility of 
crosstalk between neurotrophic factor and mGluRs signalling pathways.  
Aside from the prevention of the neurodegeneration of the dopaminergic neurons 
and its functionality, the concept of regeneration of the damaged dopaminergic 
innervation has recently become another therapeutic target of PD (Deierborg et al, 
2008; and Hong et al, 2008). The transplantation of the mesenchymal stem cells in rat 
brains in 6-OHDA PD models facilitates the neuronal regenerative via the 
neurotrophic effect of BDNF, GDNF and other neurotrophic factors (Glueckert et al, 
2008; Mahay et al, 2008; Sango et al, 2008; and Wang et al, 2008a). Furthermore, the 
intrastriatal infusion of GDNF and CDNF prevents the further loss of dopaminergic 
neurons and also regenerates the dopaminergic tract which has already undergone the 
degeneration (Lindholm et al, 2007). Indeed, the clinical use of them is under the 
examination and some reports do not illustrate a pronounced therapeutic effect of 
these neurotrophic factors (Ericson et al, 2005; Patel and Gill, 2007). Most 
importantly, the neurotrophic factors decrease the medication dependence, eliminate 
the off-drug symptoms and slow down the neurodegeneration of PD. Therefore, 
taking these together, it was speculated that if the (S)-DCPG-mediated 
neuroprotection involves astrocytic secretion of neurotrophic factors it still provides 
the neuroprotective effect via the neurotrophic factors action and possibly the 
neuroregeneration of the nigrostriatal tract.  
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7.2.4 The reversal of proteasome inhibition  
We have also demonstrated that (S)-DCPG administration prevented the 
formation of α-synuclein deposition or LB-like inclusions in the lactacystein model. 
Due to the irreversible nature by which lactacystin inhibits the proteasome, (S)-DCPG 
induced prevention of α-synuclein deposition must occur via an indirect route. (S)-
DCPG could stimulate increased expression of proteasomes subunits via the 
activation of PI3K/AKT pathway (Belova et al, 2006; and Russell et al, 2008). 
Furthermore, the inhibition of proteasome is overcome by certain neurotrophic factors 
which promote the expression of new proteasome subunits (Shi et al, 2005; Nagoshi 
et al, 2005; and Belova et al, 2006).  
Putatively, the formation of LB is associated with the formation of aggresomes 
in which the microtubular and heat shock proteins are involved (Olanow et al, 2004). 
Therefore, this machinery of unwanted and misfolded proteins aggregation provides a 
potential target for the elimination of LB and further development of therapeutic 
approaches for LB-associated disorders.  
 
7.3 The implication and significance of neuroprotection by the group 
III mGluRs ligands  
The neuroprotective effects of PHCCC and (S)-DCPG were still present when 
the ligands were injected systemically. Therefore, it could be concluded that 
activation/modulation of mGluR4 and 8 by systemic administration of selective 
ligands slows down the progressive loss of dopaminergic neurons in 6-OHDA PD 
model. The failure of post lesion administered PHCCC in reversing the lactacystin 
induced neurotoxicity may indicate that PHCCC may only be effective at the early 
stage, however a full dos response was not conducted in this model.  
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7.3.1 Safety and Effectiveness of treatment with PHCCC and (S)-DCPG  
7.3.1.1 Safety and specificity of treatment with PHCCC and (S)-DCPG 
Only recently, a study examining the anti-schizophrenic properties of (S)-DCPG 
in animal models indicated that (S)-DCPG administered systemically was able to 
penetrate into the rat brain (Robbins et al, 2007). In the current study, we 
demonstrated that systemic administration of (S)-DCPG was still neuroprotective 
against the 6-OHDA toxicity. Therefore, (S)-DCPG has potential to provide 
therapeutic effects in clinical PD. However, there are some precautions as to the 
clinical usage of (S)-DCPG. Firstly, high concentration of (S)-DCPG administered 
systemically induces certain unwanted adverse effects, anxiety, which may be due to 
the activation of mGluR8 in other nuclei in human brains (Schmid and Fendt. 2006; 
and Jiang et al, 2007). Interestingly, dysfunction of mGluR8 in pancreatic cells leads 
to obesity in rats (Brice et al, 2002; and Tong et al, 2002), which may further worsen 
the loss of dopaminergic neurons in the SNc (Quesada et al, 2008). Due to the 
specificity of (S)-DCPG for mGluR8 one might expect that fewer side-effects would 
be induced when compared to a non-selective ligand. However, the expression pattern 
of mGluRs in human brain is far from clear. This is an important gap in our 
knowledge and would give us potential clues as to where mGluR8 activation may 
produce side effects. Presuming that the expression of mGluR8 in the human SNc is 
the same as in the rat from our own studies, it could be hypothesised that the 
activation of mGluR8 may be able to induce neuroprotection in PD patients. 
Similarly, systemically administered PHCCC has been shown to penetrate into 
the CNS (Battaglia et al, 2006; and Ngomba et al, 2008). However, since PHCCC is a 
not only an allosteric modulator of mGluR4 but also a weak antagonist of mGluR1b  
and an agonist of mGluR6, it could be expected that PHCCC may induce certain 
systemic and CNS side effects (Annoura et al, 1996; Maj et al, 2003; Marino et al, 
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2003; and Beqollari and Kammermeier, 2008). For instance, cognitive deficits may be 
induced when the cortical and hippocampal mGluR1 are blocked by PHCCC 
(Melendez et al, 2004; El-Kouhen et al, 2006; Sukhotina et al, 2008). Furthermore, 
the antagonism of group I mGluRs may affect the cardiac function via the inhibition 
of PLC and PKC pathway (Iglesias et al, 2007). However, the use of more selective 
allosteric modulators at mGluR4 such as 2-methyl-6-(2-phenylethenyl)pyridine (SIB-
1893) may overcome such side effects.  
Although PHCCC and (S)-DCPG provided specific neuroprotection in PD 
models, potential side effects may be possibly induced due to the systemic expression 
of mGluR1, mGluR4 and 8. Therefore, a series of detail studies of the 
pharmacokinetic and toxicological study of PHCCC and (S)-DCPG are essential for 
extending the neuroprotective and therapeutic studies into clinical trials. The toxicity 
of these ligands is also awaited.  
 
7.3.1.2 Long-term effectiveness of PHCCC and (S)-DCPG 
L-DOPA is the principle medication for PD management. However, L-DOPA 
induced a series of adverse effect, such as dyskinesia, (Carlsson, 2002; Lundblad et al, 
2004; and Rajput and Rajput, 2006). Therefore, a long-term side effect free treatment 
for PD is urgently required.  
According to previous report from this group, the failure of the high 
concentration of L-AP4 to provide any neuroprotection was possibly due to the 
internalisation of group III mGluRs, especially mGluR4 (Mathiesen and Ramirez, 
2006; and Vernon et al, 2007b). However, both PHCCC and (S)-DCPG, administered 
sub-chronically for 7 consecutive days focally into the SNc, provided concentration-
dependent neuroprotection in the 6-OHDA model even at the highest dose. Since 
PHCCC binds to the allosteric site of mGluR4, which is located at the transmembrane 
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domain but not the extracellular orthosteric domain, the activation of mGluR4 by 
allosteric site may not induce receptor internalization. Therefore, as a mGluR4 
allosteric modulator PHCCC still produces neuroprotective effects on degenerating 
dopaminergic neurons in the SNc in the 6-OHDA model even at high concentrations. 
However, in the lactacystin model the same dose of PHCCC that was neuroprotective 
in the 6-OHDA, but administered for 14 days, failed to have any neuroprotective 
effect against lactacystin induced toxicity. This could suggest that either PHCCC is 
only effective in the early stages of the lesion when it was administered in the case of 
6-OHDA lesioning versus 7 days post lesioning in the case with lactacystin. 
Alternately, it could suggest that longer administration of PHCCC may ultimately lead 
to desensitisation/internalisation of the mGluR4 receptor. Further studies are required 
to investigate either concept. Therefore, PHCCC may not be effective in clinical 
treatment of PD since by the time PD is diagnosed the patient is in the advanced stage 
of neurodegeneration. 
Unlike mGluR4, there is no current evidence concerning the internalisation of 
mGluR8 following continuous activation by agonists. Therefore, the long-term 
activation of mGluR8 by (S)-DCPG would hopefully not induce any unwanted effect 
due to the desensitisation of mGluR8.  
In the current study, the activation of microglia was reduced by (S)-DCPG. 
Indeed, anti-inflammatory compounds administrated chronically and acutely have 
been shown to prevent dopaminergic degeneration in the SNc in several models of PD 
(Hirsch et al, 2005; Abuirmeileh et al, 2007; Park et al, 2007; and Qin et al, 2007). 
Therefore, the inhibition of microglial activation by sub-chronic focal and systemic 
administration of (S)-DCPG in this study may provide a long-term anti-
neuroinflammatory effect in PD patients (see section 4.3.6-7). Additionally, the 
astrocytic release of neurotrophic factors provides a long-term neuroprotective action 
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in PD (Slevin et al, 2007). If (S)-DCPG promotes the astrocytic functional changes, 
the astrocytic release of neurotrophic peptides may provide a long-term effect in the 
neuroprotection against the neurotoxicity in PD.   
 
7.3.2 Combined treatment of group mGluRs ligands for neuroprotection in PD 
Originally, one of the objectives of this study was to investigate the involvement 
of different subtypes of group III mGluRs in the neuroprotection against 6-OHDA. 
From the data presented, it was found that modulation at both mGluR4 and 8 are 
neuroprotective but possibly by different mechanism. Neuroprotection by PHCCC 
may be mediated via the down-regulation of glutamate and its excitotoxicity whilst 
(S)-DCPG may rely on anti-inflammatory and other direct neuroprotective actions. 
Therefore, the usage of L-AP4, the board spectrum agonist of group III mGluRs 
should be able to provide a neuroprotection with the combined effect of activation of 
both mGluR4 and 8. However L-AP4 is not clinically applicable because of poor 
brain bioavailability. In contrast, (1S,3R,4S)-1-Aminocyclopentane-1,3,4-
tricarboxylic acid (ACPT-I), which is a selective agonist at mGluR4a and 8 and is 
brain penetrant, potentially induces anti-Parkinsonian effect by activating these two 
subtypes (Ossowska et al, 2007). Due to the specificity of ACPT-I for mGluR4a and 8, 
there should not be any additional effects due to the activation of mGluR7 which is 
activated by high concentration of L-AP4. However, the use of ACPT-I may also be 
affected by the potential problem of inducing receptor desensitisation due to the 
internalisation of mGluR4.  
Furthermore, in the current study, we demonstrated the allosteric effect of 
PHCCC in enhancing the neuroprotective effect of L-AP4. A relatively low 
concentration of L-AP4 was required to produce marked neuroprotection without any 
evidence of loss of effectiveness at high concentrations of PHCCC. Therefore, the 
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combined treatment of PHCCC with a brain penetrant mGluR4 agonist, such as 
ACPT-I or a selective mGluR4 agonist when developed, may also have potential in 
preventing the dopaminergic neurodegeneration in the SNc in clinical treatment. 
Indeed, the allosteric effect of PHCCC on potentiating the ACPT-I has been reported 
previously (Kłak et al, 2007). Furthermore, the low dose of any mGluR4 agonist 
required when combined with PHCCC may avoid the potential confound of receptor 
internalisation, however further research is required to prove this. 
Additionally, 2-methyl-6-(2-phenylethenyl)pyridine (SIB-1893), 2-methyl-6-
phenylethynyl pyridine hydrochloride (MPEP) and (+/-)-cis-2-(3,5-
dichlorphenylcarbamoyl) cyclohexanecarboxylic acid (VU0155041),  acts as the 
allosteric potentiator of mGluR4 and thus enhances the receptor activating effect of L-
AP4 (Mathiesen et al, 2003; Niswender et al, 2008). Indeed, the combined treatment 
with MPEP and L-AP4 provides a synergistic effect of neuroprotection against the 6-
OHDA induced neurodegeneration (Vernon et al, 2008). Therefore the combined 
treatment of MPEP, SIB-1893 or VU0155041 and ACPT-I may also be able to 
produce a synergistic neuroprotection of nigral dopaminergic neurons in the clinical 
PD (Mathiesen et al, 2003; Niswender et al, 2008; and Łuszczki et al, 2005).  
 
7.4 Future work  
7.4.1 In vivo approaches for further investigation of therapeutic effect of PHCCC 
& (S)-DCPG 
Although we have clear demonstrated their neuroprotective properties there is 
lack of the evidence as to whether (S)-DCPG and PHCCC would produce 
symptomatic relief of PD. In particular, the correction of the motor deficits by 
PHCCC and (S)-DCPG is essential for confirming their therapeutic significance. Such 
behavioural assessment could be examined by observing the asymmetric deficits e.g. 
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forelimb placement in 6-OHDA and lactacystin lesioned animals.  
Additionally, the neuroprotective mechanisms of PHCCC and (S)-DCPG have 
not been fully elucidated. In the current study, PHCCC potentially inhibited glutamate 
mediated excitotoxicity in the dopaminergic neurons. However, it is not known 
whether PHCCC modulates glutamate released from STN and other sub-cortical 
nuclei in the models utilised in these studies. Such questions could be addressed by 
the use of microdialysis and subsequent analysis of neurotransmitters by HPLC from 
probes inserted into the SNc. 
Utilising similar behavioural and physiological designs, the therapeutic effects 
of PHCCC and (S)-DCPG could also be investigated in other PD animal models such 
as MPTP and rotenone which induce the dysfunction of the mitochondrial complexes. 
Unlike 6-OHDA, rotenone and MPTP are administrated via the systemic routes, yet 
they are still specifically toxic to the dopaminergic neurons.  
 
7.4.2 Ex vivo and in vitro approaches for further investigation of the 
neuroprotective mechanism of PHCCC and (S)-DCPG 
(S)-DCPG induced neuroprotection may occur mainly via the prevention of 
activation/deactivation of microglia. Although we demonstrated microglial expression 
of mGluR8, the direct effect of (S)-DCPG on the potential for microglia to activate or 
whether (S)-DCPG can dampen down microglial activation has yet to be investigated. 
To study the role of (S)-DCPG on the microglial activation, the known microglial 
activator LPS could be focally injected to the SNc. If (S)-DCPG still prevents the 
LPS-induced microglial activation, it would provide further evidence that (S)-DCPG 
directly modulates microglial activation. By immunostaining with different antibodies 
to detect pro-inflammatory factors, the modulatory effect of (S)-DCPG on the 
neuroinflammation development could be examined. Moreover, the expression of the 
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neurotrophic factors receptors could be examined in the dopaminergic neuronal 
cultures and even for microglia and astrocytes.  
Alternately, in vitro microglial cultures, such as BV-2 and N9, and primary 
microglial could provide a test bed for examining the effect of (S)-DCPG on 
microglial activation. By estimating the cell activity, morphological changes and the 
cellular release of inflammatory factors, the potential modulatory effects of (S)-DCPG 
could be examined. Furthermore, the direct neuroprotective effect of (S)-DCPG could 
be investigated in dopaminergic cell lines, such PC12 and SH-SY5Y cells, and 
mesencephalic dopaminergic primary cell cultures.  
Similarly, astrocytic culture could also be employed to study the potential 
modulatory effects of (S)-DCPG. There are several astrocytic cell lines available such 
as C6, GBM-29 and other human glioblastoma. The effects of (S)-DCPG alone or 
following astrocytic activation could be studied. The potential effects of changes in 
astrocytic or microglial secretion on neuronal survival could be further investigated 
using co-culture techniques.  
Due to the artificial nature of in vivo cell culture techniques any potential 
findings will need to be confirmed in suitable animal models. Particularly, some of the 
receptors of neurotrophic factors, such as RET, has already been detected in the 
dopaminergic neuronal culture and even in primate which may also be down-
regulated when exposed to the dopaminergic toxins (Li et al, 2006; Hirata and Kiuchi, 
2007; Dass et al, 2006). Therefore, the expression of these receptors would confirm a 
possible receptor-mediated mechanism of neuroprotection in dopaminergic neurons in 
human cases.  
Finally, it was hypothesised that (S)-DCPG may prevent lactacystin-induced 
dopaminergic neuronal death via the up regulation of the proteasome subunits 
expression. Such a hypothesis could be tested in neuronal cell cultures exposed to 
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lactacystein with or with (S)-DCPG, to see whether drug treatment increases mRNA 
expression for the various proteasome components or the activity of the proteasome. 
 
7.4.3 Localization of group III mGluRs in rat and human tissue 
To the best of my knowledge, there are no detailed reports concerning the 
expression of Group III mGlu receptors in human BG. mRNA for mGluR4 and 8 has 
been detected in the SNr, SNc, STN, thalamus and caudate/putamen (Messenger et al, 
2002) however no receptor localisation studies have been carried out which may also 
provide important clues as to potential side effects of such drugs. In order to reflect 
the potential neuroprotective mechanism in this study with 6-OHDA and lactacystin 
rodent models, it is crucial to provide evidence that mGluR4 and 8 are present in the 
rat SNc. To further investigate the potential use of group III mGluRs ligands in the 
clinical treatment of PD, the cellular expression of mGluR4 and 8 should be examined 
in post-mortem human tissue. 
 
7.5 Conclusion  
Taking these results together, this thesis provides evidence that pharmacological 
activation of mGluR4 by allosteric potentiator, PHCCC, and mGluR8 by (S)-DCPG 
following focal administration resulted in significant neuroprotection in 6-OHDA 
rodent model of PD. Such neuroprotection was maintained after systemic 
administration of both (S)-DCPG and PHCCC in the 6-OHDA model. However, (S)-
DCPG but not PHCCC provided significant neuroprotection against lactacystin-
induced dopaminergic neuronal loss when administered focally into the SNc. Such 
data provides substantive evidence to support the further examination of the potential 
of modulation of group III mGluRs, particularly mGluR8, in the treatment of PD. 
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